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Abstract

With the growing trend of globalization and rapid development of high technologies,
emerging economies face more challenges in technology development because they are
chasing a fast-moving frontier. They need to identify global technology trends and adapt
to local needs and capabilities. Strategies for technology development differ among
countries at different developmental stages.
In this research, a technology policy choice framework is developed to link
prospective high-tech areas, technology development strategies, and various innovative
resources. The research approach is to develop a hierarchical decision model (HDM) and
apply the analytic hierarchical process (AHP). Experts are invited from diverse sources to
provide a balanced perspective representing different stakeholders. This research focuses
on the fast developing Chinese biopharmaceutical industry as a case study.
The results of this research have identified thirteen prospective biotech areas that
China should invest more resources for development. These technology areas include:
recombinant

therapeutic

proteins,

recombinant

vaccines,

monoclonal

antibody

technology, cell and tissue engineering, gene therapy, antisense therapy, RNAi,
nanobiotechnology,

synthetic

biology,

bioinformatics,

pharmacogenetics,

gene

sequencing, and biotechnology diagnostics. For most of these technology areas, the
results have indicated an imitative innovation strategy should be taken as a better strategy
under current technological conditions in China. The research has further found that hightech small-to-medium companies and multinational corporations are major innovation
contributors in the Chinese biopharmaceutical sector.
i

The research outcomes can serve as guidelines in resource allocation and policy
making for technology development. Based on the overall research findings, policymakers can apply more specific policy instruments to support innovation activities.
Appropriate policy measures may help the country to construct an innovative ecosystem
that can serve as the driving force for future technology development.
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Chapter 1 – Introduction

1.1 Problem Statement
“No nation can afford to be without its own independent Science and Technology
capacity.” [1]

--- Kofi Annan

Innovations in science and technology (S&T) constitute the core of national
competitiveness [2]. Nations across the world invest heavily in high technology
innovations, but they are facing different challenges due to different developmental
contexts.

Western developed countries need to

maintain their

technological

competitiveness and sustain their innovative leadership [3] [4]. Emerging economies aim
to improve technological competitiveness through catching up and leapfrogging [5] [6].
Strategic innovation policy for effective technology development has become a key issue
for all countries. The fundamental and common problem is how nations achieve and
sustain S&T competitiveness.
With the growing trend of globalization and rapid development of high technologies,
emerging economies face more challenges because they are chasing a fast-moving
technological frontier. They need to identify global technology trends and adapt them
according to local needs and capabilities. Even though technology programs such as
foresight studies generally provide broad pictures about the future, implementation of
various high technologies remains a common challenge. The development of high-tech
industries suggests that it is necessary but difficult to find balance between local and
global, internal and external innovation. How much an industry can benefit from external
alliances largely depends on the effectiveness and efficiency of the national innovation
1

system [7]. Emerging economies may rely more on learning advanced technologies from
advanced countries, but they face the “make or buy” dilemma in technology development.
International technology transfer can be a major channel to obtain state-of-the-art
technologies from advanced countries. However, it is also a high-risk process since there
is no guarantee that technology transfer would result in future innovation for the host
country. A comprehensive technology development framework at the strategic level
becomes necessary in the present environment of global competition.
Strategies for technology development differ among countries because of huge gaps
in terms of social values, economic status, and political environments. Technology policy
issues vary significantly due to the diversified conditions between developed and
developing countries. While many Western developed countries strictly control high-tech
export, China adopted a countermeasure policy of “Trading of Domestic Market for
Technology.” This policy deliberately trades market access for technologies, obliging
foreign investors to share technologies if they want to sell to the Chinese market. German
scholars found that the strategy is unique because only large economies with high
potential markets (China and India) can apply it [8]. However, many scholars cast doubts
on this policy, questioning whether this unique catch-up process can foster innovation.
Literature suggests that such a policy is not successful in many high-tech sectors [9] [10].
Scholars suggest that a multi-level perspective is necessary for technology policy to
consider the complex factors of various levels including macro-, meso-, and micro-scale
issues [11]. Further research is needed on policy making to strengthen technological
competitiveness and innovative capability in the long run.

2

1.2 Research Objective and Questions
The objective of this research is to develop a hierarchical decision model to assist
technology policy decision makers in leveraging various technologies, strategies, and
resources for sustainable innovation. Make or buy has long been a strategic problem for
technology development in emerging economies. For instance, international technology
transfer has been viewed as a direct contributor toward technology advancement, but it
can also stifle domestic innovation when treated improperly. There are no current models
to arrive at effective policy design that can align development strategies and resources
allocation toward long-term technological innovation. This study develops such a
research framework that can assist decision makers in emerging economies to develop
guidelines for investments toward the goal of technological innovation. This research will
explore different strategies in technological development, and find efficient pathways to
allocate various input resources for innovation. This research will be achieved through
exploring prospective technology areas, strategic factors, innovation resources, and
measuring related judgments from expert panels.
Through literature review, five research questions have been formulated to deal with
current problems and support the research objective. These research questions (RQ) are
summarized as: RQ1 - What technologies to develop and acquire for emerging economies?
RQ2 - What strategies are more efficient in technological development and innovation?
RQ3 - What innovation inputs can promote and accelerate the development process? RQ4
- How should technologies, strategies, and resources be prioritized to strengthen
competitiveness and support innovation? RQ5 - Where are the areas of disagreements
among stakeholders? What are the related policy implications? The model will be applied
3

to the fast-growing Chinese pharmaceutical industry as a case study, so the questions will
be answered and demonstrated through detailed research in China’s context.

1.3 Research Methodology
To cope with the questions and achieve objectives, a hierarchical decision model
(HDM) is developed. The model has the purpose of leveraging controllable resources to
foster long-term innovation. The methodology to be utilized is Analytic Delphi study.
Delphi offers a technique to make assessments over future uncertainties and strategic
concerns. AHP will be applied to quantify experts’ judgments on identified criteria or
issues. Expert panels are formed of diverse sources to provide a balanced perspective
representing industry and government.
Figure 1 provides a schematic overview of the research process. It is divided into
seven phases. Related and supportive research in each phase is briefly discussed. In Table
1, these research phases are linked to the above-mentioned research questions.

4

Phase 1:
Literature Review
Phase 2:
Identify Prospective
Technology Areas

Phase 5:
HDM Development
-Mission
-Technologies
-Strategies
-Resources

Phase 3:
Identify Technology
Development Strategies
Phase 4:
Identify Innovation
Resources

Phase 6:
Data Collection &
Analysis
Phase 7:
Result Validations &
Recommendations

Figure 1: Outline of Research Approach

Phase 1 – Literature Review: The purpose of the review is to develop a solid
background and understanding of the research topics. Major aspects include international
technology transfer, innovation systems, technology foresight, and technology policies.
Research gaps will be identified and highlighted.
Phase 2 – Identification of Technology Areas: The rationale of this phase is to
identify global technology trends and adapt them to local needs and capabilities. This
means identifying potential high tech areas where competitive advantages can be
achieved through catching up and leapfrogging. The related and supportive research
includes foresight/forecasting studies, industrial report, market analysis, academic
research, expert recommendations, etc. The outcome will be a narrowed list of the
technology alternatives. The list will serve as input to the following research phases

5

where strategic judgment is required. The studies in Phase 2 address the research question
of identifying appropriate technologies to be developed by emerging economies.
Phase 3 – Identification of Technology Development Strategies: This part will
investigate different strategies in the technological development process. Related studies
will compare different conditions in developed countries and emerging economies. The
chosen strategies will be based on the host country’s developmental context, technology
level, and research capabilities. Studies in Phase 3 explore the research question
regarding what strategies are more efficient in technology development.
Phase 4 – Identification of Innovation Resources: This part serves to identify
effective innovation input to support technological development strategies. Since
innovation resources may vary from country to country and from industry to industry,
this related study will focus on the innovation systems in emerging economies.
Environmental factors such as framework conditions will be considered accordingly. Due
to investment constraints, a combination of input resources will be identified and tailored
toward the overall innovation objective. Studies in Phase 4 will answer the research
question of what input resources can promote and facilitate the technology development
process.
Phase 5 – HDM Development: Develop a hierarchy structure to illustrate the multilevel relationships represented in the situation and the judgment process. The research
model utilizes information collected in the above phases as alternatives and criteria inputs
for the decision process. The hierarchy includes the mission, technology alternatives,
development strategies, and innovation resources. The criteria in the hierarchical decision
model are presented to the expert panels for further validation.
6

Phase 6 – Data Collection and Analysis: Pair-wise comparison research instruments
will be developed and sent to expert panel members to determine the weights of criteria
in the hierarchical structure. According to their expertise fields, the expert panel will
quantify the relative weight of importance for the elements in each level. Consistency
level and disagreement of the experts will be calculated. Studies in Phase 5 and 6 will
answer the research question of how to prioritize various technologies, strategies, and
resources for competiveness and innovation.
Phase 7 – Result Validation and Recommendations: The quantification results will
be validated and analyzed. The relationship between the elements in different levels will
be clarified and explained. Sensitivity analysis will be employed to help improve the
understanding of relationships among different levels. The analysis quantifies the range
of difference of the optimal set if there are changes in related sub-criteria, and provides
the basis to assist policy-makers in modifying the hierarchy for selection of the optimum
strategy. Based on result analysis, discussions and recommendations will be given.
Studies in Phase 7 explore the research question in the area of disagreement and related
implications.
According to the overall research findings, policy-makers can apply more specific
policy instruments such as direct and indirect funding, regulation support, and
improvement in framework conditions. More detailed public policies will be potential
areas for future research.
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Research Phases

Research Questions Addressed

Phase 2 – Identification of Prospective
Technology Areas

1. What technology to develop and acquire for
emerging economies?

Phase 3 – Identification of Technology
Development Strategies

2. What strategies are more efficient in
technological development and leapfrogging?

Phase 4 – Identification of Innovation
Resources

3. What innovation inputs can promote and
accelerate the development process?

Phase 5 – Hierarchical Model Development
Phase 6 – Data Collection and Analysis

4. How should technologies, strategies, and
resources be prioritized to strengthen
competitiveness and support innovation?

Phase 7 – Result Validation and
Recommendations

5. Where are the areas of disagreements and
agreements? What are the related policy
implications?

Table 1: Connecting Research Phases and Research Questions

1.4 Research Applications
To demonstrate the model in detail, the research will develop a case application from
the perspective of China. Among other developing countries, China is in the critical
period of trying to catch up with developed countries and implementing a new path of
industrialization. The issue of how to accelerate development and foster technological
innovation has aroused great concern from government, industry and academic sectors, at
the same time, provided an opportunity for research.
China has been developing fast in terms of economic and social achievements, with
a lot of visible improvements but also many underlying weaknesses in technology
management. The Chinese innovation system is still at an early stage and its development
is always determined by the macro environment. In order to achieve national
competitiveness in S&T, the country needs to improve its innovative capacity. One of the
most determinative factors is its strength of sustained innovation in a globalized
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environment. The core objective of the country is to locate its right position in the global
innovation networks, and to construct an innovation infrastructure that can serve as the
driving force for future development. Appropriate technology policy measures can
integrate domestic innovation efforts along with foreign innovation resources. Such
measures may help the country to catch up with the developed world or even leap ahead
into the global innovation frontier. The dissertation develops a research model to help in
achieving this objective. The research results may also be helpful to other emerging
economies for achieving innovation objectives and promoting national competitiveness.

1.5 Outline of Dissertation
Chapter 1 provides an introduction and gives an overview of the dissertation.
Research background, objectives, and approaches are briefly presented to give a complete
picture of the study.
Chapter 2 constitutes the theoretical foundations supporting the research. It contains
a comprehensive search of literature in major areas including international technology
transfer, innovation management, technology foresight, technology policy, and related
methodologies. Outstanding gaps are identified that motivate the research.
Chapter 3 links the literature gaps with research questions, and further clarifies the
research goals. It presents the research methodology, research framework, and research
approach. The research process is divided into several phases and discussed in detail.
Chapter 4 develops a case application for the model, which is about the
biopharmaceutical industry in China. The customized model criteria, as well as the
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structure, are validated by experts. Research instruments are developed to quantify expert
judgment. The data collection process is discussed.
Chapter 5 presents the quantification results in charts and tables. The overall
contributions of criteria are calculated in matrices. The data are analyzed for
inconsistencies, disagreement, and sensitivity.
Chapter 6 discusses the result implications according to various levels in the model.
Policy recommendations are included based on research results as well as experts’
feedbacks during the validation process.
Chapter 7 concludes the research from the aspects of contributions, assumptions,
limitations, and future research areas.
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Chapter 2 – Literature Review

The literature reviewed in preparation for this research is focused on several major
aspects – international technology transfer, innovation management, technology foresight,
technology policies, and related methodologies. The purpose of this chapter is to develop
a solid background and understanding of the research topics. In each section, technology
policy and strategies are examined in various countries. A special section will focus on
technology management issues in China. Literature gaps are highlighted at the end of this
chapter.

2.1 International Technology Transfer
International technology transfer is a direct approach to improve the national
technology level and strengthen national competence. As many emerging economies face
the question of ‘‘make or buy’’ in technology development, introducing new technologies
from advanced countries can serve as a fast track to boost the speed of catching up [12].
Through technology import, host countries can often shorten the learning time, enjoy the
latecomer advantage, and achieve technology leapfrogging. However, international
technology transfer is not an easy process. Barriers exist due to different conditions
among countries in terms of social values, economic development, and technology level.
There are more complicated issues if technology exporters belong to the developed world,
while the technology importers come from the developing world. Scholars suggest that
technology transfer needs to be perceived in terms of achieving three core objectives [13]:
1) the introduction of new techniques by means of investment in new plants; 2) the
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improvement of existing techniques; and 3) the generation of new knowledge. This
section will analyze various issues related to international technology transfer and
identify literature gaps for improvement.

2.1.1 Levels of International Technology Transfer
International technology transfer can be studied from different perspectives. One
approach is to focus on the entities involved in the process, i.e. technology exporter,
technology importer, and technology itself. Another approach is to explore the growing
trends of international technology transfer from different perspectives of various levels. A
careful examination of the literature reveals that international technology transfer issues
can be categorized into several interrelated levels including: national level, enterprise
level, and technology level [14] [15]. International technology transfer is a complicated
system process that involves not only the activities of market and economy, but also
politics, culture, and society. Many obstacles still exist and are unsolved at each of these
levels. A good understanding of influential factors provides better insight for policymaking.
At the national level, literature findings show that there are many environmental
factors influencing international technology transfer, which include policy, economic
growth, and market trend. For example, technology transfer needs appropriate legislation
on intellectual property protection. It is also directly influenced by market need and
investment. International technology transfer and acquisition should align with national
goal in technology development. Macro-level regulations and incentives can have major
impacts on the efficiency of the technology transfer process. International technology
12

transfer, especially high-tech exports and imports, are being strictly controlled by
governments at the national level. Western developed countries have issued various
regulations regarding cross-border technological transactions. These restrictions have
largely deterred international technology transfer activities. For example, the United
States has limited technology transfer to China in many high-tech areas, which includes:
electronics and communications technologies, ship-building, airplane, satellite, materials,
nuclear energy, etc [16]. This policy even inflicts many other EU countries working in
high-tech projects with China. As a result, China cannot solely rely on international
technology transfer in high-tech industries. Indigenous innovation should be emphasized
and promoted at the national level.
At the enterprise level, many actors of international technology transfer have been
identified in the literature. In the process of technical transactions, strategies of
stakeholders are the determinants for the success of international technology transfer. The
technology development process can be accelerated by cooperative interactions among
the players. This is closely related to the robustness of technological innovation systems.
Multinational companies are important sources for emerging economies to acquire
foreign technologies, but there are many factors to consider such as intensified
competition, crowding out of domestic enterprises and newcomers. Recent literature
showed that international technology transfer can exist in some new channels such as
R&D collaboration and cross border M&A. Technology learning has also been enhanced
by some non-formal channels which include academic communication, flow of scientists
and engineers, etc. These channels are new opportunities for the emerging economies to
accelerate their catching up process.
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At the technology level, many studies focus on the issues of technology selection
and assessment. Characteristics of technology play a significant role in international
technology transfer. These features may include availability, maturity, adaptability, and
gaps, etc. From the perspective of developing countries, an emerging technology can
provide a window of opportunity for technology leapfrogging [17]. Much has been
written in the literature about the need to transfer appropriate technologies for developing
countries. Therefore, technology adaptability in a foreign market is an important factor
for the success of international technology transfer [18]. Technology gaps describe the
distance between the domestic technological competency level and international state-ofthe-arts technologies. Literature examining institutions and technological development
found technology gap may either enhance or deter the efficiency of international
technology transfer. Technology management techniques can be applied to international
technology transfer for evaluation of technology alternatives, selection and acquisition of
appropriate technologies. Emerging high-tech areas bring new challenges for developing
countries to catch up and realize the latecomer advantage. Not only do they need to select
the right technological direction, but they also need to accumulate technology learning
capabilities.

2.1.2 Technology Transfer and Innovation
The intimate connection between technology transfer and innovation has been
highlighted in the literature. For example, scholars claim that technology transfer is a key
contributor to innovation performance, competitiveness and economic development of a
country [19]. Some scholars developed linear growth models to illustrate technology
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progress in industrializing economies. The development process was seen as a series of
successive upgrading in parallel with a nation's economic environment.
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Figure 2: Linear Models of Technology Progress in Industrializing Economies

In Figure 2, Guan et al. (2006) presented a technological progress trajectory for the
catching up countries from imitation to innovation which comprises acquisition,
assimilation and improvement of technology [19]. Wang and Zhou (1999) considered the
role of foreign enterprises and created a model of “transfer-digestion-absorptioninnovation-dissemination” from China’s perspective of increasing involvement in
international production and trade activities [20]. Leonard-Barton (1995) proposed a
model to describe import substitution, which starts from import kits, progresses to
localization of parts and components, then to product redesign, and finally to novel
product design [21]. Hobday (1995) suggested a linear model for newly industrialized
countries: from the first stage of cheap labor assembling, through the second stage of
original equipment manufacturing (OEM), then to the third stage original design
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manufacturing (ODM), and finally to original brand-name manufacturing (OBM). The
author emphasized the importance of OEM as a learning platform, calling it “an enduring
technological training school for latecomers” [22].
Most of the above models connect international technology transfer with the concept
of innovation or improvement in technology. However, implementation in the real world
is not as easy as the models have depicted. For example, the literature has conceded that
there are many problems, or at least it is still a difficult task for China. Scholars [20]
argued that lack of sufficient technological capability is a major inadequacy at the firm
level for implementation. The restructuring of the Chinese R&D system from a centrally
planned mechanism into a flexible system should be an attempt to solve the problem. The
literature has reported that China spent more on technology acquisition—the earliest
stage of the technological progress trajectory but much less on the last two stages than
Japan and Korea when their economies started booming [19]. Scholars also pointed out
that the proportion of hardware transfer is high [23]. Except for some large-sized
companies, most importers stay at the level of cooperation in transferring hardware.
There is a negative influence on domestic industry in that it is a mature technology which
is still largely transferred. Facing incessantly changing technologies and intense global
competition, Chinese authors argued that the country should acquire more state-of-the-art
technologies that lead to innovation and improvement [24].
Although international technology transfer can be an effective strategy to catch up
with the leading countries in many high-tech sectors, it may not necessarily result in
future innovation of the receiver. For instance, the literature explored the relationship
between technology transfer activities and innovation performance with special reference
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to Chinese industrial firms. Based on a nationwide survey covering more than 2000 firms,
statistical results showed that technology transfer activities may impede the innovation
performance of high-tech firms [19]. Recent research (2011) shows that regarding
international R&D spillovers facilitated by FDI, the spillover effect on indigenous
technical change is mostly insignificant or negative except in the medium low-technology
sectors [25]. These facts mainly result from low absorption capabilities of domestic
industries. Therefore, it is critical for policy makers to better utilize technology transfer
as a tool to foster innovation and sustain future development. Many scholars from
developing countries focus on how latecomers can catch up with advanced countries by
leapfrogging or direct innovation at the technological frontier [26-28]. Lee (2005)
identified two catch-up modes: Taiwan followed the sequential steps of OEM, ODM and
OBM, by learning from foreign countries; Korea jumped from OEM directly to OBM
without consolidating design technology. The author suggests that China might be a third
model mixing elements of both Korean and Taiwanese models, but more research is
needed [29].

2.1.3 Different Motivations and Interests
During the process of technological transactions, there are noticeable differences in
strategic objectives among the host government, foreign technology providers, and
domestic partners. Their strategies are the determinants for the success of international
technology transfer. Scholars argued that research should not only analyze technology
strategy in subsidiaries of MNEs, but also examine how such development differs from
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that of domestic firms [30]. Their differences decisively affect the implementation of
technology transfer.

2.1.3.1 Foreign Interests
The motivations of foreign technology providers have been studied in detail in the
literature. Through four cases of Swedish manufacturing firms which have transferred
technology to China, the literature generalized some of the Western companies’
motivations for transferring technology to China. These include [14]:
1) Access to the Chinese market for China’s future development potentials;
2) Achieve Short-term revenues through direct sales of machinery or plants;
3) Utilization of China’s low labor costs and improving access to certain resources;
4) Achieve long-term revenue from their equity investment in joint ventures.
The above motivations cannot be easily realized, and major barriers or difficulties
for Western companies exist in many aspects. A major threat to foreign companies arises
from losing the technological lead to China in high-tech sectors. Most foreign companies
are aware of this threat and are sensitive about raising potential Chinese competitors [31].
In the short run, there might be more common interests than conflicts between the foreign
companies and their Chinese counterparts, such as growth in local market share and profit.
However, in the long run, the Chinese counterparts might emerge as international
competitors and capture more market share globally. Considering all the good prospects
of the original motivations, this issue might therefore be a “double-edged sword” for the
foreign companies. The literature also examined the question of technology transfer from
the perspective of techno-economic security and how companies respond to the
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possibility of losing competitive advantage through misappropriation or leakage. Technoeconomic security raises the issue from a company level to a political level. Since this
risk is often exacerbated by insufficient legal protection of Intellectual Property Rights
(IPR) in China, the Europe Union officially urged China to strengthen related protection.
The issue of techno-economic security relating to technology transfer to China also has a
special significance because of uncertainty about, and non-transparency of, the legislation
compared to Western systems [31].

2.1.3.2 Local Interests
The motivations of Chinese technology receivers are quite different from their
foreign counterparts. Firstly, they focus on the acquisition of advanced technology,
reputable trademark, technical and managerial know-how; Secondly, they want to gain
access to international markets through export of the product produced by means of the
acquired technology and earnings of foreign exchange; Thirdly, they want to become
competitive in the local market and secure a technological base for long-term profits;
Fourthly, they hope to develop R&D capacity; Last but not least, they may benefit from
government’s subsidies which encourage technical cooperation with foreign firms [14].
There are many difficulties for the domestic players to implement the above goals.
For example, based on a questionnaire survey covering 200 sample companies and
factories in mechanical industries in China, the literature provided a detailed analysis on
various difficulties perceived by Chinese technology importers [23]. Major difficulties
include inappropriate technology, limited access to overseas market information,
misunderstanding and lack of mutual trust, steep price of the advanced technology,
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unmatched engineering standard, incompatible production management system, training
and on-spot service support, difficulties improving the transferred technology, and extra
restrictions in the contract articles. Many uncertainty factors may influence the purchase
behaviors of foreign technologies by the Chinese companies. Their practical
considerations for evaluating foreign technologies can include: domestic market value of
the technology, profit return from the technology, foreign advanced level of the
technology, market value cited from other exporters, market value of an alternative
technology, domestic advanced level of the technology, international market value of the
technology, method of payment for purchasing the technology, risk level of the
technology import for recipient firms, and supplier’s cost for the technology (R&D and
transferring cost) [23]

2.1.4 Implications for Emerging Economies
Although international technology transfer is a fast track in technology development,
it may not naturally result in long-term innovation, or sustainable innovation [32]. It is
widely accepted that the adoption of transferred or purchased technologies has both
positive and negative impacts on domestic companies. Technology transfer activities will
generally improve production and market performance of many domestic firms, but it
might also impede the innovation performance of high-tech firms. Many domestic firms
have been relying on costly generation technologies (e.g. key equipment and apparatuses),
resulting in negative impacts of technology transfer on cultivating their core competence
[19]. Most domestic companies of developing countries stay at the bottom segment of the
“smiling curve”, where production generates low marginal profit [33]. Although these
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companies can receive a certain degree of technology transfer through outsourcing, the
high-tech core is always retained by MNCs in the developed countries. Research [34] has
shown that many outward-oriented and highly competitive industries, which are based on
imported technology and foreign affiliates, seem to have had limited impact on local
production and on the diffusion of technology in domestic industry.
From the perspective of emerging economies, there are more issues to consider about
the negative effects brought by foreign investment. The entrance of MNCs may
deteriorate the industry infrastructure of developing countries. Although the
demonstration effect may lead domestic companies to upgrade their technology level, it
also intensifies market competition. With a weaker technology edge and limited capital
support, domestic competitors are easily ruled out of the market by technology lock-in.
The technology absorptive capacity of the domestic company is the primary factor as to
whether it can take advantage of spillovers [35, 36]. This will in turn depend on the
company’s strength of investment in R&D. However, R&D expenditures of domestic
firms can rarely parallel those of large MNCs. Moreover, MNCs have different R&D
strategies when going abroad, and they tend to minimize spillovers so as to keep
competitive advantages [37]. In recent years, MNCs are getting more involved in vertical
technology transfer. This new trend has shown that MNCs prefer to establish wholly
owned subsidiaries in foreign countries. As a result, knowledge transfers tend to be
internalized between the MNC and its wholly owned subsidiaries [38]. This makes
domestic companies unlikely to benefit from technology transfer.
To resolve the differences in motivations and interests, the policies of the host country can have a crucial influence on technology transfer and its outcome. Technology
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importers should adjust their technology acquisition strategy on the basis of their actual
level of economic development, technological accumulation and long-term industrial
plans. Scholars have developed an extension of the technology acceptance model (TAM)
to study international technology transfer. Several antecedents have significant influence
on the success of technology transfer, which include: technological compatibility, ease of
adoption, technical and economic benefits to the adopting firm [39]. Therefore, decision
makers need to prioritize various factors in technology development. A fairer policy
should be considered for both domestic enterprises and foreign technology providers.
Mutual understandings are required for both sides. Finding ways of increasing the
effectiveness of technology transfer has strategic implications for both the host country
and foreign investors.
From a broader perspective, the innovation process is a cooperative interrelation
between enterprises and other actors. International technology transfer should be utilized
as a supportive strategy to accelerate technology development and promote innovation.
The goal of the host government is to achieve long-term social benefits for the host
country through the acquisition of advanced technologies. This means localization of
high-tech products and improvement of innovation capabilities of domestic industries.
However, domestic companies are weaker in terms of technology level and knowledge
accumulations. Due to intense market competition, these companies lack enough
resources for long-term R&D. With the growing pace of internationalization, domestic
enterprises are eager to transfer better technologies from foreign countries to increase
market competency in the shortest amount of time. The issues faced by the host
government are to adjust related policies and provide an innovative environment, thus
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promoting industrial innovation capability. The goal is to leap into the ranks among
technology leaders and thus engender a competitive status worldwide.

2.2 Innovation Management
Based on issues identified in international technology transfer, this section aims to
further examine innovation and technology policy. Starting from the innovation theory,
this section explores various types of innovation systems and related government
innovation policies. With such literature reviewed, the analysis will focus on innovation
management issues in emerging economies.

2.2.1 Innovation as National Competence
It has been widely accepted that innovation is the engine for development in the
Western developed countries. Porter (2002) indicated that innovation has become the
most important source of competitive advantage in advanced economies, and building
innovative capacity has a strong relationship to a country's overall competitiveness and
level of prosperity [40]. Technological competitiveness is often measured by the
innovation capability of industries in a country. The innovation concept in Western
market economies has gone through several stages. During the 1950s and 1960s, the
industrial innovation process, was generally perceived as a linear progression from
scientific discovery, through technological development in firms, to the marketplace
(Figure 3) [41]. Starting from the 1970s, perceptions of the innovation process began to
change with a marked shift towards emphasizing market need (Figure 4) [41]. According
to the new model, the market was the source of ideas for directing R&D, which had a
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merely reactive role in the process. In the mid-1980s, a new model combining the
technology push and market pull emerged, and was widely adopted by both industry and
academia (Figure 5) [41].
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Figure 3: Technology Push Model
Source: Rothwell (1994)
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Figure 4: Market Pull Model
Source: Rothwell (1994)

Scholars also developed more complicated models to include various kinds of
influencing factors of innovation. The following model (Figure 5) divided the innovation
process into a series of functionally distinct but interacting and interdependent stages. In
other words the process of innovation represents the confluence of technological
capabilities and market-needs [41]. In recent research, Nemet (2009) proposed that the
factor “Government Led” should be added to “Technology Push” and “Market Pull” [42].
In developing countries, governments can develop policies to encourage transfer of
advanced technologies from developed countries. From different viewpoints, many
scholars from emerging economies focus on how latecomer countries can catch up with
advanced countries through leapfrogging or disruptive innovation [26-28].
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2.2.2 The Evolution of Innovation Systems
The linear models of innovation are somehow limited in scope and do not cover the
whole picture of complexity. Both industry and academia noticed that innovations were
influenced by many environmental factors. Freeman argued that, to realize large technoeconomic system transitions, society needs to develop a new model of innovation,
combining some features of the much criticized linear model with features of the
systemic innovation model [43]. This leads to the emergence of an innovation system as a
tool to understand the interactions of innovation activities. An innovation system is a very
important determinant of technological change. The emergence of a new system and
changes in existing systems co-evolve with the process of technological change [44].
Here we explore how the concept of innovation systems evolved.
Innovation is characterized by complicated feedback mechanisms and mutual
interactions involving science, technology, learning, production, policy, and demand [4547]. Edquist claimed that “firms never innovate in isolation” [45]. In this process,
innovators interact with other organizations to develop and exchange various kinds of
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knowledge, information, and other resources. These organizations can include other firms
(upstream, downstream, or even competitors), universities, research institutes,
government agencies etc. Various types of relationships can be established among these
innovators during their innovation process. Therefore, innovating firms should not be
regarded as isolated or individual decision making units [45, 48]. According to Elzen and
Wieczorek, innovations emerge in multiple interrelated societal domains, including
technology, economics, politics, and culture [49]. All of these studies indicate that firms
operate within Innovation Systems. In recent years, more discussions and research about
developing competitiveness and technological advancement have dealt with innovation
systems. Mainly, four types of innovation systems are studied, which include National
Innovation systems, Regional Innovation Systems, Sectoral Innovation Systems, and
Technological Innovation Systems.
Freeman introduced the concept of National Innovation Systems (NIS) in 1987 [2]. It
was further developed by Lundvall and Nelson in the early 1990s [50] [51]. NIS includes
not only industries and firms, but also various actors and organizations of related fields in
science and technology. Freeman defines NIS as a network of public and private
institutions that through its activity and interaction creates, brings, modifies and spreads
new technologies. Scholars defines NIS as “a system of interacting private and public
firms, universities, and government agencies aiming at the production of science and
technology within national borders” [52]. Metcalfe defines that a NIS is “a set of distinct
institutions which jointly and individually contribute to the development and diffusion of
new technologies and which provide the framework within which governments form and
implement policies to influence the innovation process” [53]. These definitions show that
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NIS is a social and dynamic system, characterized by positive feedback and reproduction.
The processes of learning and innovation can be promoted by the elements of the
Innovation System that reinforce each other, or conversely, that block such processes
when they combine into constellations that are unfavorable [50].
The Regional Innovation System (RIS) concept was evolved from the NIS concept.
Krugman carried out some related research in regional innovation environments,
innovation networks, and innovation clusters [54]. Other scholars further developed the
RIS concept from the perspective of system evolution and regional innovative
infrastructure [55] [56] [57]. Doloreux focused on the key elements in a RIS, where firms,
institutions, knowledge structures and holistic innovation policies played important roles.
He emphasizes three aspects of RIS, including interactive learning, milieu and
embeddedness [58]. Several conceptual models have been developed for RIS, such as the
triple helix model, which illustrates a top-down approach to the RIS focusing on the
R&D functions of universities, public and private research institutes and corporations
[59]. RIS is characterized by its regional features which can include a whole set of norms,
attitudes, and routines that slowly evolve over time. These assets can make it difficult for
actors from other regions to imitate similar practices, thereby protect the technological
edge of the first mover region [60] [61]. Regional assets can have significant impacts on
the innovation behaviors of actors within the region.
Sectoral innovation system (SIS) is another concept evolved from the NIS origin.
Breschi and Malerba defined it as “a system (group) of firms developing and making a
sector’s products and generating and utilizing a sector’s technologies” [62]. Actors in SIS
may share some specific knowledge areas, technologies, needs, and demand. The focus of
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SIS lies on agents and firms, which put much emphasis on non-market interactions and
on the processes of transformation of the system [63]. Malerba further suggested that the
SIS framework has three major dimensions: knowledge and technological domain; actors
and networks domain; and institutions domain [64]. SIS reveals the fact that different
circumstances and conditions exist among various industrial sectors. For example, each
sector operates under different technological regimes, which are characterized by
particular combinations of opportunity and conditions, degrees of cumulativeness of
technological knowledge and characteristics of the relevant knowledge base [65]. The
research of SIS focuses on the relationships among firms through considering the impact
of their surviving environment. The boundaries of SIS emerge from the specific
conditions of each sector, by focusing on the sources of knowledge and on the role of the
environment in the process of knowledge transmission [62].
Technological Innovation System is defined as “a network or networks of agents
interacting in a specific technology area under a particular institutional infrastructure to
generate, diffuse, and utilize technology”[66]. TIS consists of networks of firms, R&D
infrastructure, educational institutions, and policy-making bodies [67]. In comparison to
other innovation systems, the TIS approach focuses on specific technology areas. There
can be many technological systems in a NIS, but the national borders do not necessarily
form the boundaries of the system [65]. TIS may not necessarily be restricted within any
sectoral branch. The national boundary may constitute a natural limit of technological
systems, or it can further form regional or local subsystems. The boundaries of TIS
depend on various circumstances including the technological and market requirements,
the capabilities of various agents, and the degree of interdependence among agents [66].
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TIS are often used to analyze an emerging system rather than a mature system. As the
systems evolve over time, the need for longitudinal studies is justified [65].
The innovation system includes three levels: macro perspective (NIS), meso
perspective (RIS and SIS), and micro perspective (TIS). In order to achieve the desired
performance of a system, it is necessary to understand the inner mechanism in the system,
and it is also important to explore the outer dependencies among different systems.
Technological innovation systems play important roles in developing a regional
innovation environment, while the sectoral innovation networks and regional innovation
systems can be embedded in the national innovation networks. Chung (2002) suggests
that a regional innovation system is a good tool to generate an effective national
innovation system, as it can effectively create different sectoral innovation systems in
different regions [68]. The sectoral system experiences changes in a dynamic
evolutionary process, which in turn affects many elements of the system. The TIS are the
fundamental elements of various RIS and SIS, which in turn, are embedded in the NIS.
From the perspective of a specific technology, TIS cut through both the geographical and
the sectoral dimensions [44]. There are several different perspectives of studying
innovation systems. Most commonly is to study the interdependency of different
innovation systems within a country. Another approach is to compare innovation systems
that are different from country to country, i.e. developed countries, developing countries,
transitional economies, etc. Still another approach is to study relationships and
interdependency of innovation systems among themselves. Owing to the differences in
histories and traditions of different nations, and also in their size and development stage,
the structure of national innovation systems differs substantially across the globe.
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2.2.3 Globalization of Innovation Resources
In the era of globalized competition, the speed of high tech development and the
capability of sustained innovation are vital for enterprises' survival. The concept of NIS
provided a metric to study actors sharing a common culture, history, language, social and
political regime within the national boundaries [45]. However, the trend of globalization
and economic liberalization brings new challenges to this limitation. The emergence of
global synergic innovations is getting more prevalent and dispersive across the world.
The question is whether geographic boundaries are still relevant or not in high tech
innovation.
Innovation systems were originally utilized to study the Western developed world.
Since innovation has become the most influential factor for technological development
and national competitiveness, the Western developed countries have made it a priority in
policy-making. These countries have done so by creating and strengthening their NIS to
promote technological and economic development [69]. The innovation system
framework often links various national innovation resources (education, R&D institutes,
and enterprises) to technological outputs (publications, patents, and new products).
Fukuda (2008) argues that technology policy should generate innovation with a view to
constructing co-evolution among heterogeneous players with different degrees of
competitive advantage. Each player is required to recognize and develop its core
competence through learning inspired by other players. The agility, adaptability, and
alliance among heterogeneous players should be maintained and enhanced [4].
Innovation systems define the ecosystems of related entities, and ensure that potential
innovation resources are effectively explored and utilized.
30

In recent years, an increasing number of geographically dispersed innovation
networks have been formed between developing and developed countries. This is
partially due to the expansion of multinationals from the developed countries. To fit the
challenges of globalization, multinational companies are trying to utilize more dispersive
innovation resources through establishing strategic alliances with companies from
developing countries. For example, there are many types of international technology
transfer activities such as original equipment manufacturers (OEMs), original design
manufacturers (ODMs), electronics manufacturing service (EMS), and virtual
organization (VO) [70]. Related studies indicate that the more progressive liberalization
and deregulation of international trade and investment are, the more rapid the
development and diffusion of technology will be, which will fundamentally change the
global competitive dynamics in which MNCs operate [28]. Cooperative alliances have
become an increasingly important part of the competitive landscape of multinationals
[71]. It is a novel domain to deepen the research of systemic innovation based on
matching foreign MNCs to SMEs and comprehend the pros and cons of global innovation
networks. However, there are relatively few studies linking the innovation resources at
both the macro and micro level to how an improvement could result in raising the mutual
national Innovation Capacity [72].

2.2.4 National Innovation Strategy
Countries have different innovation strategies due to their differences in social,
economic, and technological conditions. Here we explore national innovation strategies
in developed countries and emerging economies respectively.
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In 2010, the U.S. Federal government asked the National Research Council (NRC)
of the National Academy of Sciences to review and analyze the S&T advancement
strategies of six competing countries (Brazil, Russia, India, China, Japan, and Singapore)
and to judge their likely impact on the U.S. at present and in the future. The result was
published in a report titled “S&T Strategies of Six Countries: Implications for the United
States.” The report argued that multiple factors affect the likelihood of achieving national
S&T goals, including the coupling of socioeconomic and cultural drivers, the
globalization of R&D, the opaqueness and the resulting unpredictability of programs, and
simply countries’ available resources, priority setting and execution, disruptions, and so
forth [73]. The report provides policy recommendations for the U.S. government based
on the findings from other countries’ strategies. Key policy implications include: 1)
Monitoring the transformation from a national to a global S&T innovation environment
portends future prosperity and security for the United States and all countries; 2) The
transfer of intellectual property by multinational corporations into domestic companies
through S&T activities should be monitored in key countries, particularly India and
China. The United States could join with Japan, and possibly the European Union, to
establish a united front against such practices; 3) The U.S. should prepare for, and
transform to a S&T innovation environment to include global exchanges in education and
R&D talent, international as well as national recruitment of R&D talent, multinational
corporate collaborations, and public policies that facilitate or restrain the leadership in
global S&T innovation; 4) The U.S. should monitor a competing country’s capacity to
facilitate the cultural changes needed to achieve its global S&T innovation environment,
which is especially important for predicting future changes in the S&T innovation
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environment; 5) Attracting quality researchers and providing research facilities and
research support as important measures for the world’s S&T talents; 6) Continue to gauge
the efficiency of research, measured by the effective uses of research talent and research
facilities, which portends the future of a county’s innovation environment; and 7)
Seeking mechanisms for sustainable U.S. government collaboration with the international
community to uncover and exploit potential S&T breakthroughs [73].
From the perspective of emerging BRIC countries, scholars have also suggested
various innovation strategies. Yang and Shu (2005) defined three types of innovation
activities in China: indigenous innovation, imitative innovation, and cooperative
innovation [74]. The concept of indigenous innovation stresses focus on the system's
(country, industry or company) predominant core technologies and core products to
improve its competitive ability [75, 76]. Imitative innovation refers to the adaptation
based on the advanced innovators’ technology, driven by the influences of the leading
innovators’ demonstration and interest mechanisms [74]. Cheng and Shiu (2008) defined
comparable concept of re-innovation as “It is the part of new product development which
studies the extension of existing innovations, which can only happen after the first
generation of a new product is launched” [77]. Re-innovation is renowned for its
potential in creating competitive advantage with reduced cost and time implications. A
Japanese scholar suggests that imitation by lagging countries can contribute to the world
welfare by making it possible for them to learn the latest technology and to become nextround innovators [78]. Cooperative innovation is a strategy to implement innovative
activities with foreign alliances and is dependent on the mutual or multi-facet cooperation
among enterprises, research institutes, and universities. The premise of cooperative
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innovation is that each side shares the common achievements and develops all together.
Accordingly, enterprises with competitive relations and conflicting interest can work
hand in hand to gain profits and development momentum [74]. Active cooperation
between firms can enable them to achieve outcomes that they could not achieve on their
own, while allowing each individual partner enterprise to realize its own strategic goals
[79].
An important reason for indigenous innovation is forced by the fact that some
developed countries restricted high tech exports to emerging economies including China
[80] [81]. Moreover, in some high-tech industries such as biopharmaceuticals, China
needs to pay high prices importing foreign products, and this has led the government to
develop indigenous technologies. As the latecomer approaches the technological frontier,
so its strategies will shift from imitation to innovation [82]. This has been the case for
many of the Asian countries. A common question is: Is it likely to stay stuck in catch-up
mode as a perpetual imitator, or can it build its absorptive capacity to the point that it can
sustain genuine innovation [83]? Indigenous innovation is a strategy with bright prospect
for China, but the real question is how to balance it with other innovation strategies [84],
i.e., imitative innovation and collaborative innovation, to build up the innovation capacity
more efficiently and effectively. Fu and Gong (2011) suggested a “two-leg forward
strategy” to maximize the benefits from existing knowledge and accelerate the catch-up
process, where both indigenous innovation and acquisition of foreign knowledge are
needed, but with the optimal mixture differing among sectors and stages of development.
An effective technology policy package may thus be country-, region- and industry-

34

specific, but well-focused policies to foster the absorptive capacity and innovation
capabilities of indigenous firms are always crucial for success [25].

2.2.5 Challenges of Innovation Governance in Emerging Economies
Following the global trend of innovation, emerging economies such as the BRICs are
investing more resources to develop their innovation capability. However, the large
majority of available studies ignore the fact that the characteristics of technological
change of industrializing economies are largely shaped from the outside realms of foreign
institutions in industrialized countries [85].
A major challenge for governments is how to construct effective and efficient
innovation infrastructure. In many aspects, the BRIC countries, due to their stage of
development, have essentially different innovation infrastructures when compared with
the advanced economies. There is little evidence that current frameworks of innovation
research in developed nations are also workable for countries like the BRICs. Viotti [85]
found that that the NIS theoretical and conceptual framework is not appropriate for
dealing with the processes of technological change of industrializing economies, which
are extremely different from those of industrialized countries. Emerging economies have
very different environmental contexts and changing agents. Transition from the
traditional institutions towards the innovation model of growth involves formation of
better mechanisms for social development based on the balancing of new innovation
resources [86]. To such an extent, the construction of an effective and robust innovation
structure is extremely necessary. This calls for the need of leveraging and prioritizing
various input resources that buildup the innovation capability of the country. Thus
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concentrating resources in the areas where the host country’s competitive advantages can
be achieved helps to boost innovation, which is a key factor that determines the
competitive status of the national economy [87].
The inclusion of domestic S&T networks into the global systems of innovation also
brings up new challenges. National innovation strategies should be designed and selected
according to the developmental context of the host country. Technological innovation is a
contextual process whose relevance should be assessed depending on the socio-economic
condition it is embedded in [88]. It is a difficult task for transitional economies due to the
legacy of inefficient or weaker innovation systems. Sectoral differences also bring
challenges in policy making. For example, the private sector dominates biotechnology
research in industrialized countries, but there are major market failures in developing
countries [89]. The innovation system approach needs to be adapted to the situation in
developing countries if it is to be allied to capacity building. Analytical efforts to better
understand how more complete innovation and competence building mechanisms may be
constructed in the present environment of global competition and networking need to be
made [46]. The Global Innovation Index called for the necessity of national innovation
strategy, but it did not propose a central operating model for widespread implementation
issues [90]. This dissertation will probe into the background, rationale, and impacts of
technology policy. Based on such findings, a research framework and methodology are
developed for policy decision making.
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2.3 Technology Foresight
This section attempts to review technology foresight from the perspective of
innovation systems and globalization. It includes several important aspects of technology
foresight studies: evolution, policy impact, and implementation issues. Special emphasis
will look into recent foresight activities in the BRIC countries. Martin (1995) defines
technology foresight as “the process involved in systematically attempting to look into
the longer-term future of science, technology, the economy, and society with the aim of
identifying the areas of strategic research and the emerging generic technologies likely to
yield the greatest economic and social benefits” [91]. This concept and rationale are
compliant with the policy needs to deal with the increasingly globalized science &
technology development.

2.3.1 Foresight Initiatives in Developed Countries
Nowadays, technology foresight has been adopted on a large scale across the world.
However, most available foresight studies are shaped by the practices and methodologies
from the developed countries, especially Japan and the United States. Nevertheless, the
two countries have totally different attitude toward government-lead foresight activities.
Japan is the most enthusiastic country in carrying out national technology foresight
studies, but the United States does not have such large-scale foresight activities at the
national level.
Major themes for technology foresight in the United States have been examined in
the literature: strong contribution to foresight methodology development, important
narrowly focused foresight efforts in some federal agencies, and no holistic national
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foresight studies [92]. Firstly, most of the widely applied foresight methodologies were
developed by US researchers. These tools include: the Delphi methods, scenario planning,
Analytic Hierarchical Process (AHP), technology roadmapping, technology assessment,
and impact assessment. Secondly, some decentralized foresight studies have been
undertaken at the sectoral levels. These foresight initiatives have been lead by agencies
such as the US Environmental Protection Agency, the Department of Defense, and the
Department of Energy. Thirdly, although there have been some foresight-like efforts in
identifying critical technologies during the 1990s [93], there are so far no comprehensive
national level foresight studies in the United States, and it is unlikely there will be any in
the near future. There is no growing interest for national foresight from the Federal
government. The United States relies more on the market mechanism to establish
priorities and allocate resources [92].
National technology foresight studies in Japan are typically based on large-scale
Delphi surveys addressed to experts in a wide range of fields. The foresight studies have
been repeated approximately every five years since 1971. During this long time span, the
scope of work and the range of methods applied have also expanded [94]. The first
Delphi study took three rounds, but the Delphi studies of following years only took two
rounds. The fifth, sixth, and seventh surveys started to address socio-economic needs
regarding Japan’s future. The eighth Delphi Survey was conducted in 2004. It addressed
a 30-year period from 2006 to 2035. Although the study was still based on Delphi, some
other methods were added for improvement. These new tools include: Bibliometrics,
Scenario analysis, Socio-economic needs analysis, cluster analysis, and AHP. The eighth
survey consisted of 13 fields, 130 areas, 858 topics, and about 2300 participant experts,
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most of which are researchers, engineers, public and business executives [95]. Some key
questions include: the importance of technology, time of realization, leading countries,
and necessity of government measures. As a country with extremely scarce resources,
Japan continued its foresight activity for forty years and observed that it was an effective
tool for future development [94]. Although the Delphi methodology was imported from
the United States, it has been adapted and improved to suit Japan’s circumstances.
Technology foresight is useful in setting stable framework conditions for technology
development and improving engagement with policy-making in Japan [94].

2.3.2 Generations of Technology Foresight
The evolution of foresight activities has been significant since the 1990s. It was
applied to various environmental settings which included the organizational, industrial,
regional, national, or supranational level. Foresight scopes covered everything from
limited technical experiments to major government initiatives. The timescale of foresight
ranges from the immediate future to the far horizon. The range of actors involved, the
process and methods used, and even the status of the activity varies considerably [96].
Scholars developed diverse foresight models to reflect the increasing changes.
Johnston proposed five stages in the chronology of foresight, with technology forecasting
and futurism leading to technology foresight, from which emerged foresight, with its
wider understanding of the economic and social processes that shape technology [97, 98].
The author explored the strong progression within foresight studies towards being
embedded within and directed towards planning and decision-making processes at
various levels. Georghiou progressively posited a generational model of foresight in the
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last few years (Figure 6) [99-101]. The development of the generation models has
witnessed the fast evolution of foresight studies to match with the research of innovation.
For the first generation foresight the key issues are accuracy of prediction and diffusion
of technologies. In the second generation the take-up of priorities and connections of both
industrial and academic participants become key issues, while the third generation
implies the involvement of more stakeholders and looks for broader social concerns [96].
The fourth generation foresight moves into the distributed roles in innovation systems. To
certain extent, the fifth generation will further touch on the complex policy issues of
globalized innovation systems.

FIRST
GENERATION
Technology
Forecasts

SECOND
GENERATION
Technology and
Markets
THIRD
GENERATION
Technology, markets
& social dimension

Continue to Exist or
Even Strengthen

FIFTH
GENERATION
Structural & broad
policy focus

FOURTH
GENERATION
Distributed Role in
Innovation System

Source: Georghiou (2001, 2003, 2006), Park (2007)

Figure 6: Generations of Technology Foresight
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2.3.3 Technology Foresight and Innovation
Martin and Johnston first argued that technology foresight wires up and strengthens
the connections within the national innovation system so that knowledge can flow more
freely among the constituent actors, and the system as a whole can become more
effective at learning and innovating [102]. Technology foresight exercise can be applied
at organizational, industrial, regional, and national levels. From a similar perspective,
comparable research on innovation systems also has a multilevel structure. Four major
types of innovation systems are studied in the literature, including National Innovation
Systems (NIS), Regional Innovation Systems (RIS), Sectoral Innovation Systems (SIS),
and Technological Innovation Systems (TIS). These innovation systems can be classified
into three levels: macro perspective (NIS), meso perspective (RIS and SIS), and micro
perspective (TIS). These innovation systems often link various national innovation
resources (universities, R&D institutes, and enterprises) toward technological outputs
(publications, patents, and new products). Figure 7 shows the connections between
technology foresight and innovation systems.

Industrial Foresight

Sectoral Innovation
System (SIS)

Regional Foresight

Regional Innovation
System (RIS)

National Foresight

National Innovation
System (NIS)

Figure 7: Connections between Technology Foresight and Innovation Systems
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Technology foresight and innovation system research should be closely integrated so
as to get a comprehensive understanding of emerging technologies and their social
impacts. Foresight should be used to build up the new social structures, especially in the
context of the more distributed and open innovation systems [96]. When governments
carry out technology foresight, they should consider the broader influences from social,
economic, and technological development. Related framework conditions have to be
evaluated: the engagement of industry, the regulations, public support, the R&D
infrastructure, the availability of personnel, etc. [103]. Both foreign and domestic
technology development trends should be considered. Various types of technologies
should also be distinguished, which include: core technology, key technology, and
generic technology. Equilibrium should be achieved for long-term technology
development and planning.
Technology foresight activities should adapt to the changes brought by globalization
of innovation resources. Environmental differences stem from country specific
characteristics such as policy risk, financial instability, and market fluctuations. Countries
of different sizes and capacities have different positions in the global innovation networks.
The necessity for international cooperation is very different in some countries. For
example, Germany has an open S&T system with exchanges of knowledge to and from
the neighbor countries, as it is a member country of the European Union benefitting from
joint R&D ventures within Europe. On the other hand, Japan’s S&T system is
traditionally isolated, and not engaged in close joint R&D with other countries [103]. In
the era of globalization and internationalization, the speed of technology development
and innovation is vital for survival. By using national boundaries, actors sharing a
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common culture, history, language, social and political institutions are identified [45].
However, science and technology systems, such as innovation systems, are becoming
more integrated across national boundaries, raising questions about how an individual
country can best benefit from the changing situations [102]. The speed of globally
synergic innovation has been accelerated by economic liberalization. The geographic
locations of global innovation cradles are getting more dispersive than ever before. These
issues have raised new topics in the research of technology foresight.

2.3.4 Technology Foresight in Emerging Economies
National foresight studies are expanding from the industrialized economies to the
developing countries in recent years. However, foresight activities and related social
impacts in emerging economies have not been studied much in the literature, especially
as a group of countries with similar characteristics. A common feature in these countries
is the proliferation of new institutions and innovation systems resulting from transitional
economies. This section will focus on the characteristics of national technology foresight
activities in the BRICs, exploring the roles of foresight in technology development.
Common problems and challenges will be discussed.

2.3.4.1 Foresight in Brazil
Although many Western techniques have been adopted in Brazil’s foresight studies,
heavy economic and political instability of the 1980s (energy shock and recession) led to
seriously faulty (extrapolative) forecasts [104]. Some Brazilian scholars argued that the
synergy between Competitive Intelligence, Knowledge Management and Technological
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Foresight should be regarded as a new mechanism to support decision-making for
sustainable development and innovation [105, 106]. Many recent Brazilian foresight
programs have been criticized as follows:
1) The approaches by no means guarantee that the outcomes are easy to be
implemented [107].
2) There was no real evidences of the proper use of foresight results, and some
programs were discontinued without apparent reasons [108].
3) It is difficult to translate foresight findings into policy recommendations with a
long-term vision. There are suggestions that a more systemic view should have been
preferred in Brazil’s foresight research [109].
Globalization-related impacts impose the need for implementing new strategies in
the industrial and technological sectors of Brazil [110]. Foresight practices in Brazil not
only need to emphasize issues about catching up with advanced countries, but they also
need to consider issues about competing against emerging economies with similar
conditions. This pattern has been demonstrated in some recent Brazilian foresight studies
[106]. In an increasingly globalized context, the Brazilian market was opened to foreign
competition, placing more emphasis on technological innovation, quality, and
competition. However, among the many actions and issues with which Brazil needs to
deal is how to take advantage of its unique local assets that can provide competitive
advantages in the global environment [111]. Despite being the world’s eighth largest
economy, Brazil’s innovative capability is still unsatisfactory. This gap between the
generation of science and innovation is also typical of other emergent countries [112].
The country needs to construct a more efficient national innovation system with an
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operating structure integrated with the global innovation networks. Technology foresight
should play a more important role in such a process. However, as shown in the literature,
Brazilian foresight studies experienced difficulties in implementing the foresight results
or providing policy recommendations. This should be an area for future improvement.

2.3.4.2 Foresight in Russia
Foresight studies of the Russia Federation have features of a catching up economy.
Russian scholars raised the question regarding whether Russia will develop catching-up
with modernization or whether it will invent its own approach for exploring the future
[113]. The selection of critical technologies in Russia should meet several criteria:
Competitiveness, Contribution to economic growth, and overcoming dependence on
imports [87]. Russia’s development relies heavily on the exploitation of natural resources
and raw materials, including energy, agriculture, and natural mineral processing.
Although a leader in some high-tech areas, Russia still lags behind the major developed
countries.

Globalization

provides

Russia

new

opportunities

in

technological

collaborations with advanced countries. How to strengthen the global competitive
advantages of Russia is an important aspect in Russia’s policy making. Foresight reports
state that the transition of Russia’s economics to innovation development is impossible
without the formation of a globally competitive national innovation system and the
creation of legal, financial and social institutions that would ensure interactions among
the education, science, and business enterprise [86]. Although Russia has most of the
elements in its National Innovation System, they are neither efficient nor are they
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optimized to foster innovation [114]. The Russian foresight agenda for the future should
include the construction of an integrated national innovation system [115].
The “Concept for Long-Term Russian S&T Forecast till 2025” program was
developed in association with key ministries, science and business representatives in
2007. The main recommendations made to policy-makers were to develop measures to
support spin-offs and start-ups, research teams and institutes, as well as training and
education [116]. Among all the leading countries, Russia only leads in about 10% of the
technology topics. The United States leads in more than 50% of all technology topics,
followed by European Union and Japan, each with more than 30%. The results are
comparable with Russia’s innovation statistics in the last few years. As shown in Table 2
[117], only about 10% of Russian innovations are really new worldwide (in principle). It
also means that about 90% of Russia’s developed technologies already exist in other
countries.

Including
New for country New in principle

Year

Total

2000

688

569

72

12.7%

2001

637

543

44

8.1%

2002

727

606

70

11.6%

2003

821

582

56

9.6%

2004

676

569

52

9.1%

2005

637

538

60

11.2%

2006

735

642

52

8.1%

Average

703

578

58

10.0%

Table 2: New Technologies Developed in Russia
Source: Eliseeva (2010)
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Ratio

2.3.4.3 Foresight in India
The only national foresight program implemented in India is the Technology Vision
2020 foresight program between 1993 and 1996. Although the program was completed
more than 15 years ago, no such national level foresight study with comparable scale has
been conducted since then. There are some follow-up projects taking place independently,
including some regional or sectoral practices, but only in limited scale. The program
results highlighted the fact that appropriateness of technology should be the guiding
principle in India. It should be noted that what could be a critical technology for India
may not be so for other developed countries such as the U.S. [118]. The technology needs
of India ranged from strategic emerging technologies to rural development related
technologies, all of which should be cost effective to match the domestic socio-economic
needs [119]. The Home Grown Technology (HGT) program is an approach of the
government to support the development of technologies by indigenous actors. The
program supported 77 HGT projects, but was formally closed in the year 2005. Analysis
of the programs reveals some shortcomings [120]: lack of funding for large projects,
inadequate scale of operation, poor assessment of technology operations, lack of
technically skilled manpower, and technology shifts which led to low market potential.
The theme of technology programs in India has strong characteristics of catching-up
toward the developed countries. This conforms with government’s goal which aims at
increasing technological competitiveness and self-reliance, especially in high-tech areas
[121]. India has suffered from the technology-control regimes of advanced nations.
Developing indigenous capabilities for self-reliance in critical technology areas where
denials of technology transfers by advanced countries are India’s strategic priorities [122].
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However, developing indigenous technologies may encounter enormous difficulties if the
domestic innovative capacities are not ready or cannot provide enough support for
innovation. Therefore, the country’s innovation infrastructure will need to be crafted with
due foresight and careful planning. With a new context of globalization and interdependence, an integrated approach to strategic technology planning will be essential to
developing the requisite capabilities for the future [122]. This calls for a new generation
of technology foresight in India.

2.3.4.4 Foresight in China
The technology foresight concept was introduced into China in the 1990s, but there
was no formal foresight initiative in China until 2001, when two regional foresight
studies were initiated in Beijing and Shanghai respectively. The Technology Foresight
Towards 2020 program was a national-level practice led by the Chinese Academy of
Sciences (CAS) from 2003 to 2006. The research consisted of two stages, and each stage
covered 4 different high-tech fields [123]. A total of 8 fields, 62 sub-fields, and 737
technology topics were studied. The foresight methodology was based on expert panels,
scenario analysis, and the Delphi method. Scenarios were designed for achieving a broadbased medium-level wealth society. Expert panel meetings played an important role in
the selection of technology topics. During the Delphi survey, more than 1500 experts
from selected areas responded to the questionnaires [124]. The methodologies of
technology foresight in China are based on adapting practices from developed countries,
including Japan, Germany, UK, and Korea. The foresight results showed that resource
allocation is the most important issue to be faced by the government. The findings
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highlight some potential improvement areas for policy-makers. For instance, under the
criteria “Difficulty of Realization”, the results reveal some constraints on the technology
development: 1) regulation, policy, and standards, 2) human resources, 3) research
funding, and 4) basic research infrastructure, etc.
There are some interesting investigations in the survey about China’s current
technological level compared with leading countries. When comparing the 483
technology topics with advanced countries, China is leading in only one topic, which is
the “Chinese character & information processing technology.” Since Western developed
countries do not use Chinese characters, it is obvious that China can become the absolute
leader in this field. For other high-tech areas, China has 20 technologies (less than 5%)
on a par with international leading standards. Most technology fields (more than 90%) are
lagging behind for 5 years or more (Table 3) [125].

Technology Fields

China
Leading

China on a par China Lagging China Lagging
with Leader
5 Years
6-10 Years

Information and
communications
Biotech and life science

1

5

66

3

0

7

76

0

New materials

0

6

49

9

Energy

0

2

81

0

Resources and environment

0

0

99

1

Advanced manufacturing

0

0

52

26

Total

1

20

423

39

Table 3: China’s Technological Level Compared with Other Countries
Source: MOST (2004)

Foresight revealed that China’s technology level is lagging behind advanced
Western countries. Table 4 shows the results of technology leading countries [123]. The
USA leads in all technology fields, followed by Japan and the European Union. Russia
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ranked fourth, and other countries are barely perceived as technology leaders. One
exception is South Africa, which leads in the energy sector for a certain type of coal and
petroleum processing technology.
USA
1st 2nd

Japan
1st 2nd

EU
2nd

Russia
1st 2nd

Others
1st 2nd

Field

No. of
Topics

Information,
Communications and
Electronics

150

150

0

1

97

0

56

0

0

0

0

Energy Technology

72

50

17

5

17

15

38

2

1

1

0

Materials S&T

86

73

11

12

68

2

6

0

1

0

0

Bio-tech & Medicine

101

94

7

6

23

1

74

0

0

0

0

90

79

10

8

48

4

34

0

0

0

0

82

64

13

7

17

14

52

1

2

0

0

78

72

4

4

24

3

51

0

0

0

0

Space Technology

78

76

2

0

0

0

50

2

26

0

0

Total

737

658

64

43

294

39

361

5

30

1

0

Advanced
Manufacturing
Resources &
Environment
Chemistry &
Chemical Tech

1st

Table 4: Technology Leading Countries
Source: CAS (2006)

2.3.5 Common Challenges of Foresight in Emerging Economies
Catching-up is the main theme of technology development in emerging economies.
As we can see from the above comparative analysis, technology levels in BRIC are
generally lagging behind world leading standards. Therefore, identifying critical
technology areas that are suitable for leapfrogging is a primary concern. Since these
countries differ in terms of historic evolution, economic development, technology
capacity, and other social factors, technology foresight activities have to consider local
needs, capabilities, and social differences. For example, an Indian scholar argued that
critical technologies in India may not be that critical for the United States [118].
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Appropriate technologies suitable for breakthrough development should be selected and
prioritized accordingly. Since no country, however rich, can afford to pursue all the
possible opportunities in science and technology, there needs to be better mechanisms for
choosing between competing alternatives and resources [102]. They should focus on
areas where comparative advantage can be achieved through technology leapfrogging.
New models and approaches should be developed to identify and take advantage of
opportunity windows, and to underpin areas of strategic research likely to yield the
greatest economic and social benefits.
Another common challenge is how to transfer foresight results into effective policy
measures and implementation strategies. The BRIC countries faced the problem of how
to implement the technology topics identified in their foresight studies. There is evidence
that in many emerging economies, after carrying out their foresight studies, the
implementation of technologies was disappointing because little effort was dedicated
toward strategic innovation management. One important reason for BRIC to rely more on
independent innovation is forced by political reasons that major developed countries have
strict export control of high technologies. The implication is that successful foresight
must include understanding of the interaction of foresight outputs with the strategic
behavior of policy and economic actors [126]. Globalization of innovation resources has
increasingly changed the culture of technology development as well as the strategic
behavior of the implementing bodies. The foresight programs have to cover both the
technology status in the world and in host country. Brazilian scholars have used the term
“gloCalization” to describe the strategy of “think globally, act locally” [105]. This idea
perfectly matches the goal of technology development today. Latecomer countries should
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try to avoid “reinventing the wheel” or remaking the mistakes of advanced countries.
This may be achieved by learning through foreign experience, and adapting to its own
situation but not by just following. Therefore, the decision on innovation strategy is an
extremely important topic in an increasingly globalized innovation environment.

2.4 Technology Policy
It is technology that builds the core competence of nations. High technology has
become the key factor in promoting regional economies and realizing sustainable
development. Strengthening technology competitiveness and enhancing innovative
capability have been the principal objectives for all countries. Government interventions
in technology development are very common worldwide nowadays. Technology policy
has the goal of making the best use of technology to achieve the national goals of
improved quality of life for all citizens, continued competitive economic growth, and
national security [127]. Through their responsibilities for social welfare and economic
development, governments have profoundly shaped the nature of innovation within and
across countries. They especially look to innovation in response to the great challenges of
the age — in energy, health, and the environment [128]. Based on findings from the
literature, this section discusses the political issues and feasible pathways for a
government to enact technological policies and for industries to foster innovation.
Different framework conditions between developed and developing countries have made
the topic more complicated to study. Here we examine government policy related to hightech industries from the perspectives of both.
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2.4.1 Technology Policy in Industrialized Countries
Governments of developed countries are increasingly concerned with the impact of
technology on their international competitiveness. The United States and other Western
countries are attempting to develop effective technology policies that are in tune with
global market realities [129]. Even though developed countries are in the frontier of
technology development, they worry greatly about technological competitiveness, and
how to maintain their competitive lead over other countries [3]. The United States now
faces more challenges from technology competitors around the world. The agencies of
the Federal government have conducted series of studies on how to strengthen national
S&T competitiveness [3]. Most developed countries invest huge amount of capital in
R&D to maintain their technological competitive edge. The U.S. introduced the
American Competitiveness Initiative (ACI) in 2006, a major policy initiative to ensure
that the United States continues to be the world's leader in S&T [130]. The ACI plans to
commit $50 billion to increase funding for R&D and $86 billion for R&D tax incentives
in ten years [131]. The target areas for these investments are high-tech industries that are
important to the U.S. economy. In the past two decades, America's research-intensive
industries:

aerospace,

chemicals,

pharmaceuticals,

communications

equipment,

computers and office equipment, scientific instruments, semiconductors, and software
have been growing at about twice the rate of the economy as a whole [132]. The
government’s support aims to sustain these achievements through continuous innovation
at the technology frontiers.
Technology policy in developed countries focuses on providing various supports for
innovations. Through technology and innovation policy, the government can guide the
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industry moving it in a preferred direction that caters to social and economic interests.
However, market failures have been noticed by economists and politicians in some high
tech industries [133]. For instance, President Obama’s innovation strategy report (2009)
has highlighted the priorities in technology policy as follows: “There are certain sectors
of exceptional national importance where the market is unlikely to produce the desirable
outcomes on its own. These include developing alternative energy sources, reducing costs
and improving lives with health IT, and manufacturing advanced vehicles. In these
industries where markets may fail on their own, government can be part of the solution”
[134]. In fact, many high-tech sectors need heavy investment and have long development
cycles that cannot be supported merely by the market mechanism. Examples of such
sectors can include: aerospace, defense, healthcare, energy, and environmental protection.
Private companies may not be able to afford long-term R&D investment for 10 to 20
years, or even longer periods. Only the government can guide and subsidize such projects
for decent paybacks in the long run. Long-term R&D is an engine for sustainable growth,
thus it is important for governmental policy to provide more support for private
companies that conduct “challenging” or “future-business oriented” R&D activities [135].

2.4.2 Technology Export Control
Uneven development is a common phenomenon of the world economy, and the
technology gap is vast among different countries. Not only do countries invest heavily to
develop new technologies, but they also apply various measures to protect their high-tech
competitive edge. The transfers of technology, including technology exports and imports,
have to strictly conform to a government’s regulations. Different countries have issued
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numerous legal terms and regulations regarding cross-border technical transactions.
These regulations are updated frequently to strengthen a government’s control of
international technology transactions. Many technology exporting countries, especially
Western developed countries, have strict limits on high-tech exports to foreign countries
to prevent technology leakage which may potentially damage national competitiveness
and other interests.
The United States has very strict and systematic control of technology exports. The
Export Administration Act (EAA) and Export Administration Regulations (EAR) build
the foundation of America’s legislation on commodity and technology exports [136].
Although it expired in 1989, the EAA is still in effect through the President’s powers
under the International Emergency Economic Powers Act (IEEPA). According to these
regulations, technology exports must be approved by the federal government through
licensing. The licenses are divided into General License and Validated License. The later
has more restrictions that will take longer to process. The Department of Commerce
maintains a Commodity Control List [137], which includes all sensitive commodity or
technologies that need special censorship. This list of sensitive exports includes
telecommunications and advanced electronic equipment, precision machine tools,
guidance technology, aerospace and jet engine technology, synthetic materials,
specialized manufacturing and testing equipment, and so forth [138]. The list contents are
frequently updated by the federal government to include newly developed technologies.
Another important aspect is the destination or end user of the export. Foreign countries
except Canada are divided into seven categories: Z, S, Y, W, Q, T, and V. Each category
represents different controls on exports. For example, countries belonging to Z category
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are under a complete embargo. According to various regulations, the United States has
restricted technology transfer to China in many high-tech areas, including information
and communications technologies (ICT), shipbuilding, aviation, space & satellite, and
nuclear power [16]. Moreover, the American Congress passed the Exon-Florio
Amendment (EFA) to the 1988 Omnibus Trade and Competitiveness Act [139]. EFA
aimed to prohibit any foreign acquisition, merger, or takeover that might impair U.S.
national security. It is certain that the concept of national security includes both
traditional foreign policy criteria and defense issues. However, it is controversial whether
economic considerations should be included. Indeed, there are inherent links among
national security, industrial security, free trade, and the free flow of capital across borders.
From the applications of EFA in recent years, it can be inferred that the term “national
security” be interpreted broadly to include economic considerations. Many cross-border
economic and technological activities are restricted by these regulations [140].

2.4.3 Technology Policy in Emerging Economies
While the developed nations try to maintain their technology advantage by
tightening export control measures, many industrializing countries are trying to improve
technological competitiveness and innovative capability [6]. Examples of these countries
include China, India, and Brazil. The trend of globalization has significantly improved
the condition for these latecomers’ catching-up process. Innovation resources are
allocated more diversely around the world. New learning channels are now available for
the emerging economies. Technological innovation can be a high risk and expensive
economic investment, but the risk and cost of learning from available technologies are far
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below that of innovation. Many industrializing countries develop policies to attract FDI
and encourage transfer of advanced technologies from abroad. These measures include:
investment grants, taxes incentives, reduced tariffs, export subsidy, education and
training. These are attractive terms for MNCs to introduce new technologies into
latecomer countries.
Rapid development and intense competition of high technology have pushed
emerging economies to develop more effective policies. Major policy considerations
include national security, economic growth, social improvement, and foreign affairs. The
success of the East Asian Tigers brought attention to the fact that most newly
industrialized countries had been very interventionist during their early development
stages. Examples of such countries include Japan, South Korea, and Taiwan. Their
governments had enacted many regulations in trade, FDI, technology transfer and
domestic resource allocation [133]. These policies often aimed at improving local
competency and weakening the reliance on foreign technologies or products. Many
countries require FDI in the form of joint ventures rather than wholly owned subsidiaries
of MNCs. In countries like Japan and South Korea, during their developing stages, when
policy gave priority to technology acquisition, MNCs were prohibited from establishing
wholly owned subsidiaries [141, 142]. Since FDI can either foster or restrain the
development of domestic industries, it is the government’s role to balance the interests of
both local and foreign stakeholders and thus guide and regulate investment. In order to
make diffusion and spillover happen, technology policy in host countries should try to
improve absorptive capability and innovative capacity.
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The concept of technology leapfrogging was brought forward from the research of
East Asia’s miracle, especially from the experience of Japan and South Korea [143, 144].
Hobday (1994) argued that a developing country may leapfrog some steps and catch up to
a developed country directly, bypassing huge investments in technological accumulation
[145]. Path dependency in technology development can assist latecomers to achieve
technology leapfrogging. The rapid development of new technologies also provided
emerging economies with “windows of opportunities” to realize the latecomer advantage.
The premise is that not only do they need to accumulate enough technology capabilities,
but they also need to select the right technological direction that fits into the global
innovation networks. Most of the windows of opportunity will emerge in high technology
fields such as nanotechnology, biotechnology, and information technology. However,
each of these fields consists of different areas, and adopting a single technology policy is
not optimal for all. Accordingly, countries should carefully adopt a set of technology
policies so that each policy is aimed at addressing the specific requirements of a specific
high-tech category [146]. Technology development can be viewed as a vibrant process
where innovations are driven by investment, market, and policies. Since the government
has the control of resources, it can provide support to guide development in key
technology areas. Macro policies can also impact on the efficiency of innovation systems.
The best use of policy instruments can protect the interests of stakeholders, and promote
their innovation activities.
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2.4.4 Policy Instruments for Innovation
The search for effective policy instruments to foster innovation has long been a task
for decision makers and researchers in technology management. Here we review the
major types of policy tools. These research findings will provide the foundations for
future result analysis and recommendations in policy making.
Innovation policies have been studied from different perspectives, and scholars have
established categories that include: direct funding, indirect support, and information and
learning [147]. As presented in Table 5 [147], the 3 major areas include 15 policy tools.
Firstly, the direct funding part is primarily to identify appropriate actors in the innovation
system, and provide them with R&D contracts or funding. Secondly, the indirect support
part provides the innovators with more benefits in terms of credits and services. Thirdly,
the information and learning part emphasizes the general industrial support measures. In
addition to these three major aspects, the author also mentioned that macro conditions
may influence innovation. These factors are commonly categorized into framework
conditions.
Through studying policy practices applied in 25 member countries of the EU, Reid
and Peter (2008) explored the sectoral differences of innovation policies [148]. The
authors gathered hundreds of innovation-related policy measures from 11 different
sectors. There are clearly sectors with an above average number of innovation policy
measures such as biotechnology (129), ICT (128), and energy (117). Some other sectors
have fewer measures, such as machinery (94) and textiles (96). An implication from this
study is that each sector has a different innovation structure and patterns. Most of these
policy instruments are geared to support various actors in each specific sector.
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Categories
Direct Funding

Indirect Support

Information and
Learning

Policy tools





R&D contracts with private firms
R&D contracts and grants with universities.
Intramural R&D conducted in government laboratories.
R&D contracts with consortia that include two or more actors.

 Patent protection.
 R&D tax credits.
 Tax credits or production subsidies for firms bringing new
technologies to market.
 Tax credits or rebates for purchasers of new technologies.
 Government procurement.
 Demonstration projects.






Education and training
Codification and diffusion of technical knowledge
Technical standards-setting.
Technology and/or industrial extension services.
Publicity, persuasion, consumer information
Table 5: Policies for Innovation
Source: Reid and Peter (2008)

As governments’ goals and expectations toward technological innovation may vary
from country to country and from sector to sector, different sets of policy tools or
instruments will be developed to support various actors. It is understandable that each
country has a unique framework context due to social, economic, and technological
differences. These variations should be considered when developing innovation policies.
Since this model will take China as a case study, framework conditions or limitations in
China will be discussed in later chapter sections.

2.4.5 Implications for Priority Setting on Technology Policy
The necessity of priority setting in technology policy design cannot be
overemphasized. The rapid development of high technology has made stable technology
policy a difficult task in every country. The ever changing environment of world politics
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and economies has further complicated the uncertainties in policy-making. Like many
other public policy measures in society, technology policy is selective in nature. It is not
uncommon that various funding and benefits are given to inappropriate innovators that
cannot meet the government’s original plan as they were expected. Therefore, it is
necessary to study the causal factors and intrinsic relationship of policy issues involved.
Scholars define national technology strategy as a portfolio of desired related technology
areas that receive governmental supports in the form of specialized goals for each branch
of technology. This strategy assigns well-defined tasks and responsibilities to the
pertinent innovators that are responsible for implementing the goals for each technology
areas [146]. The authors argue that prioritization should be emphasized in the policymaking process. Technology policy has the goal of directing technology development and
innovation through leveraging limited resources. In both the short-term and long-term,
policy should be prioritized so as to guide various innovators in their innovation process
and maximize their innovative outputs.

2.5 Technology Development in China
Technology development and policy in China has been a topic of wide concern
worldwide. As the largest technology importer in the world, China generates many
business opportunities and attracts a lot of investments from developed countries. The
lucrative Chinese market is a focal interest globally not only because of its growing rate
and size, but also due to its increasing involvement and influence in the world economy.
Policy measures in China can typically represent the interests of many other emerging
economies such as Brazil and India. It is meaningful for other countries to better
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understand similar issues and enact effective technology policies. As a developing
country, the establishment of technology policy in China has been lagging behind the
developed world. This section identifies some of the challenges and problems in China’s
innovation systems and related policy issues.

2.5.1 National Technology Programs in China
Since China’s political regime still carries many characteristics of a planned
economy, technology policies are often implemented along with national level
technology programs. This section will summarize some important national technology
programs introduced by the central government since the 1980s. Most of these programs
served to give direction for S&T research, which focuses on the development of hightech industries, technology transfer, and acquisition. Through studying the objectives of
these technology programs, we can further identify the trends of technology policies in
China.
The National Key R&D Program (1982) aimed to modernize traditional industries,
upgrade industrial structures, and enhance high-tech industries. The contents of this
program were to analyze international trends of S&T development, and carry out research
on key S&T issues in China. The Program was fully funded by the central government,
and was meant to concentrate the nation's resources to tackle major S&T issues [149].
The 863 High-tech Program (1986) was the most prominent national technology
program in the last century. The title of the program means that it was initiated in March
1986. This program was formulated to focus on most high-tech areas for the 21st century.
It covered biotechnology, information, automation, energy, advanced materials, space,
62

laser, and marine technology. The program’s objective was to develop high-tech
industries for China’s mid- and long-term economic and social development.[149] [150]
[151]
The Torch Program (1988) was initiated by the Ministry of S&T as a guidance
program for technological development. It provided support for establishing research
facilities, encouraging foreign high-tech investment, and fostering the development of
domestic high-tech companies in special zones throughout China. With this program, the
central government selected and funded research programs with high market potential
and commercialization prospects [152]. This program highlighted the national policy of
reforms and opening to the world.
The S&T Achievements Spreading Program (1990) was an important technology
program aimed at bridging the gaps among different regions across China. The purpose
was to apply and realize technological achievements to the development of rural areas in
China. Technology transfer and diffusion activities from advanced coastal areas to
backward inland provinces were written as national strategy [149].
The S&T Innovation Strategic Action Plan (2001) was launched in the new century,
and it signifies that the objectives of technology programs are changing to focus on
innovation. The program consisted of several subordinate plans, mostly in basic research,
including life sciences, biotechnology, alternative energy, and environmental protection.
It included many projects that were dedicated to the establishment of infrastructure and
supporting facilities in these areas [153].
National Medium- to Long-Term Plan for S&T Development (2006-2020). In
January 2006, the Chinese National Council convened the first S&T conference of the
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new century in Beijing. During this conference, Chairman Hu, Jintao proposed the
strategic objective of constructing China into an innovative country within 15 years (by
the year 2020) [154]. The goal was written into the plan as a long-term policy, which
implies that China is resolute to boost its technology level to match that of developed
countries. The core of this program is to promote China's innovation capability and to
rely more on domestic research and development. The plan emphasizes raising
innovation capabilities to generate original invention through basic research [153].

2.5.2 Landscape of Innovation in China
By reviewing China’s national technology programs, we can identify that the main
theme of its policy on technology development has been switching toward innovation,
but how can the Chinese NIS operate effectively? It depends on the strengths of various
innovators or technology implementers. Technology policies need to consider and
address the many issues faced by stakeholders and actors. Through reviewing recent
literature, this section examines the unique characteristics of each participant or innovator
in the innovation system. The situation in China is more complicated than many other
developing countries due to its legacy of a central planned economy. The analysis will
focus on issues faced by some key actors in China’s evolving innovation systems. The
following table presents recent literature (2006-2011) on technology development and
innovation in China (Table 6). The stakeholders and innovators being examined in these
studies have been identified and listed. Analysis will be followed to discuss major
barriers and obstacles faced by each of these identified stakeholders.
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Author
J. Wu and N.
Pangarkar [155]
P. Fan [156]

W. S. Siu et al.
[157]

Year Innovators
Studied
2006 MNCs,
SMEs,
SOEs
2006 SOEs

2006 SMEs

X. D. Chen and G. 2006 MNCs
Reger [158]

J. Duanmu, F. M.
Fai [159]

2007 MNCs,
SMEs

Xiaohui Liu,
2007 FR&D,
Trevor Buck [160]
MNCs
Xudong Gao, et
al. [32]

2007 MNCs,
SMEs,
SOEs

K. Motohashi and 2007 SOEs,
X. Yun [161]
SMEs,
PRIs,
University
G. Hutschenreiter 2007 SOEs,
and G. Zhang
PRIs
[154]

K. Chen and M.
Kenney [162]

2007 PRIs,
University

Xiaohui Liu,
Huan Zou [163]

2008 FR&D

K. Fisher-Vanden, 2008 SOEs
G.H. Jefferson
[164]
J. Zheng et al.
[165]

2008 SOEs

W. Hong [166]

2008 University

Brief Summary
Explores how domestic firms in emerging markets can
counter the threat posed by the entry of MNCs. Performance
levels depend on the strategy adopted by the firm
Domestic firms should focus on in-house R&D development
to build their innovation capability, supplemented with
external alliances.
Examines the interplay of government intervention,
manufacturing systems and business approaches and impacts
upon the new product development of SMEs in China.
The motives for German FDI are long-term based and marketoriented, which can be characterized through seeking new
markets and enlarging market shares. Technology transfer is
mainly dedicated to production and managerial facilities.
Investigates vertical knowledge transfers from inwardinvested multinational enterprises to indigenous Chinese
suppliers
Foreign R&D activities by multinational enterprises in a host
country significantly affect the innovation performance of
domestic firms
Development of strong manufacturing capabilities may not be
an effective strategy for domestic firms competing against
MNEs. The way to go is developing innovation capabilities
and core technologies.
Chinese manufacturing firms still possess only a low level of
technological capability. Collaboration with PRIs and
universities needs to be promoted.
Technology imports, and international technology transfer
will continue to play important roles in China’s development,
but the country needs to continue investing in R&D and
education and to overcome the institutional and structural
weaknesses
Explores the role of URIs in the development of the Chinese
economy through the comparison of developments of regional
technology clusters
Foreign R&D activities by MNCs in China significantly affect
the innovation in domestic firms and there exist both intraindustry and inter-industry spillovers
Explores different purposes of internal R&D and Technology
imports. Chinese firms simultaneously expend resources on
disparate forms of technical change that embody different
factor biases.
China's reform measures often resulted in one-time level
effects on productivity, but further institutional reforms are
required to consolidate China’s move to a full-fledged market
economy
Examines university–industry collaborations in China, and
shows a decentralizing / localizing trend in knowledge flow.
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S. Girma and Y.
D. Gong [167]

2008 SOEs,
MNCs

J. Y. Kim and L.
Y. Zhang [168]

2008 SOEs,
MNCs

K. Asakawa and
A. Som [169]

2008 FR&D,
MNCs

S. Girma and Y.
D. Gong [170]

2008 SOEs

K. Kiyota et al.
[171]

2008 MNCs,
CMOs

Reforming the largely inefficient SOEs presents a major
challenge. Limited regional linkages and low level of
absorptive capacity are found to be the main reasons for the
disappointing performance.
This paper investigates the clustering of Chinese electronics
manufacturers with foreign producers. It analyzes how
MNCs’ collaboration with local firms fosters local economic
development.
Compares the MNCs in managing their R&D in China and
India. The paper supports the trend that more innovation is
required by firms and managers to strategize their R&D
investments in China.
Competition from sectoral FDI has a deleterious impact on
the growth and survival probability of SOEs.

Examines the determinants of the backward vertical linkages
of Japanese foreign affiliates in manufacturing, focusing on
the local backward linkages, or local procurement in China.
L. G. Ying [172] 2008 FR&D,
The Chinese R&D productivity growth depends on the
CROs
simultaneous expansion of the domestic and foreign
knowledge stock in China. It largely depends on spillovers of
the pioneer R&D.
H. Kroll and I.
2008 University, Spin-offs have been proven to be appropriate solutions for
Liefner [173]
SMEs
technology transfer at Chinese universities, but many of the
companies still suffer from defective incentive structures and
lack of performance.
Y. Zhou [174]
2008 MNCs,
Examines how the synergy between China’s domestic market
CMOs
and the international market has affected its most competitive
indigenous companies.
G. Bin [175]
2008 FR&D,
Investigates the contributions of four technology acquisition
MNCs
channels including: in-house R&D, foreign technology
transfer, domestic technology transfer, and inter-industry
R&D spillover.
S. Girma, et al.
2009 MNCs,
Inward FDI at the sector level has a negative effect on
[176]
SOEs
innovative activity in SOEs on average, but there is a positive
effect of FDI on SOEs that export, invest in human capital, or
undertake R&D.
Dong Chen, et al. 2009 MNCs
As emerging markets develop, foreign firms are being viewed
[177]
less and less as providers of capital and/or technology, and
more as integral parts of society
K. S. Swan, B. B. 2009 MNCs
The relationship between a perceived influence of China on
Allred [178]
technology strategy and MNC subsidiary process technology
sourcing strategy is moderated by the innovation context
F. Hatani [179]
2009 MNCs
Drawing on the global value chain analysis and institutional
views, MNCs inhibit technology spillovers even at the lower
tiers of the supply hierarchy within the emerging economy
context.
J. C. Guan, et al.
2009 SOEs,
Innovation activities of Chinese firms were mainly directed at
[180]
SMEs.
quality improvement. SMEs that obtain support from the
government generally perform better.
J. Fan, et al. [181] 2009 MNCs
China’s FDI inflow is inefficiently large because weak
institutions deter domestic investment while special initiatives
that attract FDI are thus either unsupported or not unique to
China.
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C. Huang and N.
Sharif [182]

2009 SMEs

Brandt and Thun
[183]

2010 MNCs,
SOEs,
SMEs.

Kroll and Schiller
[184]

2010 PRIs

Lu, Tao, and
Yang [185]

2010 SOEs

Motohashi and
Yuan [186]

2010 MNCs

Tian [187]

2010 MNCs

Tang and Hussler
[84]

Fu and Gong [25]

2011 SOEs,
SMEs,
PRIs,
University
2011 FR&D

Koichiro Kimura
[188]

2011 SOEs,
SMEs

Foreign-funded companies were less active than Guangdong
domestic companies in pursuing research and development
(R&D) and innovation activities.
Industrial upgrading efforts are often domestically driven,
intense competition exists between both domestic and foreign
firms, which stimulates the upgrading efforts of domestic
firms
Domestic firms continue to depend more on foreign
technology transfer than domestic technologies. PRIs will
depend on improved management and a new funding system.
Local governments can help SOEs gain access to cheaper
production inputs, but these enterprises may be used to pursue
private benefits for officials
MNCs have vertical spillovers to Chinese firms. In some
industries, only a small amount of vertical spillover effects are
found. Horizontal spillovers do not exist in both.
MNCs can manage technology spillovers through selection of
entry modes, selection of technologies, and selection of
investment priorities in the affiliates they establish in China.
The Chinese NIS should be reconsidered and designed to
improve the absorption and innovation capability of domestic
firms and to strengthen their interactions.
Although foreign investment appears to contribute to static
industry capabilities, foreign R&D activities have exerted a
significant negative effect on the technical change of Chinese
firms.
The Chinese firms need to strategically choose between
“make or buy” decisions when they face technology gaps
against foreign firms.

Table 6: Journal Articles on Technology Innovation in China

2.5.2.1 Higher Education Institutions
Higher Education Institutions (HEIs) have long been key players in technology
development and innovation activities. HEIs were seen as having two tasks — to train
high-level qualified personnel with professional skills and to develop science, technology
and culture [189]. There are more than 1000 state owned universities in China, of which
200 have been regarded as strong in research (National 211 Program). Some selected
premium universities are equipped with good research facilities and laboratories, where
students and faculties can carry out scientific research in high-tech areas. Universities
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participate in technology development through various channels, including cooperation
with industry, collaboration with governmental departments, establishment of high
technology spin-offs, and academic communication with other universities.
Although expanding at high speeds, Chinese universities still encounter many
obstacles hindering their development in recent years. First of all, the central government
is not able to provide enough funding for all. Most Chinese universities suffer from
budget constraints, and many of the universities have to seek funding or even try to make
a profit by themselves. Secondly, the academic programs are not designed toward longterm national goals. Programs in basic research give way to commercially related streams
such as business and computer applications. Thirdly, only a very few Chinese universities
have state-of-the-art equipment; therefore, R&D activities in many universities are below
standard. Fourthly, Chinese universities experience difficulties in recruiting competent
faculties. More graduates choose to work in industry, especially for foreign companies,
where the salaries are higher. Most elite graduates seek opportunities to go abroad, either
furthering their studies or careers. Last but not least, the performance evaluation system,
distribution of benefits, and protection of IPR are also notable issues in Chinese
universities [166] [173].

2.5.2.2 Public Research Institutes
Public research institutes (PRIs) are major sources of technological innovation in
China. Their mission is mainly to serve the ministerial departments and enterprises within
their industry. Due to the legacy of the centrally planned structure, technological R&D
activities in these institutes were managed by vertical administration from the
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government departments. However, in recent years, research institutes are encouraged to
work with the industry, undertake research projects from other sources, and make profits
from the outcomes of their research. Research institutes have gained more autonomy or
have become completely independent of the government. These institutes decide which
research projects to pursue and how to raise funds for projects and salaries [189].
The original purpose of these reforms was to alleviate the funding burden of the
central government. However, such technology policies have brought negative impacts to
the balanced growth of PRIs. To a certain extent, the S&T system reform is intrinsically
prioritized for commercialization, which has weakened the development of basic research
and public-benefit-oriented research [162]. Those applied-oriented research institutes
have gained the most benefit from the reform, whereas those involved in basic research
cannot easily obtain enough funding, neither can they attract or recruit enough top-level
researchers. The situation is similar to the problems encountered by the Chinese
universities. More importantly, the supply of public-benefit-oriented research has been
insufficient to meet the basic demand of the nation. For example, the SARS scare in 2003
exposed the weakness of the public health system to defend the nation against serious
diseases [149]. Many challenges remain with regard to how to improve the efficiency of
PRIs and, more strategically, as to what role the they should play in China’s emerging
enterprise-centered innovation system [154].

2.5.2.3 State-owned Enterprises
State-owned enterprises (SOEs) are medium- to large-sized companies left by the
centrally planned system, and they are referred as "the eldest sons of China.” These
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enterprises used to enjoy preferential treatment in terms of policy and resource allocation
through government planning [180]. In recent economic reforms, some SOEs have been
transformed into other categories of ownership such as shareholding enterprises, limited
liability firms, and privatized SOEs. Except for the last category, the privatized SOEs, the
government still maintains the majority share control of companies in the other two
categories. The corporate governance mechanism in these companies is quite different
from other types of companies. Top executives have to be appointed by the government
and their experiences in these companies are continual building blocks of their political
careers. As a result, these managers tend to focus on short-term economic performance
rather than risky long-term strategic investment in R&D [167].
Funding and allocation of resources for thousands of SOEs across the country have
long been an important concern for the Chinese government. The above mentioned
economic reforms in recent years were to reduce such expenses and to increase revenues.
However, SOEs’ performances did not improve as much as expected, and they began to
face more challenges under new conditions. There is a large spread in returns between the
performance of the small number of state firms that do well and the bulk of them that do
very poorly [165]. According to OECD (2008) reports, Chinese SOEs still record much
lower levels of productivity than other firms, often appear to be less efficient knowledge
producers and often lack the basis for R&D [190]. Scholars found that while R&D
activities are more concentrated among SOEs, these enterprises are not efficient in
knowledge production [191]. More recently, many SOEs have lost their previous
monopolistic advantages due to economic reforms. Although SOEs continue to enjoy
some priority of access to resources, their statuses are much weakened to a lower level.
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Another concern is about the property ownership of SOEs, especially on the issue of
infringing state assets caused by privatization. To sustain the transition process, the
central government has been forced to pay more attention to developing S&T policy that
fits the strategic orientations of different forms of enterprises, particularly those of SOEs
[180].

2.5.2.4 Small- to Medium-sized Enterprises
China’s economic reform in the last thirty years has resulted in the rapid expansion
of the private sector. Small- to Medium-sized Enterprises (SMEs), which mostly consist
of new ventures, have played a significant role and have largely contributed to industrial
development. The growth of privately-owned SMEs also signaled that the Chinese NIS
are transforming to a market-oriented economy. Many high-tech SMEs are emerging
firms specializing in niche areas of some sub-sectors. They aim to profit by achieving
competitive advantage in these market segments. SMEs usually favor more on market
value than advanced level of technology. Therefore, their R&D activities are more likely
to be targeted toward problem-solving rather than long-term basic research.
Although growing at high speed, the Chinese SMEs have faced many obstacles in
recent years. Waves of SME bankruptcies have trickled out of China during the recent
global economic recession. Growing financial troubles among high-tech SMEs pose an
immediate challenge to China’s technology policy. SMEs have not only encountered
difficulties of limited financing channels, but have also experience excessive increases in
raw material prices and labor costs. According to OECD (2008) reports, China’s financial
system does not meet the funding needs of private firms, notably SMEs. The capital
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market is underdeveloped and SMEs find it difficult to secure loans since banks favor
large companies, particularly SOEs. Smaller, privately owned firms thus largely depend
on self-funding [190]. Moreover, some policies focused on SOEs have at the same time
crowded out support to non-state owned companies even though they hold a large
potential [154]. Export oriented SMEs face a series of problems, including: appreciation
of the Yuan, shrinking foreign demands, surging costs of raw materials, and competition
looming from other developing countries. Many other factors such as increased interest
rates and heavy taxes are adding up to deteriorate the survival environment for SMEs. In
order to support the development of SMEs, the government needs to increase financing
and resolve the unfavorable conditions.

2.5.2.5 Joint Ventures and MNCs
Equity joint ventures (EJVs) are cooperation between the foreign MNCs and
domestic companies. EJVs have been a preferred mode for the Chinese central
government to acquire and introduce high technology from abroad. The policy of
“trading domestic market for foreign technologies” has been adopted since the 1980s and
the government expects foreign investors to transfer technologies when they work
together with domestic partners. Many MNCs who invested in China chose to form joint
ventures with Chinese partners. Two external factors appeared to be the major
determinants of this choice which are environment factors and the market factors. JVs
would be preferred for the MNCs when they are not familiar with the environmental of
the host country. The domestic partner can provide them the knowledge in dealing with
customers and local officials. For many Western firms, China offers the attraction of a
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large domestic market for capital goods, intermediate products, and final goods and
services. To others China may hold the promise of becoming a low-cost production base
from which it could eventually serve not only the domestic market, but also the global
market [14].
In recent years, EJVs in China have met bottlenecks for further development.
Although China’s entry into the WTO has reinforced foreign direct investment (FDI),
these FDIs tend to favor low-tech industries that extract more resources from China [155].
The quality of enterprise level cooperation and related international technology transfer is
at a relatively low level, and high-tech components are barely transferred. As a result,
technological innovation only improved in several limited industries, and S&T
achievements in many high-tech areas still grow at very slow rate. Another concern is
that the MNCs are switching away from choosing EJVs as an entry mode. The Wholly
Foreign Owned Enterprise (WFOE) is a more prevalent set-up among many foreign
companies [168]. It is generally accepted that such a governance mode can ensure MNCs
to withhold knowledge leakage and protect the technology edge. An additional reason for
the phenomenon is that the Chinese government did not provide better policy support for
EJVs over WFOEs. In order to sustain MNCs’ contribution to domestic innovation,
policy design should induce foreign investors toward target high-tech areas, and
introduce technologies with internationally accepted quality standards. The government
should offer favorable policy measures such as land, subsidy, taxation, and industry-level
education and training.
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2.5.2.6 Foreign R&D Centers
A growing number of Western and Japanese firms have been launching their R&D
operations in China [169]. This has no doubt brought China a new channel of
international technology transfer [160]. On the one hand, some companies have
established foreign owned in-house R&D facilities in China. On the other hand, many
companies have setup virtual R&D networks, building partnerships with domestic
companies and research institutes, as well as universities to conduct research. A wholly
owned in-house R&D center in China can recruit and train high quality employees. It also
helps the foreign side to have better control over the research process, as well as their
investment [163]. A virtual network is a good choice for firms to reduce risks and costs.
Risk sharing occurs when separate entities invest in a common risky endeavor. Through
cooperation with other firms, each entity pays only a fraction of the investment. This
allows research to be done more efficiently. It expands a company’s capacity, increases
flexibility, and reduces fixed infrastructure. R&D contributions are not limited only to
China, but are also expandable to other countries, or even globally.
A notable problem is that there are more “D” activities than “R” activities in the
foreign R&D centers. In many cases explored by available research, “development” is a
dominant part of R&D in China. Part of the reason is that foreign investors tend to focus
on the development of technologies that are immediately applicable to the Chinese
market, while neglecting long-term basic research. Although many of the investigated
foreign investors expressed a wish to expand the “research” part, including knowledge
transfer, they have so far been reluctant to do so, because they see serious problems in
China [31]. Some of the common issues include lack of quality local researchers, weak
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IPR protection, and a lack of policy support. Firstly, many companies try to expand their
R&D activities through cooperation with local universities, which can have a strong
bearing on recruiting prospective graduates and qualified talents [175]. Secondly, some
investors considered the R&D facilities as being very sensitive in terms of maintaining
and increasing competitive advantage [169]. As long as the IPR issues still exist in China,
foreign companies tend to keep their core R&D in headquarters or split up their R&D
activities among various units to reduce risks of losing core knowledge and technology
[31]. Thirdly, since different actors are competing for resources, policies are not geared to
support foreign R&D centers. For example, many restrictions and regulations apply to
foreign research in China, ranging from resource exploration to exploitation. Summarily,
if the Chinese government were to better utilize foreign R&D centers as innovation
instrument, policy measures need to be enhanced to guide and support their growth.

2.5.3 Framework Conditions for Innovation
Due to the differences in social, economic, and technological development, each
country has different framework conditions for innovation. These include various
institutional limitations to be considered in policy making. Since this research will take
China as a case study, it is necessary to discuss related constraints in China’s innovation
environment. China is shifting from a central-planned system to a “socialist market
economy”, and its NIS is undergoing a transitional process. Innovation policy should
consider lifting or mitigating various limitations to improve the conditions for innovation.
The legacy of the central-planned economy has left China with a relatively stronger
state-owned enterprise system but a weaker private sector. According to a statistical
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report in 2010, the revenue of the top 500 private Chinese companies combined cannot
win over that of the top two state-owned companies [192]. SOEs are still holding a
favored position of technology development in China. Private-owned SMEs are in an
inferior position in market competition as well as R&D activities. Due to intense market
competition, domestic companies tend to focus on short-term revenue and financial
performance. In general, the ratio of R&D investments to sales revenue of domestic
enterprises is much lower than that of multinational companies. Domestic companies
favor acquiring and transferring technologies that lead to easily replicated fields. This
situation may lead to market failure in domestic industries, such as China’s automotive
sector. After opening up for more than 30 years, China is still heavily relying on imported
automobiles and parts. Considering the fact that neighboring countries such as Japan and
South Korea had successfully established their automotive industries in only 20 years, the
Chinese policy makers should reconsider their strategies in technology development.
Government intervention and regulatory changes should be adjusted to promote business
R&D and innovation.
The distinctive Chinese R&D system is another critical issue in promoting
innovative capability. Universities and research institutes are still under direct control of
the government. Ideology issues and bureaucracy are still prevalent and have deterred the
improvement of innovation conditions. For example, students are forced to take multiple
courses in Socialism and Marxism. All universities and research institutes are required to
have a Party Committee, and its members have to be included in the administrative and
management levels. Such a management structure deeply interferes with teaching and
academic research. Due to a better research environment and less control, as well as
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higher pay, many high quality scientists and engineers choose to work for foreign-owned
companies. Although increased investment in universities and public research institutes
can be a major solution to ease the problem, structural reforms are needed to improve
innovative conditions and lift unnecessary political barriers.
At the national level, high-tech export controls over China have to be considered in
policy decision. Technology exporting countries have various regulations to maintain
their national interests and competitive advantage. These policies prohibit advanced
technologies from being transferred across borders. The implications for U.S. foreign
policy revealed the fact: “When it comes to advanced technology, national security can
no longer be viewed in pure military terms; economic security is also a vital
consideration” [129]. Moreover, the U.S. has allied with major developed countries to
enact strict limits on technology transactions related to China. So far there are very
limited actions that the Chinese government can take, except through formal foreign
policy negotiations or lobbying activities. Although China has been isolated from the
Western world for many decades, it becomes very necessary for the country to improve
international relationships in the background of globalization.
At the enterprise level, multinational companies have common concerns about
intellectual capital protection issues, which constrain their willingness to bring new
technologies into China. Without appropriate IPR protection, MNCs may take the risk of
losing competitive advantages to Chinese counterparts. It is not uncommon to see in a
joint venture when the local side learned all core technologies and then the foreign side
was kicked away. This is the reason why some MNCs are reluctant to fully transfer their
core technologies to developing countries. It is a challenge for them to balance the
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collaboration and competition with domestic companies. Much research evidence shows
that multinationals will hesitate to make investment in developing countries if their
interests are not protected. This will influence their strategies of technology transfer, and
lead to the transfer of low-tech products [193]. Research reveals that strong protection of
IPRs can promote international technology transfer and bring more FDI for late-comer
countries [194, 195]. Therefore, policy makers should consider improving the regulative
framework to protect foreign investments.
The above discussions briefly covered major institutional limitations of innovation
policy in China. Overall, policy initiatives should be designed to improve institutional
environments

through

better

regulation,

standardization,

intellectual

property

management, training of workforce, etc. [148]. The innovation efficiency of actors is
highly impacted from above by macro-level institutional factors, and from below by
micro-level technological issues. It is natural to link these influence factors with the
innovation infrastructure in the host country. As a result, it is necessary for policy makers
to identify major actors and mitigate related institutional limitations. This may provide
the actors a better environment in which to develop new technologies and thus contribute
to technological innovation in the long run.

2.5.4 Challenges of Innovation Management in China
Technological innovation in China’s high-tech sectors has been deeply influenced by
industrial policies implemented by the central government. The country has gone through
a long way to catch up with the developed world. China’s NIS is still fast evolving and
has caused much difficulty in policy-making. Although the central government has taken
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initiatives to facilitate interactions among various innovation players through many
national technology programs, policy actions concerning innovation system reforms
aimed at improving innovation performance and efficiency are still very limited. This is
mainly due the complexity of China’s innovation infrastructure as a fast transforming
economy: Tylecote (2006) argued that dual innovation systems co-exist in transitional
China [196]. One is an upper level innovation system which mimics its counterpart in
developed economies and focuses on the development of advanced technology. The other
is a lower level innovation system which has its roots in locally embedded industries. Li
(2009) suggests that during the catch-up or transition process, overall economic and
innovation performance depends largely on how China coordinates the two system levels
[197].
Despite rapid growth in the last three decades, China is still weak in many high-tech
sectors but stronger in some low-tech areas. Most domestic companies rely on overconsumption of natural resources, and specialize in labor intensive sectors. FDI tend to
favor low-tech industries that extract more resources from China. Although China’s
joining the WTO has further reinforced FDI, the market environment did not improve
much for the domestic players, as they began to face more intense competitions from all
over the world. As a result of globalization, many foreign investors have established
localized R&D facilities in China trying to benefit from cheaper resources [198] [199]
[169]. These investments have no doubt increased China’s research capacity in some
low-tech areas, but the question is how China can effectively integrate these resources to
achieve sustainable innovation. Scholars suggest that China needs to find ways to better
integrate inward FDIs into the emerging Chinese innovation system [154].Generally
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speaking, China needs to improve its technology policy through balancing foreign
technology learning and indigenous innovation [84].
As an emerging economy with transitional innovation systems, China does not have
effective innovation measurement mechanisms that can fully consider its unique macro
environmental context. A benchmarking method from the Organization for Economic
Co-operation and Development (OECD) has been adopted in the last few years. The
Chinese Ministry of Science and Technology (MOST) formally requested OECD to carry
out a review of innovation capacity in China. The review process was implemented as a
joint OECD-MOST project, which took place from 2005 to 2007 [190]. OECD sent
multiple experts and consultants to a station in China, where they guided the local
researchers to carry out related studies. From a Western perspective, the report gives
comparative analysis of the Chinese national innovation systems. The reports highlighted
some key challenges to be faced to achieve China’s ambition to base its future economic
and social progress on a stronger national innovation system. First, there are downsides to
the current growth pattern to rely on basic and large-scale production capabilities. The
country should strive to make the transition to a more innovation-driven and sustainable
growth model. Second, technology policy should serve to improve the framework
conditions for innovation. Third, the government should foster an enterprise-centered NIS.
Fourth, policy measures are needed in the repositioning and upgrading of the public R&D
system. Fifth, the government should prepare to meet the challenges and opportunities of
globalization. Lastly, the report suggested strengthening innovation governance [190]. As
we compare these OECD suggestions to literature findings, they align to each other.
Although the OECD’s report identified many problems in the Chinese NIS, there are still
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some noticeable deficiencies. Firstly, it did not give detailed solutions especially when
dealing with sector-specific issues. Secondly, the report came up with some suggestions,
but how to prioritize limited resources was left open. Thirdly, as a government (MOST)
initiative, it did not criticize or evaluate some disputed technology policies, i.e. trading of
the domestic market for foreign technology. Furthermore, the analysis on globalization of
innovation resources is not enough, and it does not come up with a new implementation
methodology.

2.5.5 Implications for Technology Policy in China
As it would be difficult to separate the national strategies of the Chinese government
from those of the Chinese enterprise, one must add as motives the economic and
industrial aims of the state that consist of foreign exchange earnings, import substitution,
creation of new jobs, and improvement of industrial productivity, quality and capacity
[14]. Given that the central government continues to exert a leaden impact on industrial
innovation, technological policies should be adjusted in a timely manner to match the
rapidly changing economic and social context.
Policy measures implemented by the central government were in a predicament in
recent years. For example, “Trading of domestic market for foreign technology” has been
a major strategy of China's technology policy to attract FDI and promote technology
development since the 1980s. In a broader sense, this policy covers all measures that
acquire foreign technology through granting foreign companies free access to the
domestic market. There have been many disputes on the outcome of this policy in China,
and the topic has aroused wide attention in academia. The main argument is, “Can
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technology be exchanged for by market share?” The rationale of this strategy assumes
that China could use the latecomer advantages to upgrade its industrial structure and
technology level. In the mean time, China can save lots of foreign exchange on
technology by just giving away some market share. However, in some high-tech
industries, the advantage of latecomers has scarcely been realized, domestic innovation
capacity makes little improvement, and the technological gap is further widened. In some
extreme cases, such as the automobile industry, domestic enterprises have even fallen
into the trap of reliance on import of core technologies. In recent years, a similar
technology policy has been applied again on technology transfer deals in the high-speed
rail industry. China introduced Electric Multiple Units technology from four different
countries (Japan, Germany, France, and Canada), but the core technologies are still
controlled by the foreign side [10]. A major difficulty is that China lacks the innovation
capacity to fully absorb foreign technologies. The government has many things to do in
order to improve the country’s innovation systems.
The government should strategically allocate both foreign and domestic innovative
resources under the new condition of globalization. Technology policies should consider
the interests of foreign investors. There are some areas in which policies and initiatives at
the national level could protect the interests of foreign firms. These include the protection
of intellectual property and trade liberalization. Swedish scholars found many
challenging aspects for the foreign companies while negotiating technology transactions
with the Chinese side [14]: The legacy of a centralized system, a poor infrastructure, a
distinct culture and foreigners’ lack of access to adequate information on the Chinese
technology. China’s entry into the WTO in 2001 marked a new era in technology
82

development. However, the WTO agreements cannot remove all the preconditions
imposed on foreign investors. For example, China did not sign under the article which
removes the requirements for transferring technology when establishing joint ventures
with domestic partners. It is likely that China will continue to impose many restrictive
conditions on foreign companies. Therefore, there is a necessity at the national level to
give better transparency in policy-making, especially regulative measures for foreign
companies. The construction of a sound regulatory framework for investment and a better
enforcement of Chinese regulations on intellectual property rights are prime examples to
solve the problems [31].
Since policy is selective in nature, prioritization and optimization of innovation
resources are very necessary. The literature has identified that a government’s
management of resources and related constraints and impetus are most important in
policy making. Since the central government has the privilege of resource allocation, it
can therefore establish regulations or offer incentives and favorable measures to promote
technology development. Scholars have introduced a conceptual framework that
addresses major determinants of technology development and transfer in China [189].
The determinants include the ideology, economic system, and constraints and impetus.
Although the authors have identified the importance of government’s management of
resources and related constraints and impetus, no prioritization strategy was made or
proposed (Figure 8) [189]. Moreover, little consideration has been given to include the
increasing influence of foreign companies, which have been argued by many studies to
have extensive impact on technology development and innovation. In order to increase
industrial innovative capacity and strengthen China’s national innovation system, policy
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should be designed to guide and support innovators that can contribute more toward
technology development.
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Figure 8: A Framework for Technology Development in China
Source: Liu and Jiang (2001)

Overall, there are still many difficulties in China’s macro policy regarding
technology development. These include ideology issues (Market System and Planned
System) as indicated in Figure 8 [189]. However, such issues will not be included in this
research because they are beyond the control of researchers or individuals. Instead, this
research will focus on how to transform resource advantage into technology edge; how to
better integrate international technology transfer toward long-term innovation. As China
gained access into the WTO in the last decade, the country faces both opportunities and
challenges resulting from globalization. To overcome various difficulties, the tasks of the
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government are to optimize its technology policy, select appropriate strategies, and
improve its domestic innovation structure.

2.6 Methodology Review
As discussed in previous sections, the impacts on technology development are
complex and multi-leveled. Therefore, methodologies from different perspectives should
be employed to carry out related research. Salo and Salmenkaita (2002) suggested that
there are synergies between three intelligence tools that serve to inform policy decisions,
i.e., technology foresight, technology assessment,

and

research technological

development program evaluation [200]. Methodologies related to these criteria will be
reviewed to study technology policy, enterprise strategy, and technology selection.

2.6.1 Foresight Methodology
Foresight and forecasting methodologies have been widely studied during the last
few decades. Literature has explored related topics from various perspectives, and
provided different threads for further research. Scholars studied technology foresight
activities in some Central European countries, and found foresight an effective tool for
the development of science and technology policy [103]. Oner and Saritas, (2005)
combined the research on national development planning with technology foresight
studies, and proposed a new model for systems analysis of technology policy in Turkey’s
five-year development plans [201]. Some other scholars studied technology foresight
activities in Brazil. They focused on methodology analysis, and the results were used to
guide government agencies to fund nanotechnology R&D to help raise competitiveness
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of the country [106]. Georghiou and Keenan (2006) argued that assessing the effects of
foresight requires an understanding of many aspects of public policy. To be effective it
needs to be tuned into the strategic behavior and cycles of policy and economic actors
[96].
The selection of technology foresight methods involves a broader knowledge of
foresight scope, objective, and criteria, all of which may vary with the actors participating
in foresight activities. Foresight is a process that involves consultative procedures to
ensure feedback to and from relevant actors. The main aspects of this process can be
summarized as 'the five Cs' : 1) concentration on the longer term; 2) coordination
between the stakeholders’ visions, intentions and actions; 3) consensus on research areas
that seem particularly promising; 4) communication; and 5) commitment to the
implementation of R&D policies [91, 200]. Since many types of methods are available
for this complex process, classification of these methods becomes an important issue.
Generally, there are three ways to categorize foresight methodologies: 1. Exploratory or
Normative methods; 2. Expert-based, Evidence-based, or Assumption-based methods;
and 3. Quantitative or Qualitative methods. The third approach is supported by Porter
(2004) and many other scholars [202]. Popper (2008) further divided the category into
Quantitative, Semi-Quantitative, and Qualitative methods (Figure 9) [203].
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Figure 9: Diamond of Foresight Methodologies
Source: Popper (2008)

Quantitative techniques are used to monitor measurable variables and apply
statistical techniques to process and analyze numerical data or indicators. Some
frequently used quantitative methods include bibliometrics, modeling and simulation, and
trend extrapolation. Qualitative methods are also frequently applied techniques in
technology foresight activities. These techniques provide interpretations to development
and observations. However, such analyses tend to be subjective and based on particular
standpoints, perspectives, and perceptions. Some widely used foresight methods include
literature review, expert panels and scenarios, all of which are qualitative. Semiquantitative methods apply mathematical principles to quantify the opinions of experts.
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Such methods include cross-impact analysis; Delphi; critical technologies; multi-criteria
analysis; quantitative scenarios; stake-holder mapping; and technology roadmapping [204]
[205].
Due to the multifaceted environmental settings and requirements, combination of
above methodologies is the trend in foresight and forecasting studies. Methods can be
combined in many different ways to create a comprehensive methodology for the
complex and lengthy foresight process. It is obvious that any methodological approach
should be sensitive to the impacts sought from foresight. Ideally, methods should be
selected and combined to achieve certain impacts [206]. In academic literature, scholars
develop methodologies through some smaller scale forecasting studies. Banuls and
Salmeron (2006) proposed a Scenario-Based Assessment Model (SBAM), which is a
combination of the Delphi Method, Analytic Hierarchy Process (AHP), and Cross-Impact
Analysis [207]. P. Gerdsri (2009) used AHP and expert judgment quantifications to
develop national R&D strategies for agricultural nanotechnology in Thailand [208, 209].
N. Gerdsri and D. Kocaoglu (2004) proposed a systematic approach to strategically
identify emerging technologies in order to achieve technological competitiveness. The
authors combined the Delphi method and Hierarchical Decision Model to build a
technology development envelope (TDE), which serves as inputs for the technology
roadmapping process [210, 211]. Some other scholars carried out research on emerging
technologies through the integration of bibliometrics with scenario planning, trend curves,
and historical analogies. System dynamics is also used to simulate the dynamic
ecosystem of the technology development [212]. Bengisu and Nekhili (2006) presented a
method of forecasting emerging technologies with the aid of S&T databases, which was
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applied to emerging technologies in the Vision 2023 foresight program previously
conducted for Turkey [213].
The review of the existing integrated methodologies has shown some room for
improvement: (1) the methodologies need to be optimized and adapted to the changes in
the fourth and fifth generation of foresights; (2) the restrictions of environmental and
social conditions have to be considered across countries or regions; (3) some integrated
methodologies have unbalanced integration of quantitative and qualitative tools; (4) some
studies relied only on limited members of expert panels, and not all stakeholders were
included, the later being crucial for real world technology implementation; and (5)
Technology foresight evolved from technology forecasting, covering a broader scope,
and it is still evolving fast. Foresight should be used in exploring future opportunities for
setting investment priorities in science and innovation activities and building new
networks and linkages across fields, sectors and markets, or around problems [96]. These
attributes well fit the research requirement of innovation systems.

2.6.2 Technology Assessment
Technology assessment has been widely applied in public policy-making and in
business decision-making [214]. It encompasses activities which analyze and evaluate the
anticipated impacts of a given technology, examines areas of potential social conflict
caused by its deployment, promotes a constructive dialogue between the stakeholders,
and produces recommendations for improving the technology and the terms of its
application [215]. Technology assessment techniques can be applied at various levels for
the evaluation of technology alternatives, selection and acquisition of appropriate
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technologies, and strategic technological planning. Many technology assessment
approaches and tools have been identified to conduct related research, which include:
structural modeling, scenario analysis, impact analysis, risk assessment, decision analysis,
cost benefit analysis, Delphi, and evaluation of emerging technologies [214].
The characteristics of technology are the key factors in the process of technology
assessment. These features may include technology status, maturity, adaptability, and
availability. For example, in the process of international technology transfer,
technological characteristics determine the value of specific transfer objects between the
provider and receiver. Technological unevenness endures primarily due to the spread of
ideas and is contingent on active attempts by firms to learn, imitate, and adapt existing
technologies [85, 216]. At the national level, technology gaps exist because countries
invest differently in education, R&D, and other inputs [217, 218]. Here we focus the
discussion on several important assessment features including: technology trajectory,
technology adaptability, technology distance, and other characteristics.
Technology assessment is closely related to both existing technological trajectories
and institutionalized regime practices that have inherent advantages in determining the
direction of socio-technical change [11]. Technology trajectory can be illustrated by Scurves. Both the process of an emerging technology’s evolution and the pattern of its
adoption in the market can be illustrated to conform to S-shaped curves. When compared
with traditional technologies, emerging technologies may have market uncertainty and
unknown impact on industrial development. These new technologies generate potential
market opportunities for new investments, thus bringing great challenges to decision
makers. From the perspective of developing countries, an emerging technology can
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further provide a window of opportunity for technology leapfrogging, which can trigger
significant improvements to domestic industrial structure. Technology transfer can take
place at any stage of the technology life cycle, but not all technologies have the chance to
reach their natural limits on the S-curve. A replacing technology may form another Scurve through establishing a brand new technology trajectory if it satisfies the same
market need, and there will be a trend for companies to replace the incumbent technology
with new technology. For many MNCs in the developed world, a better choice is to sell
or transfer the current technology rather than completely abandon it. This process has
been illustrated by the “Flying Geese” model proposed by Japanese scholars [219].
Scholars proposed a reverse product life-cycle model which explores this trend in
technology development [220]. For new firms in the industrializing economies, they are
more likely to choose the technology at an early stage on the S-curves. However, that
may bring challenges for the MNCs since it raises new potential competitors [34].
Technology feasibility and adaptability in an unknown market is a notable criterion
for technology assessment. Scholars [221, 222] have argued that, in order to understand
the complexity of adaptability, research should deal with all three intertwined dimensions
of the construct, which include: technology, market, and organization-related factors.
Much has been written in the literature about developing and transferring appropriate
technology for developing countries. For example, technology transfer in an international
context is subjected to more diversified environmental conditions, such as cultural
differences, thus creating greater challenges [223]. There are numerous examples of
unsuccessful launches of new products in developing countries. Some are caused simply
by marketing failures, while other examples which go beyond such simple failures are
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product designs which depart from local custom as regards tastes, habits, and preferences
and thus may never be accepted [224]. The adaptation and modification of technology
should be viewed from a strategic and organizational perspective, as technical integration
of the technology provider’s process with the acquirer’s system must make allowance for
different operating contexts [225]. Literature has pointed out that technological novelty is
sometimes far less important than relevance [226]. For instance, in the pharmaceutical
industry, appropriate technologies are more important for serving the purpose of direct
applications for reducing risk of infection and disease; affordability and costeffectiveness; saving foreign exchange; satisfying public demand with political benefit to
the government; and promotion of social equity. A study has shown that technology
policies of developing country comprises more than choosing technology as a means to
production. They include the control of a broader selection of technical and non-technical
items that link technology to strategy through capabilities of the host country [227].
Many other technology characteristics are identified in the process of technology
assessment. Blalock and Gertler (2009) define “technology gap” as the distance from a
domestic firm's technical competency level to that of international best practice [228].
Similarly, other scholars developed concepts such as technology distance, technological
proximity,

technological position,

and

technological

diversification

[229-231].

Technology distance between partners can have an impact on their choice of cooperation
mode. However, there are some unsolved disputes about the effect of technology distance.
From one perspective, firms with a longer distance may be too far away from the best
practice, resulting in limited capability to learn, assimilate, and share knowledge, thus
causing negative effects on innovation. Firms with a smaller gap should have better
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technical competency and could easily catch up with the technology frontier. From
another perspective, firms that are further away from the technology frontier will gain
higher returns from learning. Firms with a smaller technology gap may have already
mastered similar technologies that have lower returns, but making further efforts to alter
existing practices are more difficult. Scholars from different countries carried out many
empirical studies showing that technology gap can result in either positive [232, 233] or
negative [234-236] impacts to the learning process. Some other scholars found that the
relationship can be nonlinear and U-shaped [237, 238]. It is clear that technology gaps
and distance have significant impacts on technology transfer and diffusion. However, the
characteristics such as size and direction of the impact are still unclear. Scholars [238,
239] claimed that absorptive capacity should be crucial for economies that have a
sizeable distance from the technological frontier. Therefore, it is necessary to base
technology assessment on the technological capabilities of local enterprises.
As a short summary of related literature, research revealed that technology
assessment is an important method in technological development and policy planning.
Technology policy must consider the nature of technology, market trend, and enterprise
level capabilities. Emerging technologies have distinguishing characteristics such as
market uncertainty and unknown impact on industrial development. These new
technologies offer a rich source for market opportunities that provide incentives for new
investments, thus bringing great challenges to decision makers. For late-comers,
emerging technology can further provide a window of opportunity for leapfrogging.
Developing economies catch up only when they actively learn and adapt from leaders
[240]. Their choices about how to invest, as well as the productivity of these investments
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should be based on the assessment of economic, social, and technological dimensions [50,
241].

2.6.3 The Delphi Method
The Delphi method was originally developed for the U.S. Air Force as a group
decision method [242]. It is a method for structuring group communication so that
individual experts can act as a whole in dealing with complex decision problems [243].
The Delphi method has been adopted in many countries and in a wide range of fields.
National Delphi has been conducted in Japan every five years to generate informative
projections on potential technological advances. Many other countries such as Germany,
Korea, and Britain have emulated similar efforts. The technique is applied to fields
including project selection, operations management, drug policy, and administration
management issues [244, 245].
There are several characteristics that make Delphi an effective method to create
consensus among groups of experts: 1) Anonymity; 2) Iteration; 3) Controlled feedback;
and 4) Statistical aggregation of group response [246]. The technique uses a panel of
experts who are not allowed to interact in order that their judgments will not be
influenced by each other. Anonymity provides at least two advantages: firstly, it avoids
the possibility for the panel members to be influenced by other experts’ social position or
reputation; secondly, it allows panel members to change their opinions without feeling
intimidated by others. Iterations with controlled feedback may provide the opportunity
for panel members to change their previous judgments. Everyone is given the group
results after each iteration, showing statistical values such as mean, median, and variation.
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Outliers are asked to explain their rationale to the group, which makes it possible for
others to modify their earlier judgments.
The Delphi process usually takes several rounds before obtaining consensus from the
participants. It requires that experts repeatedly express their opinions through a series of
linked questionnaires. The first round focuses on the exploration of the subject, and the
participants will contribute additional information through answering open questions. The
middle rounds involve the process of reaching a common understanding of how the group
views the issues. The final results occur in the last round after all previous information is
analyzed [247]. During the consultation process, two types of information will flow
among experts through the effort of coordinators: 1) available data previously requested
by respondents; and 2) considerations suggested as potentially relevant by other
respondents [242]. To save researcher and participants’ time and effort, the first round is
sometimes substituted by deliberate literature review. The middle rounds could be
combined due to time constraints or low response.
The literature summarizes some advantages of Delphi that make it more appropriate
than traditional methods like surveys or questionnaires [243]. 1) The problem is not
suitable for analytical techniques but could benefit from collective judgments. 2) A
relatively large number of experts are needed in order to create more interaction than
would occur typically in face-to-face meetings; 3) Experts have no history of previous
communication and may represent diverse backgrounds with respect to experience or
expertise. 4) Time and cost make frequent group meetings infeasible. 5) The efficiency of
face-to-face meetings can be increased by a supplemental group communication process.
6) High disagreement levels among experts so that the communication process must be
95

refereed and/or anonymity assured. 7) Bandwagon effects or domination by quantity or
by strength of personality must be avoided to preserve the validity of results. Although it
has many benefits, some research also points out several potential limitations of Delphi,
which include [243] [248]: 1) Deception resulting from the data retrieval; 2) Discounting
the future and considering the present more important; 3) Illusory expertise resulting
from bias; 4) Optimism or pessimism bias; 5) Prediction urge by moderators; and 6)
Simplification urge from experts.

2.6.4 Multi-criteria Decision Analysis
Multi-Criteria Decision Analysis (MCDA) is a type of research method aimed at
helping decision makers to determine overall preferences among alternative options. It is
particularly suitable for complex problems where multiple criteria are involved. MCDA
is especially useful for policy makers to evaluate a wide range of criteria including social,
economic, environmental, and technological factors. The method provides a logical, wellstructured decision-making process based on the quantitative analysis through scoring,
ranking and weighting of judgmental data.
Among many of the MCDA models, Analytic Hierarchy Process (AHP) is the most
widely applied quantitative decision-support method. It is designed for structuring,
measuring and synthesizing multiple factors or elements. The working process involves
decomposition of a complex and unstructured research problem into an organized set of
components [249]. There are several basic steps included in the process, regardless of the
nature and scope of the research problem, which include: 1) Construction of a
hierarchical model; 2) Prioritization of elements; and 3) Calculation of results. The most
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important step in MCDA is that a HDM should be developed to illustrate the problem.
Decision elements or criteria are identified and arranged into various levels according to
their relationships. In the following step, decision elements at the same level are
compared with each other regarding their contributions toward the upper level criteria.
Different types of comparison methods have been used in this step. The constant sum
method was developed by Comrey [250] and Guilford [251] and refined by Kocaoglu
[252], where a total of 100 points are allocated to the comparison values. The eigenvector
approach was adopted by Saaty [249], where 1-9 scale measurements are used. The
constant sum method gives a more precise measurement of data. In the third step, relative
priorities are calculated and synthesized by multiplying the local weights with those of
the corresponding upper level elements.
The method has several built-in advantages including simplicity of structure, ease of
use, and flexibility. It can be applied to assist complex decision-making when a relatively
large number of quantifiable or intangible criteria are involved. The method allows
calculating priorities and weights in a hierarchical structure in order to identify the most
important elements [249]. A major difficulty in decision making is to reach consensus in
a multidisciplinary expert panel. MCDA provides a tool so that the experts do not
necessarily need to agree on the relative importance or the rankings of the Criteria. Each
expert individually makes his or her judgments, and jointly contributes to a group
decision. AHP gives a clearer understanding of the situation and leads to a higher degree
of commitment to a chosen alternative [253]. AHP was successfully applied in many
research areas including technology selection, evaluation, resource allocation, health care,
policy-making and strategic planning [254-257].
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2.7 Gap Analysis
The literature review has explored the available knowledge base in the areas of
international technology transfer, innovation systems, technology foresight, technology
policy, technology development in China, and related research methodologies.

Areas

Technology
Policy

Technology
Innovation

Research Gaps

Research Opportunities

1. Latecomers face the dilemma of ‘‘make
or buy’’ decisions in high tech development
[12] [84] [258] [259].Technology export
control at various levels complicates their
problems [16] [80] [138].

There is a need to find a proper balance
between various technology
development strategies. Institutional
limitations of the host country should be
considered accordingly.

2. Latecomer countries and emerging
economies need to identify the “windows of
opportunity” for catching-up and
leapfrogging [27] [29].

Technology areas and implementation
strategies should be prioritized
according to local capabilities and needs.

3. International technology transfer
activities may not necessarily result in
sustained innovation, technology diffusion
not efficient and spillover not obvious [23]
[25] [34].

Host countries should build up domestic
absorption capability and innovation
capacity to benefit from technology
diffusion and spillovers.

4. Different attitudes toward appropriate
technology. Common concerns exist but
different interests and motivations are
obvious among the stakeholders [30] [32]
[37].

Various stakeholders should be involved
in the technology planning process. The
disagreements should be considered in
the development of technology policies.

5. Globalization brings new challenges to
the research of innovation systems;
innovation resources are across boundaries
[7] [72] [260].

GloCalization: scholars suggest that it is
necessary to find a balance between
local and global, internal and external
innovation.

6. Transitional innovation systems:
allocation of innovation resources is not
effectively linked to national or regional
tech development strategies [196] [197].

Restructuring of inefficient R&D system
and allocation of limited resource at
various levels according to innovation
strategies.

7. No viable framework has been developed
to deal with technology policy problems in
latecomer countries. A decision model for
Methodology the implementation mechanism of selected
technologies is needed in such countries
[180] [208] [261].

A research framework that incorporates
the importance of innovators and their
strategic considerations should greatly
assist decision makers.

Table 7: Research Gaps and Opportunities
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Through summarizing the literature search results, this part of the chapter analyzes
various research gaps in the above mentioned areas. Connections of literature findings to
the research opportunities are listed in Table 7. Although the research gaps were
identified from different areas, they are interrelated and all point to improvements in
technology policy design. Successful filling in of these gaps requires a comprehensive
look into the issues. To link these gaps with research goals, the following section will
critically examine and categorize them in detail.

Gap 1: Technology policy problems in latecomer countries are discussed in literature,
but no viable framework has been developed to solve these problems.
Latecomer countries face the dilemma of “make or buy” decisions in high
technology development. The literature has examined the problems, but no available
models have been developed to tackle them [12] [84] [258] [259]. There are barriers for
both “make” and “buy’’ approaches. When making the technology by themselves,
latecomer countries may not have the technology capability, so it may take huge efforts
and many years to catch up. If buying the technology from advanced countries, latecomer
countries may need to pay a high price for importing it, and they risk having to
continuously buying follow-up technologies. Since no country, however rich, can afford
to pursue all the possible opportunities in science and technology, there needs to be better
mechanisms for choosing between competing alternatives and resources [102]. Due to
limited technology capability, it is unrealistic for any latecomer country to aim at
exploring all high-tech areas on their own effort. It is especially meaningful that they
should avoid “reinventing the wheel” or remaking the mistakes of advanced countries.
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This may be achieved by learning through foreign experience, and adapting to their
situations but not by just following. Globalization offers new opportunities in technology
learning. Selecting the right strategy in technology development may help in taking the
advantage of such opportunities, and accelerate the catching up process.
Technology export control at various levels complicates the problem of high-tech
development in latecomer countries. Technology blockades at national and enterprise
levels make it difficult for latecomers to learn from advanced countries. Major developed
countries have strict export control of high technologies. For example, the US Commerce
Department’s Bureau of Industry and Security restricted American companies from
selling many sensitive high-tech products to China [16] [80]. This policy negatively
inflicts other countries working on projects with China. Recently, Brazilian companies
working in the Sino-Brazilian satellite project were denied access to American products
considered sensitive [80]. Moreover, at the enterprise level, many MNCs hesitate to
transfer high technologies to foreign countries for the protection of their competitive
advantages. These institutional limitations have pushed many emerging economies to rely
on indigenous innovation.

Gap 2: Emerging economies and latecomers need to identify the “windows of
opportunity” for technology leapfrogging.
Scholars have argued that in the early phases of a given technology trajectory, latecomer countries may enjoy windows of opportunity which allow them to catch up [17].
However, early-stage technologies are highly risky for investment. Many efforts by the
local governments have failed because such technologies are not sustainable in the host
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country [18]. Late-comer countries often lack the necessary technological accumulations
and innovative capacities. Therefore, it is unrealistic for them to devote everything to
uncertain high technology areas. It is better for them to focus on areas where comparative
advantage can be achieved through technology leapfrogging. The host country should
assess whether the new technologies are suitable for local capability and needs. Therefore,
better approaches in technology selection should be developed to underpin strategic
research areas where the greatest economic and social benefits can be yielded.

Gap 3: International technology transfer may not necessarily result in sustainable
innovation, technology diffusion not efficient and spillover not obvious.
It is generally accepted that technology transfer activities alone may not necessarily
result in sustainable innovation. Relying too much on FDI has brought many
disadvantages in the domestic industries. Technology acquisition from firms in more
advanced countries is obviously important to firms in industrializing countries that are
trying to catch up technologically, but technology diffusion and spillover effects may not
necessarily happen [19]. Moreover, since technology suppliers are not usually willing to
disseminate core technology to other enterprises, developing countries can acquire only
some medium- or low-level technology using this source, so a technology gap exists
when compared with the latest international technology [20]. Scholars argued that the
innovation activities in Chinese manufacturing firms could not be boosted substantially
merely through the acquisition of key equipment and apparatus from abroad [19]. The
government should formulate viable technology policies for strengthening local
absorptive capability and innovative capacity.
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Gap 4: The stakeholders have different attitudes toward appropriate technology.
Common concerns exist but different interests and motivations are obvious.
It is important for technology policy makers to fully understand the diversified
motivations and interests among the players of international technology transfer. Western
technology suppliers and local technology receivers have different perceptions and
criteria for success. While the foreign side aims to penetrate the domestic market, utilize
low labor costs and maximize financial returns, domestic partners aim to acquire
advanced technology, a reputable trademark, technical or managerial know-how, R&D
capacity, and access to international markets [14]. Different interests also exist between
industry and government. Industrial players are commercially motivated for profit and
market share, while governments aim for long-term national development, social welfare,
and technological competitiveness [31]. Technology policy should consider these
different standpoints, and address such needs accordingly.

Gap 5: Globalization brought new challenges in the research of innovation systems,
national boundaries are dimmed in the development of high technologies
Globalization has brought both opportunities and challenges to countries. The
question has become who can benefit more from resource-sharing resulting from
globalization. Globalization of innovation systems has deeply influenced the culture of
technology development as well as the strategic behavior of the innovators. Tidd (2007)
identified several major issues regarding globalization. Firstly, since technology and
innovation are not evenly distributed globally, they are not easily packaged and
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transferred across regions or firms. Secondly, different national contexts significantly
influence the ability of firms to absorb and exploit such technology and innovation.
Thirdly, the position of firms in international value chains can constrain their ability to
capture the benefits of their innovation and entrepreneurship [7] [260].
Globalization results in deeper specialization, which may deter latecomer countries
from catching up in technological innovation. Due to the fact that latecomers lack
innovative capabilities in advanced technologies, they are easily trapped in inferior
positions as low-cost resource providers. Domestic companies of these countries can only
be specialized in the manufacturing of low-tech, low-value products or services, thus they
are unable to achieve sustainable innovation in the long run [262] [34]. This also causes
mature or standardized technologies and related production to be transferred to latecomer
countries [263, 264]. As a result, the latecomers cannot easily catch up with the leaders in
the areas of advanced technologies. This may further establish an endless loop in which
technological leaders can always outrun their imitators [265] [266]. Therefore the
decision of innovation strategy is an extremely important aspect to support technology
development in latecomer countries. Technology planning has to cover the technology
trends in the world, but the actual process of development must be supported by local
strengths in knowledge and innovation [88]. Brazilian scholars (Humbert 2005, Canongia
2007) have used the term “gloCalization” to describe such a strategy as “think globally,
act locally” [105]. So far, few research models have integrated this idea in technology
implementation.
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Gap 6: Transitional innovation systems - allocation of innovation resources is not
effectively linked to national or regional technology development strategies.
Emerging economies such as the BRICs are investing more resources to develop
their innovation capability. However, there is little evidence that current frameworks or
approaches in developed nations are also workable for these countries. This is because
emerging economies have different environmental contexts and changing agents. Viotti
(2002) found that the Western NIS theoretical and conceptual framework is not
appropriate for dealing with the processes of technological change of industrializing
economies, which are extremely different from those of industrialized countries [85].
New studies are necessary since the emerging economy’s unique environmental factors
should be considered. For example, China is changing from a centrally-planned economy
into a market-oriented economy, and its NIS is fast evolving. The legacy of traditional
R&D infrastructure is notably inefficient for innovation activities. Longer-term
perspectives and strategies call for better use of limited resources. The support and goaloriented prioritization of resources for certain technologies are very necessary [103].
Allocation of resources for technological innovation is an important but complicated
issue for both government and enterprises. Technology policy should play a more
important role in the restructuring of inefficient R&D system and allocation of limited
resource at various levels to support innovation strategies.

Gap 7: A decision model for the implementation mechanism of selected technologies
is needed in latecomer countries
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Available studies have developed technology assessment and selection models to
address various social, economic, and environmental needs in latecomer countries. For
example, Baez (2005) developed a technology assessment model for the ICT industries in
Costa Rica [261] [267], and Gerdsri (2009) developed technology selection model for the
nanotechnologies in Thailand [208] [209]. However, these models did not consider the
realities of limited innovation capabilities in latecomer countries. It is impossible for
these host countries to develop and realize some of the identified high technologies
merely through their own efforts. These countries should consider learning from or
collaborating with leading countries. Many latecomer countries often aim for the best and
latest technologies, but they neglect local capabilities and innovation orientations. Bin
(2008) has urged that government policies should be combined with commonly followed
technological strategies in determining the relationship between domestic in-house R&D
and foreign technology transfer [175]. Instead of innovating in the global technology
frontiers, latecomer countries should focus on catching up. They should strive to build up
innovative capabilities in order to develop those identified high technologies.
Implementation of innovation strategies requires long-term investments in the
industrial foundations and renewing innovation activity by both public and private sectors,
and resources targeted at broad-based innovation activity should be increased at a pace
exceeding that of general economic growth [268]. A framework that incorporates the
capabilities of innovators and their strategic considerations should greatly assist decision
makers. Therefore, current technology assessment and selection models should be
extended to include strategic concerns about how to develop and realize the selected
technologies, especially in the developmental context of latecomer countries. Appropriate
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models and approaches should be designed to support policy making from a systematic
perspective. In traditional models, technology alternatives are usually located at the
bottom level of the hierarchical structure. In this research, a new model is implemented
by bumping up technology alternatives into higher levels, indicating the prospective areas
for technology development or potential areas for breakthrough innovation. This new
model links technologies and innovators with corresponding innovation strategies.

2.7.1 Short Summary of Gap Analysis
The above section has explored the available knowledge base in various areas of
technology management and identified major research gaps. These gaps are interrelated
and will lead to the improvements in new research. Scholars suggest three factors of
technological change: demand-pull, technology-push, and government-led [42].
Technology policy should assist to adjust the strategic differences among innovators.
Rapid development of high-tech industries makes stable technology policy a difficult task.
Strategies of technology development need to be adjusted in a dynamic mode to deal with
future uncertainties. By summarizing the above literature gaps, a systematic approach
should be developed in organizing and funding research in high technology sectors,
guiding the public and private sectors in their investment decisions and directions,
coordinating industries and sectors, building an efficient scientific infrastructure, and
providing insight for improvements in national technology competency. Such a model is
needed in both developed countries [4] [90] and industrializing countries [88] [146].
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2.8 Research Scope and Boundaries
By analyzing and summarizing available literature findings, the research scope can
be further clarified and defined. In order to make the research process manageable, it is
necessary to delineate the scope and boundaries of the research work. This research will
focus on crafting a research framework to formulate innovation strategies in dealing with
the uncertainties of technology development in emerging economies. It serves as a bridge
connecting high technologies and policy decision making (illustrated in Figure 10).

Figure 10: Research Scope and Bounds

On the input side, the supportive studies may include technology-oriented research
such as foresight/forecasting studies, industrial reports, product analysis, and technical
expert recommendations. On the output side, the research findings will assist decisionmakers to develop more specific policy instruments such as direct or indirect funding,
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regulation support, and other favorable measures. The design of such detailed policies
may be potential areas for future research.
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Chapter 3 – Research Methodology and Approach

Through the analysis of research gaps, this chapter clarifies the research objectives,
research goals, and research questions. The literature review revealed that many problems
coexist in the process of technology policy-making, especially for emerging economies.
This chapter will highlight major research questions and use them as a starting point to
develop the research methodology and research process.

3.1 Research Objectives, Goals, and Questions
The objective of this research is to provide a systematic framework for promoting
national S&T competitiveness and innovation capacities in high-tech sectors. The
framework serves to provide insights for both public and private stakeholders as they
strategically plan for further technological advancement. The approach of this research is
to formulate effective technology development strategies, linking prospective high-tech
areas and various innovative resources to assist the decision-making process of
technology policy.
From the gap analysis, research goals have been developed and categorized into
several major aspects including:
1) Identification of appropriate technology areas for innovation and leapfrogging.
2) Balancing different strategies in technology development.
3) Identification and allocation of limited innovation resources.
4) Prioritize technologies, strategies, and resources to support innovation.
5) Identification of disagreement among stakeholders and related implications.
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Referring to Table 7 in Chapter 2, the linkage between research gaps and research
goals (RG) is established. Five research questions are proposed as guidelines for this
research according to the research goals. The linkage between research goals and
research questions (RQ) is illustrated in Figure 11.

Figure 11: Connecting Research Gaps, Research Goals, and Research Questions

To answer the research questions and achieve research goals, it is necessary to
incorporate various influencing factors identified in the literature review section. There is
a need to construct a new research framework to obtain a proper balance of appropriate
technologies, development strategies, and innovation resources. Based on the research
methodologies used in international technology transfer, innovation systems, technology
foresight, and technology policy, a research framework will be developed to address the
above mentioned issues in technology development.
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3.2 Research Methodology
With the research questions on mind, this research utilizes an analytical approach to
create a model for exploring effective technology implementation mechanisms to align
with national innovation objectives. Experts are invited to provide judgmental data in
determining the relative relationships among the decision elements at various levels of
the model. The methodology to be utilized is an Analytic Delphi study where experts
assess the criteria related to technology, strategy, and innovation resources. The initial
research includes face-to-face consultation of experts to identify critical issues and define
the criteria. Subsequent pair-wise comparison instruments are developed based on the
results provided by the experts in the interviews. The AHP method is followed to
quantify experts’ judgmental data on the issues.
Delphi offers an approach to make assessments via a panel of experts and is the
chosen methodology because new technologies will be evaluated for an uncertain
emerging market environment, where sufficient historical data were not available to
effectively utilize other traditional quantification methodologies. Scholars have
successfully applied the traditional Delphi method in technology forecasting research at
various levels. For example, Gerdsri (2004) integrated the Delphi technique into his
dissertation to identify technology strategies [210]. Martino describes three situations
when the Delphi method is more suitable than other quantitative methods: “1) when no
historical data exists and a forecast may be needed. This situation appears usually with
the new technology; 2) when the impacts of external factors are more important than the
internal ones of the phenomena; and 3) when ethical and moral considerations dominate
the economical and technological goals of the development” [248].
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The AHP provides a systematic approach to develop priorities for alternatives based
on the experts’ judgments. A hierarchy or network structure will be constructed to
represent a decision problem. AHP utilizes pair-wise comparisons to give priorities for
the alternatives or criteria based on the experts’ opinions. The appropriate alternatives are
selected based on the quantitative solution to these rankings. AHP is selected because of
its many benefits: 1) AHP allows for the measurement of both objective and subjective
factors; 2) Consistency measures are easily derived to evaluate the quality of the
judgment; and 3) AHP enables group judgment to arrive at a unique decision that can
represent the opinions of all participants.
AHP has been proven to be an effective quantitative decision-support method to deal
with complex multi-attribute decisions. For instance, Gerdsri (2009) used AHP and
expert judgment quantifications to develop national R&D strategies for agricultural
nanotechnology in Thailand [208, 209]. The method has been widely applied in areas of
management, policy-making, and conflict resolution. It can be utilized for structuring,
measuring and synthesizing factors or elements that affect decision-making [249].
This research focuses on the implementation mechanisms and realization pathways
for prospective technology areas in emerging economies. The research direction is to
formulate policy actions rather than predict technology areas. It is based on available
world-class technology foresight or forecasting reports, and to customize those identified
technologies for implementation or realization in emerging economies. This research has
shifted away from merely forecasting the technologies, and has moved forward into the
area of decision making in strategy selection and resource allocation. Therefore, the
research results are not comparable to current technology forecasting reports and
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foresight studies because similar research has not been available yet. The outcome of this
research will serve to support government and industry decision makers to buildup
innovation capabilities for technological competitiveness. The decision making process
makes the MCDA an appropriate methodology for this research.

3.3 Research Model
To tackle the research gaps through the above methodologies, a hierarchical research
framework is developed based on pair-wise comparisons to quantify expert decisions. It
takes into consideration several factors in the research process, including appropriate
technologies, implementation strategies, and allocation of innovation resources according
to desirability for long-term benefit. Through a series of judgmental quantifications from
the experts, the prioritized value for each innovation resource can be calculated, which
represents its desirability corresponding to the improvement of innovation capacity. The
results can thus indicate better investment targets to be made in the industry for selected
high technology fields.
The structure of the model can be used to develop implementation strategies for
appropriate technologies for a host country. The HDM has four levels: mission,
technology, strategy, and resource (Figure 12).
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Mission Level:
Technological
Competitiveness and
Innovation

M

T1

T2

S1

A1

T3

S2

A2

Tk

T4

S3

A3

Strategy Level:
Technology
Development Strategies

Sj

A4

Technology Level:
Prospective
Technology Areas

Ai

Resource Level:
Innovation Resource
Alternatives

Figure 12: The Generalized Model

In Figure 12:
M: Mission – Technological Competitiveness and Innovation
Tk: Prospective Technology Areas (k)

k = 1, 2, 3 … K

Sj: Technology Development Strategies (j)

j = 1, 2, 3 … J

Ai: Innovation Resource Alternatives (i)

i = 1, 2, 3 … I

The top level declares the technological innovation mission of the host country.
Strengthening technological competitiveness and building innovative capabilities are
common objectives of technology development in both developed and developing
countries. Since this research will focus on emerging economies, the objective has been
adjusted according to the findings from related literature review sections. Here it is
defined as “Advancement of Technological Competitiveness and Innovation.” Scholars
have argued that technological competitiveness at the national level is conditional on
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three key factors: access to competitive technologies, continuous innovation, and
provision of the innovative environment [5] [6]. This matches the objective of technology
development for nations, as well as the mission level of this research.
The second level consists of a list of prospective technology areas suitable for the
target country’s development in the future. The RAND Report 2008 argued that populous,
low-income countries may achieve comparative advantage in R&D in certain areas if
such countries develop the capacity and institutions necessary to apply new technologies
[3]. The second level will identify such technology areas that support the innovation
mission. These are high-tech fields that are suitable for leapfrogging or accelerated
development in the host country. The focus of interest here is state-of-the-art
technologies, including both incremental and disruptive technologies that can serve as
possible “windows of opportunity” for innovation and leapfrogging. The selection of
technology portfolios should be integrated into the overall national planning process at
the higher level. Appropriate technologies should be developed to make effective use of
the host country’s available resources and help the country to further develop innovation
capabilities.
The third level defines how the country should strategically develop the identified
technologies. Several paths of technology development have been identified from the
literature review: indigenous innovation, imitative innovation, cooperative innovation,
and international technology transfer. In a globalized innovation network, it is necessary
to balance the strategies for technology development to increase national competency.
Scholars argue that the innovation strategies may vary from sector to sector and across
time. To reveal sector/time-specific characteristics, comparative evaluations of
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innovation strategies and their impact on organizational performance across various
sectors and in multiple time frames may produce findings of greater relevance to policy
makers [180].
The fourth level provides a list of input resources that buildup the innovation
capability of the country. They are also regarded as innovators that generate various
innovative outputs such as publications, patents, and new products. The innovation
resources include all the entities that develop, implement, or provide support for the
candidate technologies. These resources can come from different sources such as the
public sector, private sector, and even foreign countries. Technology policies should be
prioritized to strengthen the capability of these innovators, and to maximize their
innovation outputs as a whole for national technology objectives.
The generalized model is applicable to technology development scenarios in both
developed and developing countries. When applied to a developed country, the mission
level may be adjusted and redefined as “strengthening technological competitiveness
through sustained innovation” or similar. It is unrealistic for any country to invest in and
pursue all technology opportunities totally on its own effort [102]. Decisions on the
priority of investments in high technology industries for a rapidly evolving global market
are complicated issues and highly risky for governments in all countries. The inputs for
the technology level can be selected from various study reports in the related industry for
evaluation. For the strategy level, the emphasis may be different from country to country.
For example, a developed country may focus more on indigenous innovation or
collaboration, while a developing country may rely more on imitation or international
technology transfer. At the resources level, each country may have different conditions or
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environmental contexts that influence the availability of resources. Given these many
differences, the model is still applicable for any target country if the correct criteria are
identified as inputs in each level.

3.4 Research Framework
This model uses a hierarchical structure to leverage various technologies, strategies,
and resources. It combines a top-down and bottom-up approach to consider the needs and
strategies of both government and enterprises. This requires the judgmental inputs of
experts from diverse sources including government, industries, and academia. However,
this diversity may cause inconsistencies and disagreements in the research process. It is
necessary to have correct quantification measures to deal with such issues. The research
framework is illustrated in the following steps.
Step 1: Criteria Definition:
Mission (M): Technological Competitiveness and Innovation.
Prospective Technology Areas with reference to M: Tk , with k = 1, 2, 3 ….., K
Technology Development Strategies with reference to Tk : Sj , with j = 1, 2, 3 … J
Innovation Resource Alternatives with reference to Sj : Ai , with i = 1, 2, 3 … I

Step 2: Identification of Prospective Technology Areas: Tk , with k = 1, 2, 3 ….., K
Sources to finalize the technology fields:
1. Industry research reports
2. Foresight / forecasting studies
3. Academic research
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4. Expert recommendations

Step 3: Technological Development Strategies: Sj , with j = 1, 2, 3 … J
S1: Indigenous Innovation
S2: Imitative Innovation
S3: Collaborative Innovation
S4: International Technology Transfer
……
Sj : ……

Step 4: Innovation Resource Alternatives: Ai , with i = 1, 2, 3 … I
A1: Public Research Institutes
A2: University Research Programs
A3: Multinational companies
A4: State-owned Enterprises (SOEs)
A5: High-tech Small-to-Medium Enterprises (SMEs)
……
Ai : ……

Step 5: Quantification and Analysis
The quantification process utilizes the Pair-wise Comparison Method (PCM), where
experts are asked to allocate weights for the elements. By using the constant-sum method,
a total of 100 points will be assigned between any two elements at the same level.
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Under Mission (M), quantifying expert judgment of relevant technology fields to
obtain V (Tk). For each Tk (k = 1, 2 …, K), using pair-wise comparison to determine the
relative value of Tk in terms of their desirability for M.
For k = 1, 2 …, K:
Mission:

M

Prospective Tech
Areas: Tk

T1

T2

T3

……

Tk

Relative value V(Tk): 0.03

0.01

0.04

……

0.20

Figure 13: Determining the Priority Value of Prospective Technology Areas

Judgmental value of the best Tk for M is based on a scale of 0 – 100, and then
normalized to be within the range of 0 – 1.
Determine relative importance of each strategy Sj (j = 1, 2 …, J) for Tk by pair-wise
comparisons V(Sjk). Scaling and normalization methods are of the same ratio as the
above level.
For j = 1, 2 …, J:
Prospective Tech
Areas: Tk
Tech Development
Strategies: Sj
Relative value V(Sjk):

Tk

S1

S2

S3

……

Sj

0.25

0.10

0.15

……

0.50

Figure 14: Determining the Priority Value of Technology Development Strategies

Determine relative importance of Ai (i = 1, 2 …, I) for Sj by pair-wise comparisons,
V(Aij).
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For i = 1, 2 …, I:
Tech Development
Strategies: Sj

Sj

Innovation Resource
Alternatives: Ai
Relative value V(Aij):

A1

A2

A3

……

Ai

0.10

0.30

0.25

……

0.35

Figure 15: Determining the Priority Value of Innovation Resources

For any innovation resource alternative Ai, calculate the value of contribution toward
M, sort V(AiM) according to its numerical value, and discuss implications.
J

K

V ( AiM )  V ( Aij )V (S jk )V (Tk )

for i = 1, 2, … I

j 1 k 1

Step 6: Validation and Recommendation
In this Phase, the researcher will validate the results and conduct related analysis.
The intermediate results will be given back and forth among the experts. The experts will
comment on the results after reviewing the summary reports. The process will stop after
finding a greater consensus of the experts. Otherwise, the results need to be improved by
revising the judgment questions, and retaking the evaluation process. Sensitivity analysis
will assist the understanding of relationships among different levels. The analysis
quantifies the range of difference of the optimal set if there are changes in related criteria,
and it provides the basis to assist policy-makers in modifying the hierarchy for selection
of the optimum strategy. Policy recommendations will be given by interpretating the
results for identification of effective and ineffective innovation resources. The results
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support decision makers to determine where the investments and policy measures should
be given.

3.5 Inconsistencies
During the above processes, inconsistency values for the constant sum method are
calculated as follows [269]: For n elements, the constant sum calculations will result in a
total of n! orientations with vector values represented by r1, r2 ... rn for each. If the expert
is totally consistent, the relative values will be the same for each orientation. Otherwise,
if inconsistency exists it will result in differences in the relative values in different
orientations. According to Kocaoglu’s research, if the inconsistency level is less than 10%
or 0.1, the related judgmental data should be acceptable [252].
Let rij = relative value of the ith element in the jth orientation for an expert

r i = mean relative value of the ith element for that expert:
n!

r i  (1 / n! ) rij
j 1

Variance in the relative value of the ith element:
n!

(1 / n! ) (r i  rij ) 2
j 1

i = 1, 2 … n

Inconsistency of the expert in providing relative values for the n elements is defined
as:
n

n!

Inconsistency  (1 / n ) (1 / n! ) (r i  rij ) 2
i 1

j 1
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3.6 Disagreements
The methodology for measuring disagreement is based on the Ph.D. dissertation
done by N. Gerdsri (2004), and then expanded by P. Gerdsri’ Ph.D dissertation in 2009
[210, 211] [208, 209]. The intraclass correlation coefficient ( RIC ) is calculated to
measure the degree to which k judges/experts are in agreement with one another on the
ratings of n subjects/criteria. The coefficient RIC may achieve the maximum of 1 when
all experts assign the same mean values to the subjects (absolute agreement); or the value
of RIC is close to zero when there is a substantial difference between the mean judgment
values among all experts. If RIC has a negative value, the negative correlation is
generally considered as zero. It has been accepted that a RIC > 0.7 indicates a strong
agreement among the experts [270]. The intraclass correlation coefficient can be
calculated through the following equation. The related parameters are further
decomposed and described below:

R IC 
MS BS

MS BS  MS res
k
 ( k  1) MS res  ( MS BJ  MS res )
n

Where:
The mean square between-conditions MSBJ = SSBJ/dfBJ
The mean square between-subjects MSBS = SSBS/dfBS
The mean square between-residues MSres = SSres/dfres
2
T

SST   X 

( X T ) 2
nk
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k (
 X j )2   ( X T )2
SSBJ   
n
nk
j 1 



 (  Si ) 2  (  X T ) 2
 

n
nk
i 1 


n

SSBS

The residual sum of squares (SSres) SSres = SST - SSBJ - SSBS
dfBJ = between-judges degrees of freedom = k - 1
dfBS = between-subjects degrees of freedom = n - 1
dfres = residual degrees of freedom = (n-1)(k-1)
dfT = total degrees of freedom
n: denotes the number of subjects
k: denotes the number of judges
T: subscript denotes total
Based on the intraclass correlation coefficient, Shrout and Fleiss (1979) developed a
statistical procedure to test the hypothesis to discover whether or not there is an absolute
disagreement among the judges [271].
The null hypothesis is defined as:
H0: RIC = 0
H1: not H0
The null hypothesis means there is no correlation among the judges, which indicates
absolute disagreement among the experts. The authors suggested applying F-test as the
statistical measure. The F-ratio for testing the agreement among experts is defined as: FBS
= MSBS / MSRES The computed F-ratio will be compared with the critical F-values with
degrees of freedom df1 (= dfBS) and df2 (= dfRES) at a desirable level of significance. H0
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will be rejected if the F-ratio is greater than the F-critical, which means that there is no
statistically significant disagreement among the experts.

3.7 Sensitivity Analysis
In real world scenarios, there are various uncertainties that may lead to changes in
policy decision-making. For example, disruptive technologies can have significant impact
on the development of high tech industries, as well as on the decision-making in
technology policies. It is especially meaningful for this model to characterize scenarios
that could affect changes in the rankings of decision elements. This can be interpreted in
reality that when technology policies give different priorities to the prospective
technology areas, the priority rankings of supportive innovation resources may also
change accordingly. It is beneficial to measure the range of tolerance of such changes
through sensitivity analysis techniques. Having a good understanding of these changes
will give policy makers better insights on investment, incentives, regulations, and other
technology policy measures.
This study utilizes the sensitivity analysis algorithm for hierarchical decision models
presented in Chen’s dissertation and Kocaoglu's research [272] [273]. With this method,
algorithms were developed based on a series of mathematical deductions. It is an accurate
and comprehensive method to examine the impact of changes in different levels of a
hierarchical decision model on the ranking of the alternatives. In this method, tolerance is
defined as the allowable range in which a contribution value can vary without changing
the ranking order of bottom level alternatives. In order to determine the tolerance, the
allowable ranges of perturbations are always calculated first. The result will reveal the
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tolerances of contributions of technology goals to the mission while the innovation
resource rankings remaining the same. Before the application of the sensitivity analysis
algorithm, it is necessary to redefine some symbols to be used in this research.
O l : The l th objective,

l  1,2... L

In this research, the technologies have been adapted as objectives which include:
Chemical Pharmaceutical Technology, Biopharmaceutical Technology, and Herbal
Pharmaceutical Technology.
Ai : The i th action, i  1, 2... I
Here the actions represent input resources including: public research institutes,
university programs, foreign R&D centers, state-owned enterprises, and high-tech
small-to-medium enterprises.
ail : Contribution of the i th action to the l th objective
ai : Contribution of the i th action to the mission

i r : The rank of i . Ar ranks higher than Ar  n , indicating ar  ar n
ol : Contribution of the l th objective to the mission
Let’s denote the perturbation induced on one of the ol s as  l* ,
L

Where  o l *   l * 

o

l

l 1, l  l *

( ol* is used to differentiate it from the other ol )
The original ranking order of Ar and Ar  n will not reverse if

 l* 

C0
C
C
C
(if 0  0 ) or  l*  0 (if 0  0 )
Cl*
Cl*
Cl*
Cl *
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L

Where C l*  a r  n,l*  a r ,l * 

L

ol

 a rn ,l 



L

o

l 1,l l *

l

l 1,l  l*

a
l 1,l l *

r ,l



ol
L

o

l

l 1,l  l *

and C0  ar  ar n
The original ranking of all Ai will remain unchanged if the above condition is
satisfied for n = 1, and r = 1, 2 … I-1 in this research. The top choice will remain the
same if the above condition is satisfied for r = 1 and n = 1, 2 … I-1.

3.8 Expert Panels
The selection of expert panels is vital for the success of Analytic Delphi research.
The judgmental data provided by experts strongly influence the final research outcome.
According to the nature of this study, the experts will come from diverse sources to
provide a balanced perspective representing both government and industry. Stakeholders
from both domestic and foreign sources will be invited to represent different perspectives.
The experts will have several roles during the research process: to help validate the
construct and content of the hierarchical model, to provide the judgmental data of relative
impacts, and to validate the results of research [274]. Several criteria are used to select
expert panel members. Firstly, it is necessary to work with experts who have essential
knowledge sets in the research areas. They should have an in-depth understanding of the
subject. Secondly, the experts should have the availability and willingness to participate
in the research. Thirdly, they should have the ability to see technological competiveness
in a holistic way from macro and micro perspectives. Ideally, they should be able to cross
over both traditional viewpoints and unconventional angles. Last but not least, the expert
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panel should consist of balanced perspectives and biases. There should be no dominance
by loudness or silent bystanders.
The expert panel is recruited based on their expertise as well as their backgrounds. In
the hierarchical structure, the top and second levels require more technically oriented
people who are familiar with global technological trends. They also need to possess
knowledge about the characteristics of local needs, capabilities, and trends. The third and
bottom level requires more strategically oriented people who possess managerial
experience or planning perspectives. Therefore, this research will include both
“technological” and “strategic” types of experts in the priority setting process. Although
different types of experts may be independent from each other, the members possessing
multiple knowledge sets are extremely beneficial to the research. For example, senior
managers with technical backgrounds are well-suited to represent the interests of
enterprises and industry; Government officials who have a technical background, often
called technocrats, are important candidates to represent the concerns of government.
These experts can provide holistic perspectives in their judgments.
A balanced participation from various types of experts will be considered in the
research. This ensures the generation of specific knowledge and consensus by eliciting
judgments according to the unique backgrounds of the experts. The expert panel is
divided into several subgroups according to the research purpose for each level.
Subgroup-G may consist of policy makers and scientists from the government agencies;
Subgroup-F experts have backgrounds or interests in various foreign organizations;
Subgroup-L experts may come from local industrial organizations or research institutes.
This is to consider the balanced interests and perspectives among different stakeholders.
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It should be mentioned that different viewpoints are considered for each level of the
model hierarchy. Experts from different subgroups are distributed in the judgmental
quantification process for each level of the hierarchical structure. These experts serve to
provide different perspectives representing the interests of government, domestic, or
foreign stakeholders.
The diversity of viewpoints to be represented in the judgmental data will be
measured by the disagreement value during the quantification process. A major concern
of diversified participation is that the different backgrounds of the experts may lead to
potential conflict or disagreement. However, the variety of judgments can also initiate a
constructive conflict which is beneficial toward the research. By incorporating the Delphi
method, the research aims for a greater consensus in the end.

3.9 Research Validation
The validation process consists of three major aspects: construct, content, and
criterion-related validity. The purpose of validation is to enhance the credibility of the
research. Experts are invited to verify the model for construct and content validity. The
research results are tested for criterion-related validity.
Construct validity is to ensure the appropriateness and correctness of the model
structure. Experts are asked to comment on the validity of the structure, and the
feedbacks are used to improve the model. Content validity is to verify that the elements
are appropriate and cover the range of necessary decision measurements for the research.
The criteria to be validated are extracted from related academic literature and then further
refined by the researcher. Drafts of the research instruments are developed to
128

communicate the rationale of the model and related measurements to the participating
experts. Comments and feedback are consolidated by the researcher and then reviewed
again by members of the expert panel to achieve consensus. The validation results are
reflected in the preparation of the quantification research instruments. Criteria-related
validity refers to the review and verification of the final research outcomes. When the
research is done and results are analyzed, the researcher will contact the experts again to
review and confirm the validity of the results. The research outcome will be thoroughly
assessed, and practical implications and recommendations will be discussed accordingly.
These three major aspects of validation (construct, content, and criterion-related) will be
applied and discussed throughout the case application in the following Chapters.
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Chapter 4 – Case Application and Research Development

Based on the generalized research model developed in Chapter 3, a case study
focused on the Chinese biopharmaceutical sector will be presented in this Chapter. The
criteria of the hierarchical model are customized according to case conditions. The
research activities include formation of expert panels, research validations, preparation of
research instruments, and data collection.

4.1 Case Background
The pharmaceutical industry is often characterized as a research-driven sector
because of its exceptionally high ratio of R&D inputs to sales. Development of novel
drugs is very difficult because of several issues: 1) heavy investment; 2) high risks; and 3)
long development cycle. A novel drug may need to go through many lengthy processes
and stages which can easily add up to 10 - 15 years. With one wrong step over the years,
the whole project may fail. Investment can easily be hundreds of millions of dollars or
more.

4.1.1 The Pharmaceutical Market in China
China’s pharmaceutical market is one of the most dynamic in the world. It grew 22%
in 2010 to US$116 billion and ranked the fifth largest in the world [275]. With an
average annual growth rate above 20% from 2005 to 2010, it is set to overtake Japan as
the world’s second largest market by 2015 [276]. Due to the economic recession in the
Western countries, the Chinese pharmaceutical market is steadily moving up toward the
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leading position globally. However, the Chinese pharmaceutical industry faces huge
challenges in the area of technological innovation. Breakthrough technological
innovation from the domestic Chinese pharmaceutical sector is rarely seen for decades.
Although China is a major exporter of pharmaceuticals, it is specialized in the production
of crude drug substances and low-tech generics, rather than novel drugs.
The Chinese pharmaceutical market is highly fragmented and very different from the
market in developed countries. In 2010, generic drugs had about 76% of the entire
pharmaceutical market in China, while only 4% of the market was comprised of
innovative drugs still under patent protection. The remaining 20% of the market consisted
of off-patent drugs (Figure 16) [275]. The generic drugs market has the largest segment
and has mostly been controlled by domestic products. However, the profit margin is low
due to intense competition. The innovative drug market has the smallest segment and is
dominated by imported products, particularly those produced by MNCs. For the offpatent drug segment, both imported and domestically-produced branded drugs compete to
survive.
Innovative drugs within
patent protection

4%
20%

Generic
drugs

Off-patent
drugs

76%

Source: IMAP (2012)
Figure 16: Innovative and Generic Drug Market Share in China 2010
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4.1.2 The Biopharmaceutical Sector
China’s pharmaceutical industry consists of three major sectors: 1) chemical
pharmaceuticals; 2) biopharmaceuticals; and 3) traditional herbal medicines. Although
the chemical pharmaceutical technologies have been regarded as the industrial
foundations in the last century, biopharmaceutical technologies have been emerging as a
prospective area with huge growth potential. Many leading chemical pharmaceutical
companies have already tapped into the biotechnology area. There has been a paradigm
shift in industrial R&D from high-risk synthetic pharmaceuticals towards R&D in
biopharmaceuticals. The top chemical pharmaceutical companies spent tens of billions of
dollars to acquire biotechnology companies and in-licensing deals. Pfizer, Roche, Lilly,
Astra Zeneca, Glaxo Smith Kline (GSK) and Bristol Myers Squibb have all underlined
their strong commitment and highlighted their biological projects in R&D pipeline [277].
The Chinese biopharmaceutical industry has been developing rapidly in recent years.
Since this is still a new area with good prospects, both established pharmaceutical
companies and startup firms are trying to profit from the expanding market. Although the
overall innovation capability of domestic players is not very strong, research in some
specialty areas has already caught up with the level of leading countries. However, it is
generally accepted that the Chinese biopharmaceutical industry still needs to increase its
competitiveness globally, especially in high technology areas.

4.1.3 Policy Factors
The pharmaceutical sector is among the mostly regulated areas in healthcare. The
innovation capability of the industry is largely influenced by macro factors including
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regulations, economy, demographics, and technology level. For example, the
reimbursement issue needs to be considered in the Chinese market. The government
introduced the National Essential Drug List (NEDL) in 2009 to set the range of
reimbursement and lower drug prices for the general public. NEDL sets upper limits of
the retail prices for the drugs on the list. Innovative drugs are usually not included on the
reimbursement list. These drugs are graded at the highest price in the market. Since no
imbursement are available, the innovative drugs have a very limited market size. As
illustrated in Figure 16, the market share was only 4% in 2010 [275]. Therefore policy
factors can have significant impact on the direction of the pharmaceutical industry and its
development. Successful technology policy relies on a better understanding of both
global and domestic market environments. Decision makers need to evaluate related
issues and adjust their strategy accordingly. In order to build a competitive and
innovative pharmaceutical sector, both foreign factors and domestic settings call for
effective strategic orientation to adapt to global market competition.

4.2 Model Development
This section will focus on crafting the model and applying it to the emerging
Chinese biopharmaceutical sector. Decision criteria in each level of the hierarchical
model are analyzed and customized according to the conditions in China’s
biopharmaceutical sector. This provides a foundation for further validation by experts.
The model will be finalized based on the feedback from expert panels.
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4.2.1 Mission Level
The top-level mission has been defined as “Technological Competitiveness and
Innovation”[6]. This mission is applicable to the fast-developing biopharmaceutical
industry in China [278] [279]. Due to historical reasons, the technology level of the
Chinese biopharmaceutical sector remains less competitive globally, and it still faces
challenges including weak innovative capacity and lack of R&D investment. Due to the
high investment risk and long development cycle, the biopharmaceutical sector relies
heavily on regulations and support from governments. Strengthening technological
competitiveness and building up innovative capabilities are primary concerns of industry
as well as policy makers.

4.2.2 Technology Level – Prospective Technology Areas
The rationale of the model’s technology level is to identify global technology trends
and adapt to local capabilities and needs. Choosing the right technology areas and
guiding investment are major topics in technology policy. While it is unrealistic for the
Chinese biopharmaceutical industry to excel in all high technology areas, it is more
realistic to focus on key areas where the country has potential capabilities to achieve
competitive advantages. From the perspective of industrializing countries, the appropriate
technology can offer windows of opportunity to catch-up with leading countries. In other
words, China should look into the global technology frontiers and seize the opportunities
for catching up.
To represent the global technology trends and emerging areas in the model, this
research will incorporate the findings from technology forecasting reports published by
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international organizations such as the United Nations (UN) and Organization for
Economic Co-operation and Development (OECD). The UN has published the research
results in a report titled Top Ten Biotechnologies for Improving Health in Developing
Countries (Table 8) [280]. More recently in 2009, OECD published the forecasting report
Human Health Biotechnologies to 2015, which is based on the conditions of its member
countries [281] [282].

Rank
1

Biotechnology
Modified molecular technologies for affordable, simple diagnosis of infectious diseases

2

Recombinant technologies to develop vaccines against infectious diseases

3

Technologies for more efficient drug and vaccine delivery systems

4

Technologies for environmental improvement (sanitation, clean water, bioremediation)
Sequencing pathogen genomes to understand their biology and to identify new
antimicrobials
Female-controlled protection against sexually transmitted diseases, both with and
without contraceptive effect

5
6
7

Bioinformatics to identify drug targets and to examine pathogen-host interactions

8

Genetically modified crops with increased nutrients to counter specific deficiencies

9

Recombinant technology to make therapeutic products more affordable

10

Combinatorial chemistry for drug discovery
Table 8: Top Ten Biotechnologies for Improving Health in Developing Countries
Source: UNESCO (2006)

The available research indicates that different countries have different needs for
technologies due to various developmental conditions [283]. As an emerging nation,
which walks in between the developed and developing cohort, China needs to identify
prospective technology areas based on its needs and capabilities. The following model’s
criteria and definitions were developed based on the reports from the OECD and UN [280]
[281] [282], and were verified by consultations with experts.
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Recombinant therapeutic proteins – therapeutic proteins are used to treat many noncommunicable diseases. These technologies provide affordable and sustainable sources
for treatment of chronic disease [280-282].
Recombinant vaccines against infectious diseases – vaccines produced using
recombinant DNA technology. The products can be used to effectively treat infectious
diseases [280-282].
Monoclonal antibody technology – Monoclonal antibodies (mAb) can be used for
therapeutic treatment and diagnostic tests. Many therapies are undergoing clinical trials.
Most are concerned with immunological and oncology targets [281, 282].
Tissue engineering technologies – These technologies involve techniques that
replace or act directly on cells and tissues in the body. The treatment repairs tissues
damaged from injuries and diseases [281, 282].
Stem cell therapy – This type of treatment leads to the production of entire organs.
These technologies include the use of stem cells as a therapeutic method, or to repair
specific tissues or grow organs [281, 282].
Gene therapy – This technology involves the treatment of a disease by introducing a
new gene into a cell. It either uses or acts directly on nucleic acids, which are the
molecules that serve as the building blocks for DNA and RNA [281, 282].
Antisense therapy – Antisense drugs are being researched to treat a wide range of
diseases such as cardiovascular diseases, asthma, and arthritis. There are currently more
than 30 anti-sense therapies in clinical trials [281, 282].
RNAi (ribonucleic acid interference) – This includes all entries for products which
act therapeutically via an RNA interference mechanism. There have been a great number
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of research activities in this new area. Most proposed clinical uses are aimed at treating
infections [281, 282].
Nanobiotechnology for efficient drug and vaccine delivery – This type of
technology aims for improved drug delivery systems from the convergence between
biotechnology and nanotechnology [281, 282].
Synthetic biology – The design and construction of new biological parts, devices and
systems that do not exist naturally; The redesign of existing biological systems to
perform specific tasks [281, 282].
Bioinformatics to identify drug targets and examine pathogen-host interactions –
These technologies cover the manipulation and analysis of large datasets of genetic and
health information [280-282].
Pharmacogenetics – This technology identifies inherited differences (variation)
between individuals in drug metabolism and response. It can be applied in clinical trials
and prescribing practices [281, 282].
Gene sequencing – Sequencing of pathogen genomes provides ways to identify new
antimicrobials. These technologies can accelerate the process of drug discovery and fight
against infectious diseases [280-282].
Biotechnology Diagnostics – This technology includes both in vitro diagnostics and
in vivo diagnostics. Modified molecular technologies provide affordable and simple
diagnosis of infectious diseases [280-282].
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4.2.3 Strategy Level – Technology Development Strategies
The Strategy Level defines how technologies should be developed and implemented.
As an industrializing country, China faces the decisions of “Make” or “Buy”, or
somewhere in between [259]. According to the findings from the literature review section,
the following strategies are defined to describe the situation:
Indigenous Innovation – This strategy relies on the host country’s local technology
base and available innovation resources to build up indigenous competence [74-76].
Imitative Innovation – Also known as re-innovation in literature, it is based on
imitation, adaptation, and improvement of the original innovators’ technology [74] [77]
[78].
Collaborative Innovation – This strategy means the participants cooperate and
develop new ideas altogether. Competitors may share resources and work together toward
innovation [74] [79].
International Technology Transfer – This includes technology import and
acquisitions. This is a fast track to save valuable time and resources during the catchingup process [14] [19] [24] [284].

4.2.4 Resource Level – Innovation Resource Alternatives
Under the condition of a transitional economy, China’s National Innovation system
carries some characteristics from both a market economy and centrally-planned system.
Here we need to identify the key contributors toward technology development and
innovation in the Chinese biopharmaceutical sector. Subsidies and favorable policy
measures should be designed and prioritized to strengthen the performance of effective
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innovators. The following innovation resources have been identified by the literature
review.
State-Owned Enterprises (SOEs) – SOEs are medium- to large-sized companies left
by the centrally planned system. These companies constitute the main production
capacity of the Chinese pharmaceutical industry, but most of them specialize in low-tech
generics drugs. Compared with foreign counterparts, domestic pharmaceutical companies
are weaker in terms of technology level and research capabilities [259] [285] [286] [287].
High-tech Small-to-Medium Enterprises (SMEs) – These smaller companies have
emerged since the 1980s, when the government started to allow private ownership of
companies. Many small dedicated biotechnology firms (DBFs) belong to this category.
They probe into potential technology areas with the purpose of obtaining leadership
status in some niche sub-sectors [285] [288] [286].
Multinational Company and subsidiaries (MNCs) – Currently, many top MNCs have
established subsidiaries in China. These large American and European pharmaceutical
companies have dominant innovative capability in most technological areas. They act as
technology leaders in both production and R&D activities in the Chinese pharmaceutical
sector [279] [288] [289].
Contract Research Organizations (CROs) and Contract Manufacture Organizations
(CMOs) – These organizations provide services for both foreign and domestic companies.
Through learning-by-doing from leading innovators, CROs and CMOs have shown
increasing capabilities in developing advanced technologies and manufacturing practice
aligning to international standards [290] [288] [291].
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University Research Programs (URPs) – Some top research universities are
emerging forces in pharmaceutical innovation, and they have been producing more
publications and patents in recent years. Not only do these research universities innovate
through laboratories, but they also cultivate talented young students for the domestic
pharmaceutical industry [286] [288].
Equity Joint Ventures (EJVs) – This is a common way for foreign companies to
enter the Chinese biopharmaceutical sector, especially during the 1990s. Two or more
investors share the ownership and control over the equity, property (including IP), and
operation [288] [292] [287].
Public Research Institutes (PRIs) – PRIs and national R&D laboratories are owned
and managed by government departments. These organizations carry out research
projects according to government instructions [286] [288].
Foreign R&D Centers (FR&D) – In recent years, some foreign invested R&D
centers have been established in China. The biopharmaceutical sector is one of the target
areas. This has also happened in India in recent years. Foreign R&D Centers are capable
of carrying out comprehensive research to develop new medicines at the innovation
frontiers [290] [293].

4.3 Model Validation
After the decision criteria for each level of the hierarchy were prepared by the
researcher, the model was sent to related experts for validation. The researcher also
provided background information about the research along with the model. During the
validation process, each level was tested for the criteria’s preferential independence. The
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experts were asked to comment about the model construct, and they were allowed to add
and/or remove criteria as appropriate.
The prospective technology areas in the biopharmaceutical industry are extracted
from available foresight reports. There are two major reasons for these technology areas
to be validated. Firstly, these reports were published a few years ago, and they need to be
updated and validated according to recent development. For example, the OECD
forecasting report was published in 2009. If we consider the publication lag, the research
should be done between 2008 and 2009. Secondly, the OECD report represented the
findings from a club of developed countries, while this research focuses on emerging
economies. As discussed above, the rationale of the technology level is to identify global
trends and customize to local needs and capabilities. These requirements of validation
were declared in the introduction and instruction sections of related instruments
(Appendix C). The results are presented in Table 9.
Prospective Technology Areas
Recombinant Therapeutic Proteins
Recombinant Vaccines
Monoclonal Antibody
Tissue Engineering
Stem Cell Therapy
Gene Therapy
Antisense Therapy
RNAi
Nanobiotechnology
Synthetic Biology
Bioinformatics
Pharmacogenetics
Gene Sequencing
Biotechnology Diagnostics
Total Votes

Votes on Yes
13
13
13
9
9
10
10
10
12
10
11
10
10
12
13

Table 9: Validation Results for Prospective Technology Areas
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For the purpose of this research, most experts believed that the extracted technology
areas are viable in the biopharmaceutical industry. Based on such feedback, the
researcher included all identified technology areas in the model. Regarding preferential
independence, several experts suggested combining two technology areas, i.e. “tissue
engineering” and “stem cell technology” into “cell and tissue engineering.” The
researcher contacted other experts about it, and they all agreed to this change.
The technology development strategies were extracted from related literature,
including indigenous innovation, imitative innovation, collaborative innovation, and
international technology transfer. In general, most experts believe that these technology
development strategies are observable in the biopharmaceutical industry. Table 10
presents the validation results of technology development strategies.
Technology Development Strategies
Indigenous Innovation
Imitative Innovation
Collaborative Innovation
International Technology Transfer
Total Votes

Votes on Yes
12
13
13
11
13

Table 10: Validation Results for Technology Development Strategies

Regarding the resources level, the prepared list of criteria includes: University
Research Programs; Public Research Institutes; State-Owned Enterprises; High-tech
SMEs; Equity Joint Ventures; Contract Research/Manufacture Organizations; Foreign
R&D Centers; MNCs and Subsidiaries. The validation results of the innovation resources
are summarized in Table 11. Although some resources have more votes than others, most
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resources’ votes are above 70%. Therefore, all prepared resources are included in the
research.
After several iterations, the results were finalized when a consensus was reached. It
should be acknowledged that the experts’ feedback was very encouraging and
informative. The validation of decision criteria helped to answer research questions RQ1,
RQ2, and RQ3, as stated in Section 3.1.
Innovation Resources
University Research Programs
Public Research Institutes
State-owned Enterprises
High-tech Small-to-Medium Enterprises
Equity Joint Ventures
Contract Research/Manufacture Organizations
Foreign R&D Centers
Multinational Companies and Subsidiaries
Total Votes

Votes on Yes
13
13
10
13
12
11
12
13
13

Table 11: Validation Results for Innovation Resources

4.4 The Finalized Research Model

Figure 17: The Finalized Research Model
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Based on the validation results, the finalized research model is illustrated in Figure
17. In summary, there are four levels as described above, and the complete sets of criteria
associated with each level are listed below (Table 12):

Levels

Criteria

Mission Level (M):

M: Technological Competitiveness and Innovation in
Biopharmaceutical Industry
T1: Recombinant Therapeutic Proteins
T2: Recombinant Vaccines
T3: Monoclonal Antibody Technology
T4: Cell and Tissue Engineering
T5: Gene Therapy

Technology Level:
Prospective Technology
Areas (Tk):

T6: Antisense Therapy
T7: RNAi
T8: Nanobiotechnology
T9: Synthetic Biology
T10: Bioinformatics
T11: Pharmacogenetics
T12: Gene Sequencing
T13: Biotechnology Diagnostics
S1: Indigenous Innovation

Strategy Level:
Technology Development
Strategies (Sj)

S2: Imitative Innovation
S3: Collaborative Innovation
S4: International Technology Transfer
A1: University Research Programs
A2: Public Research Institutes
A3: State-owned Enterprises

Resource Level:
Innovation Resource
Alternatives (Ai):

A4: High-tech Small-to-Medium Enterprises
A5: Equity Joint Ventures
A6: Contract Research/Manufacture Organizations
A7: Foreign R&D Centers
A8: MNCs and Subsidiaries
Table 12: The Finalized Model Criteria
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4.5 Formation of Expert Panel
In this research, the model was applied to the fast-growing biopharmaceutical
industry in China. The expert panel included policy-makers from government agencies
and technology management experts from the health industries. Some of the experts were
stakeholders from the domestic and foreign organizations. These included domestic
enterprises, top multinational pharmaceutical companies and foreign research institutions.
Foreign stakeholders were included because of their technology strength and their longterm

investment

stakes

in

the

Chinese

pharmaceutical

market.

Domestic

biopharmaceutical companies were selected to represent local perspective in research and
development. The idea here is to reach a “Win-Win” situation in technology development.
A total of 20 experts participated in the research process (Table 13). According to
the University’s research policy on human subjects, the identities of the experts were
coded to protect their privacy (Appendix A, B). By following the expert recruitment
criteria discussed in Chapter 3, the expert panel was divided into three subgroups to
match the purpose of this research. Subgroup-G experts have backgrounds from various
Government agencies. All of them are senior officials or researchers from the National
Medical Policy Research Center, MOH, State Food & Drug Administration, and Center
of Drug Evaluation. Subgroup-F experts have Foreign backgrounds, and represent the
interests of various foreign organizations, which include two foreign research institutions
and three of the top-ten multinational enterprises (Roche, Sanofi-Aventis, and GSK).
Subgroup-L consists of Local experts from the domestic industry and research
organizations (non-government & without foreign backgrounds), which include bio-tech
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SMEs, industrial associations, and public research institutions. Since the experts come
from diverse sources, they can provide valuable judgment from different perspectives.

Expert

Affiliation

Subgroup - G

Subgroup - F

Subgroup - L

Exp - 1

Management

x

Exp - 2

Management

x

Exp - 3

Scientist/Researcher

x

Exp - 4

Scientist/Researcher

x

Exp - 5

Official

x

Exp - 6

Official

x

Exp - 7

Official

x

Exp - 8

Official

x

Exp - 9

Management

Exp - 10

Official

Exp - 11

Management

Exp - 12

Scientist/Researcher

x

Exp - 13

Scientist/Researcher

x

Exp - 14

Management

x

Exp - 15

Management

x

Exp - 16

Official

Exp - 17

Management

Exp - 18

Management

Exp - 19

Management

Exp - 20

Management

Total

x
x
x

x
x
x
x
x
8

7

5

Table 13: Expert Panel and Subgroups

4.6 Data Collection
The data collection process includes the design of research instruments, validation of
instruments, the formal quantification judgments, and related iterations. Here we discuss
the major steps respectively.
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Three sets of research instruments were developed to quantify the relative weights of
decision criteria at each level. There are 19 tables of pair-wise comparisons for eight
input resources, four innovation strategies, and two subgroups of technology areas. Each
table has 6 to 28 pairs of comparisons for judgment. The confidence level measurement
used Likert scaling (5 points means very high confidence, 4 points means high
confidence, 3 points means medium confidence, 2 points means low confidence, and 1
point means very low confidence). Confidence scores with medium or above scores from
the experts are acceptable for this research.
In the research instruments, the pair-wise comparison method (PCM) was used for
quantifying experts’ judgments. The constant sum (100) method was selected as the
scaling standard during the quantification process because it is more precise than the
conventional AHP’s 1-9 scaling. Experts were to compare the relative weight of every
two elements in the same level regarding their contribution to the element in the higher
level. An expert may assign any value between 1 ~ 99 to represent the relative weight of
a criterion. A larger number means a heavier weight of that criterion. For instance, if
criterion A was assigned with the value of 75, and criteria B assigned with 25, then A is
three times more important than B. Three sets of judgmental quantification instruments
were developed for the model. Each set of instruments was designed in accordance with
the requirements of a specific level. The judgmental quantification instruments are
attached in the appendices of this dissertation (Appendix D).
The robustness of the quantification instruments was first validated in several trial
runs before it was sent to the entire expert panel. This process ensured both usability and
clarity of the instruments to capture the priorities of criteria in the hierarchy. During the
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validation process, questions and suggestions on the instruments were collected for
improvements. Several minor improvements to the instruments were made based on the
feedback from the trial runs.
After all of the above preparation steps were completed, the research instruments
were formally sent to experts for quantification. Different sets of instruments were sent to
and filled out by different experts according to their expertise and areas of specialty.
During this process, necessary information and questions regarding the methodology of
the pair-wise comparisons were conducted through emails and phone calls. Due to
various reasons, the data collection process was very lengthy. Reminder emails were sent
repeatedly for feedback.
Upon receiving all of the completed research instruments from experts, the
researcher started the data analysis process using the pair-wise comparison software. The
results were calculated either in matrix or in vector formats. Some important indicators
and values such as the inconsistencies and disagreements were evaluated. As discussed in
the methodology section, if the inconsistency value is above 0.1, the input data need to be
verified with the original expert. In the data collection process, three inconsistencies were
observed, including one instance in the strategy level and two instances in the resource
level. Although all inconsistency values were very close to the 0.1 threshold, these inputs
were reported to the related expert for review. The researcher explained to them about the
inconsistency measurement, and the experts improved their judgmental inputs. Similarly,
if significant disagreement values were observed, iterations were also needed to verify
the results with related experts. These issues are not uncommon for other AHP-based
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research. In this research, such issues were resolved after several iterations of
communication with the experts. The aggregated results are presented in the next chapter.
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Chapter 5 – Results and Data Analysis

In this section, the results of data collection for each hierarchy level are calculated
and shown in figures and tables. The data analyses include disagreement measurement
and sensitivity analysis. The overall contributions of the bottom and intermediate levels
toward the mission are also calculated and presented.

5.1 Quantification Results
All judgmental data collected from the experts were first put into PCM software to
assess the relative weights of various criteria at different levels of the HDM. The
inconsistency values of the finalized results were less than 10% or 0.1, which is an
acceptable level according to available studies [208, 209]. Confidence level was
measured using the Likert scaling (5 means very high confidence, 4 means high
confidence, 3 means medium confidence, 2 means low confidence, and 1 point means
very low confidence). The scores of all levels are very close to 4, indicating that most
experts have high confidence level.

5.1.1 Contribution of Technologies to Mission
The following figure presents the results of the 13 technology areas’ contribution
toward the overall mission (Figure 18). The arithmetic means of relative priority of the
technology areas toward the mission are shown as percentages. Individual relative
priorities, mean values, and inconsistency values of each expert are shown in Table 14
and 15.
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Figure 18: Contribution of Technology Areas to Overall Mission

Group
A
Exp1
Exp2
Exp3
Exp5
Exp8
Exp9
Exp11
Exp13
Exp15
Exp18
Mean

T1:
T2:
T3:
T4:
T5:
T6:
T7:
Recombinant Recombinant Monoclonal Cell and
Gene Antisense RNAi
Inconsistency
Therapeutic Vaccines
Antibody Tissue
Therapy Therapy
Proteins
Engineering
0.13
0.13
0.21
0.16
0.16
0.10
0.12
0.010
0.28
0.25
0.13
0.06
0.11
0.09
0.09
0.052
0.21
0.21
0.21
0.13
0.10
0.09
0.06
0.014
0.18
0.14
0.22
0.11
0.12
0.11
0.12
0.009
0.35
0.20
0.26
0.07
0.04
0.04
0.04
0.020
0.28
0.28
0.22
0.08
0.08
0.02
0.06
0.020
0.20
0.38
0.21
0.07
0.07
0.04
0.03
0.079
0.26
0.25
0.20
0.10
0.09
0.04
0.07
0.087
0.18
0.16
0.25
0.16
0.08
0.06
0.12
0.007
0.23
0.11
0.25
0.09
0.13
0.10
0.10
0.035
0.23
0.21
0.22
0.10
0.10
0.07
0.08
Table 14: Contribution of Technology Areas to Mission, Group A

Group
B
Exp1
Exp2
Exp3
Exp5
Exp8
Exp9
Exp11
Exp13
Exp15
Exp18
Mean

T1:
T8:
T9:
T10:
T11:
T12:
T13:
Recombinant Nano- Synthetic BioPharmaco- Gene
Biotech
Inconsistency
Therapeutic biotech Biology informatics genetics Sequencing Diagnostics
Proteins
0.13
0.19
0.13
0.15
0.09
0.15
0.17
0.016
0.36
0.15
0.10
0.10
0.10
0.11
0.08
0.020
0.16
0.15
0.11
0.16
0.11
0.16
0.16
0.013
0.26
0.10
0.15
0.12
0.13
0.08
0.17
0.014
0.33
0.10
0.09
0.08
0.16
0.09
0.16
0.024
0.33
0.19
0.04
0.08
0.08
0.07
0.21
0.014
0.41
0.10
0.09
0.12
0.05
0.10
0.13
0.026
0.26
0.19
0.06
0.09
0.10
0.10
0.21
0.042
0.17
0.10
0.11
0.14
0.19
0.15
0.14
0.008
0.26
0.15
0.10
0.07
0.13
0.17
0.13
0.065
0.27
0.14
0.10
0.11
0.11
0.12
0.16
Table 15: Contribution of Technology Areas to Mission, Group B

151

In the above tables, the priority judgment of the 13 technology areas was split into
two groups. The purpose was to reduce the large number of pair-wise comparisons which
may induce a heavy workload for the experts. This process is referred to as chained
comparison and had been applied in available studies [252] [294]. The rationale of the
process is that each group shares a common important comparison element, which will be
utilized to normalize all other elements in each group. In this case, T1 was chosen during
the validation process as the common important criterion of the two groups. The
normalized values were calculated and are shown in Table 16 below.
Technology Areas
T1: Recombinant Therapeutic Proteins
T2: Recombinant Vaccines
T3: Monoclonal Antibody
T4: Cell and Tissue Engineering
T5: Gene Therapy
T6: Antisense Therapy
T7: RNAi
T8: Nanobiotechnology
T9: Synthetic Biology
T10: Bioinformatics
T11: Pharmacogenetics
T12: Gene Sequencing
T13: Biotechnology Diagnostics

Contribution
14%
13%
13%
6%
6%
4%
5%
7%
5%
6%
6%
7%
8%

Table 16: The Normalized Results

According to the results, T1 Recombinant Therapeutic Proteins has the highest
contribution (14%) toward the mission. T2 Recombinant Vaccines and T3 Monoclonal
Antibody Technology tie for the second and third places at 13%. T6 Antisense Therapy
contributes the least at 4% toward the mission (Table 16).
Recombinant therapeutic proteins are used to treat many non-communicable diseases
such as hematology, diabetes, endocrinology, and oncology. The technology to make
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recombinant therapeutic proteins was among the most promising biotechnologies for
improving health in developing countries. With the number of affluent people in China,
the prevalence of chronic disease is growing at staggering rates due to increased levels of
hypertension, diabetes, and obesity. This offers a huge demand for drug development in
the local market [295]. Affordable and sustainable sources of therapeutic proteins for
treating chronic disease are critical to developing countries like China [280].
Recombinant vaccines can be used to effectively treat infectious diseases. Vaccines
are widely considered as essential for disease prevention in both developing and
developed countries. Recombinant vaccines have proven to be cheaper as well as safer in
testing and production than inactivated or attenuated vaccines [283]. With a large
population, the outlook for vaccines remains bright in China. The growth rate of the
Chinese vaccine market is around 20%, and its size will reach CNY 12 billion by 2013
[296]. Focusing on this area is absolutely critical for domestic needs in China.
Monoclonal Antibody is one of the fastest growing areas in the biopharmaceutical
industry. The value of the global therapeutic mAb market exceeded US $17 billion in
2007, and many mAb applications become blockbuster drugs [297]. If China wants to be
competitive and innovative in the world’s biotech arena, mAb is an area that cannot be
overlooked.

5.1.2 Contribution of Development Strategies to Technologies Areas
This section presents the results of the relative contribution of strategies toward the
prospective technology areas. The results are illustrated in sequential order from T1 to
T13. The experts’ individual judgments for each technology area are also included. These
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findings give us the answer for “which strategy is better for the development of the target
technology.”

5.1.2.1 Strategies for T1: Recombinant Therapeutic Proteins
T1:
Recombinant
Therapeutic
Proteins
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.43
0.24
0.25
0.19
0.18
0.40
0.33
0.36
0.30

S2:
S3:
Imitative Collaborative
Innovation Innovation
0.35
0.33
0.43
0.40
0.39
0.26
0.21
0.29
0.33

0.16
0.24
0.20
0.15
0.22
0.14
0.20
0.16
0.18

S4:
Int’l Tech
Transfer
0.07
0.18
0.12
0.26
0.22
0.20
0.26
0.19
0.19

Inconsistency
0.013
0.004
0.005
0.031
0.032
0.002
0.001
0.009

Table 17: Contribution of Strategies to T1 Recombinant Therapeutic Proteins

Figure 19: Contribution of Strategies to T1 Recombinant Therapeutic Proteins

As shown in the results (Figure 19), S2 Imitative innovation strategy (33%) ranked
the first for T1 Recombinant Therapeutic Proteins, followed by S1 Indigenous innovation
strategy (30%) at the second position. S3 Collaborative innovation and S4 International
technology transfer ranked relatively low at 18% and 19% respectively. It should be
noted that the rankings of imitative innovation strategy and indigenous innovation
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strategy are relatively close, meaning that China should focus on catching up with leading
innovators, and also try to indigenously develop novel drugs in the area of recombinant
therapeutic proteins (Table 17).

5.1.2.2 Strategies for T2 Recombinant Vaccines

T2:
Recombinant
Vaccines
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.21
0.32
0.27
0.38
0.33
0.48
0.39
0.46
0.36

S2:
Imitative
Innovation
0.54
0.33
0.41
0.19
0.27
0.17
0.15
0.21
0.28

S3:
Collaborative
Innovation
0.21
0.21
0.16
0.30
0.22
0.17
0.30
0.18
0.22

S4:
Int’l Tech
Transfer
0.05
0.14
0.16
0.13
0.18
0.18
0.16
0.15
0.14

Inconsistency
0.080
0.034
0.031
0.035
0.008
0.007
0.005
0.023

Table 18: Contribution of Strategies to T2 Recombinant Vaccines

Figure 20: Contribution of Strategies to T2 Recombinant Vaccines

For T2 Recombinant Vaccines, S1 Indigenous innovation strategy ranked highest at
36%. S2 Imitative Innovation ranked second place at 28%, while S3 Collaborative
Innovation ranked third at 22%. Lastly, S4 International Technology Transfer ranked the
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lowest at 14%. The results indicate that China should focus on developing innovative
products, and building up indigenous competence in the vaccine area (Table 18 and
Figure 20).

5.1.2.3 Strategies for T3 Monoclonal Antibody Technology

T3:
Monoclonal
Antibody
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.16
0.24
0.16
0.30
0.18
0.36
0.27
0.31
0.25

S2:
Imitative
Innovation
0.68
0.36
0.67
0.28
0.22
0.29
0.25
0.32
0.38

S3:
Collaborative
Innovation
0.10
0.26
0.13
0.27
0.33
0.19
0.30
0.28
0.23

S4:
Int’l Tech
Transfer
0.06
0.14
0.04
0.15
0.27
0.16
0.18
0.09
0.14

Inconsistency
0.044
0.004
0.038
0.045
0.008
0.027
0.010
0.003

Table 19: Contribution of Strategies to T3 Monoclonal Antibody Technology

Figure 21: Contribution of Strategies to T3 Monoclonal Antibody Technology

For T3 Monoclonal Antibody Technology, S2 Imitative innovation strategy ranked
the highest at 38%. S1 Indigenous innovation ranked second at 25% and S3 Collaborative
innovation was third at 23%. Again, S4 International Technology Transfer ranked the
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lowest at only 14%. The results indicate that China should focus on catching up with
foreign leaders in the area of monoclonal antibody technologies (Table 19 and Figure 21).

5.1.2.4 Strategies for T4 Cell and Tissue Engineering

T4:
Cell & Tissue
Engineering
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.49
0.24
0.09
0.23
0.25
0.37
0.26
0.15
0.26

S2:
Imitative
Innovation
0.31
0.36
0.48
0.24
0.18
0.34
0.22
0.36
0.31

S3:
Collaborative
Innovation
0.15
0.26
0.26
0.31
0.30
0.21
0.29
0.30
0.26

S4:
Int’l Tech
Transfer
0.05
0.14
0.17
0.22
0.27
0.08
0.23
0.19
0.17

Inconsistency
0.008
0.004
0.046
0.063
0.004
0.015
0.025
0.008

Table 20: Contribution of Strategies to T4 Cell and Tissue Engineering

Figure 22: Contribution of Strategies to T4 Cell and Tissue Engineering

For T4 Cell and Tissue Engineering, S2 Imitative innovation strategy ranked the
highest at 31%. In second place, S1 Indigenous innovation and S3 Collaborative
innovation tied with each other at 26%. S4 International Technology Transfer ranked the
lowest at 17%. The results indicate that China should favor the imitative option, but the
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indigenous and collaborative approaches are also quite viable for the current conditions
(Table 20 and Figure 22).

5.1.2.5 Strategies for T5 Gene Therapy

T5:
Gene
Therapy
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.31
0.24
0.07
0.27
0.24
0.34
0.29
0.27
0.25

S2:
Imitative
Innovation
0.47
0.36
0.63
0.23
0.21
0.31
0.26
0.35
0.35

S3:
Collaborative
Innovation
0.14
0.26
0.21
0.30
0.38
0.20
0.27
0.21
0.25

S4:
Int’l Tech
Transfer
0.07
0.14
0.09
0.19
0.16
0.15
0.18
0.18
0.15

Inconsistency
0.015
0.004
0.013
0.007
0.017
0.012
0.011
0.022

Table 21: Contribution of Strategies to T5 Gene Therapy

Figure 23: Contribution of Strategies to T5 Gene Therapy

For T5 Gene Therapy, S2 Imitative innovation strategy received the highest ranking
at 35%. S1 Indigenous innovation and S3 Collaborative innovation tied again for second
place, but at 25% in this case. S4 International Technology Transfer ranked the lowest at
15%. The results indicate that China should focus on catching up with advanced countries
in the area of gene therapy.
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5.1.2.6 Strategies for T6 Antisense Therapy

T6:
Antisense
Therapy
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.35
0.13
0.08
0.08
0.26
0.30
0.18
0.23
0.20

S2:
Imitative
Innovation
0.35
0.47
0.64
0.31
0.16
0.34
0.28
0.35
0.36

S3:
Collaborative
Innovation
0.19
0.22
0.19
0.31
0.38
0.20
0.30
0.22
0.25

S4:
Int’l Tech
Transfer
0.12
0.18
0.09
0.31
0.19
0.16
0.23
0.20
0.19

Inconsistency
0.018
0.045
0.019
0.001
0.009
0.006
0.014
0.003

Table 22: Contribution of Strategies to T6 Antisense Therapy

Figure 24: Contribution of Strategies to T6 Antisense Therapy

For T6 Antisense Therapy, S2 Imitative innovation strategy ranked first at 36%. S3
Collaborative innovation ranked second at 25%. S1 Indigenous innovation ranked third at
20%, while S4 International Technology Transfer ranked slightly lower at 19%. The
results indicate that China should focus on catching up with foreign countries in the area
of antisense therapy (Table 22 and Figure 24).
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5.1.2.7 Strategies for T7 RNAi

T7:
RNAi
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.35
0.15
0.06
0.25
0.22
0.32
0.28
0.26
0.24

S2:
Imitative
Innovation
0.35
0.44
0.55
0.26
0.18
0.34
0.24
0.39
0.34

S3:
Collaborative
Innovation
0.19
0.25
0.26
0.29
0.33
0.16
0.30
0.22
0.25

S4:
Int’l Tech
Transfer
0.12
0.16
0.12
0.20
0.27
0.17
0.17
0.13
0.17

Inconsistency
0.018
0.032
0.002
0.001
0.008
0.003
0.001
0.012

Table 23: Contribution of Strategies to T7 RNAi

Figure 25: Contribution of Strategies to T7 RNAi

For T7 RNAi, S2 Imitative innovation strategy ranked first place at 34%. S3
Collaborative innovation and S1 Indigenous innovation ranked closely for second and
third places at 25% and 24% respectively. S4 International Technology Transfer ranked
the lowest at 17%. The results also indicate that China should focus on catching up with
advanced countries in the area of RNAi (Figure 25).
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5.1.2.8 Strategies for T8 Nanobiotechnology

T8:
Nanobiotech
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.25
0.10
0.06
0.24
0.23
0.28
0.27
0.23
0.21

S2:
Imitative
Innovation
0.43
0.46
0.66
0.29
0.18
0.33
0.28
0.35
0.37

S3:
Collaborative
Innovation
0.22
0.19
0.21
0.27
0.33
0.18
0.24
0.23
0.23

S4:
Int’l Tech
Transfer
0.10
0.24
0.07
0.20
0.26
0.21
0.21
0.19
0.19

Inconsistency
0.004
0.056
0.017
0.015
0.005
0.003
0.005
0.006

Table 24: Contribution of Strategies to T8 Nanobiotechnology

Figure 26: Contribution of Strategies to T8 Nanobiotechnology

For T8 Nanobiotechnology, S2 Imitative innovation strategy ranked first at 37%. S3
Collaborative innovation ranked second at 23%. S1 Indigenous innovation ranked third at
21%. S4 International Technology Transfer ranked fourth at 19%. The results are obvious
that China should focus on catching up with leading innovators in the area of
nanobiotechnology (Table 24 and Figure 26).
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5.1.2.9 Strategies for T9 Synthetic Biology

T9:
Synthetic
Biology
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.33
0.38
0.07
0.15
0.22
0.36
0.24
0.23
0.25

S2:
Imitative
Innovation
0.47
0.22
0.67
0.37
0.18
0.30
0.36
0.34
0.36

S3:
Collaborative
Innovation
0.12
0.26
0.19
0.28
0.39
0.19
0.25
0.27
0.24

S4:
Int’l Tech
Transfer
0.07
0.14
0.07
0.20
0.22
0.15
0.15
0.16
0.15

Inconsistency
0.005
0.079
0.018
0.018
0.032
0.003
0.007
0.019

Table 25: Contribution of Strategies to T9 Synthetic Biology

Figure 27: Contribution of Strategies to T9 Synthetic Biology

For T9 Synthetic Biology, S2 Imitative innovation strategy ranked first at 36%. S1
Indigenous innovation and S3 Collaborative innovation have relatively close priority at
25% and 24% respectively. S4 International Technology Transfer ranked the lowest at
15%. The results indicate that China should focus on catching up with leaders in the area
of synthetic biology (Table 25 and Figure 27).
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5.1.2.10 Strategies for T10 Bioinformatics

T10:
Bioinformatics
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.41
0.24
0.10
0.35
0.24
0.45
0.34
0.37
0.31

S2:
Imitative
Innovation
0.34
0.36
0.50
0.20
0.18
0.25
0.21
0.23
0.28

S3:
Collaborative
Innovation
0.15
0.26
0.27
0.23
0.33
0.18
0.31
0.25
0.25

S4:
Int’l Tech
Transfer
0.10
0.14
0.13
0.22
0.24
0.12
0.14
0.15
0.16

Inconsistency
0.005
0.004
0.018
0.008
0.004
0.034
0.019
0.031

Table 26: Contribution of Strategies to T10 Bioinformatics

Figure 28: Contribution of Strategies to T10 Bioinformatics

For T10 Bioinformatics, S1 Indigenous innovation strategy ranked highest at 31%.
S2 Imitative Innovation ranked second place at 28%. S3 Collaborative Innovation ranked
third at 25%. S4 International Technology Transfer ranked the lowest at 16%. The results
indicate that China should focus on developing new applications, and building up
indigenous competence in the area of bioinformatics (Table 26 and Figure 28).

163

5.1.2.11 Strategies for T11 Pharmacogenetics

T11:
Pharmacogenetics
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.33
0.22
0.04
0.27
0.25
0.29
0.23
0.27
0.24

S2:
Imitative
Innovation
0.41
0.30
0.60
0.24
0.22
0.37
0.26
0.35
0.34

S3:
Collaborative
Innovation
0.17
0.22
0.25
0.30
0.33
0.18
0.29
0.21
0.24

S4:
Int’l Tech
Transfer
0.09
0.25
0.11
0.19
0.20
0.16
0.23
0.18
0.18

Inconsistency
0.006
0.004
0.042
0.021
0.012
0.014
0.027
0.008

Table 27: Contribution of Strategies to T11 Pharmacogenetics

Figure 29: Contribution of Strategies to T11 Pharmacogenetics

For T11 Pharmacogenetics, S2 Imitative innovation strategy ranked first at 34%. S1
Indigenous innovation and S3 Collaborative innovation tied for second place at 24%. S4
International Technology Transfer ranked the last at 18%. The results indicate that China
should focus on catching up with foreign leaders in the area of pharmacogenetics (Table
27 and Figure 29).

164

5.1.2.12 Strategies for T12 Gene Sequencing

T12:
Gene
Sequencing
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.40
0.29
0.07
0.19
0.18
0.27
0.20
0.15
0.22

S2:
Imitative
Innovation
0.26
0.30
0.45
0.30
0.22
0.31
0.27
0.36
0.31

S3:
Collaborative
Innovation
0.17
0.27
0.29
0.26
0.33
0.26
0.32
0.26
0.27

S4:
Int’l Tech
Transfer
0.17
0.14
0.19
0.25
0.27
0.16
0.21
0.23
0.20

Inconsistency
0.000
0.021
0.009
0.001
0.008
0.014
0.005
0.028

Table 28: Contribution of Strategies to T12 Gene Sequencing

Figure 30: Contribution of Strategies to T12 Gene Sequencing

For T12 Gene Sequencing, S2 Imitative innovation strategy ranked first at 31%. S3
Collaborative innovation ranked second at 27%. S1 Indigenous innovation ranked third at
22%. S4 International Technology Transfer ranked fourth at 20%. The results indicate
that China should focus more on imitative innovation, and also try the collaborative
approach in the area of gene sequencing (Table 28 and Figure 30).
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5.1.2.13 Strategies for T13 Biotechnology Diagnostics

T13:
Biotech
Diagnostics
Exp4
Exp6
Exp11
Exp12
Exp15
Exp16
Exp19
Exp20
Mean

S1:
Indigenous
Innovation
0.37
0.20
0.10
0.21
0.18
0.27
0.15
0.19
0.21

S2:
Imitative
Innovation
0.37
0.30
0.56
0.32
0.20
0.35
0.31
0.33
0.34

S3:
Collaborative
Innovation
0.17
0.22
0.15
0.23
0.39
0.24
0.33
0.28
0.25

S4:
Int’l Tech
Transfer
0.09
0.27
0.19
0.23
0.24
0.15
0.21
0.20
0.20

Inconsistency
0.002
0.004
0.024
0.004
0.022
0.035
0.016
0.001

Table 29: Contribution of Strategies to T13 Biotechnology Diagnostics

Figure 31: Contribution of Strategies to T13 Biotechnology Diagnostics

For T13 Biotechnology Diagnostics, S2 Imitative innovation strategy ranked the
highest at 34%. S3 Collaborative innovation ranked second at 25%. S1 Indigenous
innovation ranked third at 21%. S4 International Technology Transfer ranked the lowest
at 20%. The results indicate that China should focus on catching up with foreign leaders
in the area of biotechnology diagnostics (Table 29 and Figure 31).
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Technology Areas
T1: Recombinant Therapeutic
Proteins
T2: Recombinant Vaccines
T3: Monoclonal Antibody
T4: Cell and Tissue Engineering
T5: Gene Therapy
T6: Antisense Therapy
T7: RNAi
T8: Nanobiotechnology
T9: Synthetic Biology
T10: Bioinformatics
T11: Pharmacogenetics
T12: Gene Sequencing
T13: Biotechnology Diagnostics

S1:
S2:
Indigenous Imitative
Innovation Innovation
0.30
0.33
0.36
0.28
0.25
0.38
0.26
0.31
0.25
0.35
0.20
0.36
0.24
0.34
0.21
0.37
0.25
0.36
0.31
0.28
0.24
0.34
0.22
0.31
0.21
0.34

S3:
S4:
Collaborative Int’l Tech
Innovation Transfer
0.18
0.19
0.22
0.14
0.23
0.14
0.26
0.17
0.25
0.15
0.25
0.19
0.25
0.17
0.23
0.19
0.24
0.15
0.25
0.16
0.24
0.18
0.27
0.20
0.25
0.20

Table 30: Summary of Strategy Level

Lastly, as a short summary of the strategy level, the above results show that imitative
innovation strategy should be selected for 11 out of the 13 technology areas. The
remaining two technology areas belong to the indigenous innovation strategy. For most
cases, the ranks of collaborative innovation strategy and indigenous innovation strategy
are relatively close, which even tied for the second place in several areas. International
technology transfer received relatively low priority for most technology areas (Table 30).

5.1.3 Contribution of Resources to Strategies
The following tables present the results of the relative contribution of the input
resources toward the innovation strategies. These findings answer the question “What
innovation resources can contribute more to the technological development strategy?” or
“What innovation resources should be emphasized in policy development toward the
preferred innovation strategy?”
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5.1.3.1 Indigenous Innovation

S1:
Indigenous
Innovation
Exp7
Exp8
Exp10
Exp11
Exp14
Exp17
Exp18
Exp19
Exp20
Mean

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
FR&D

A8:
MNCs

0.07
0.05
0.17
0.20
0.09
0.10
0.06
0.12
0.14
0.11

0.11
0.06
0.15
0.16
0.08
0.08
0.04
0.08
0.11
0.10

0.05
0.09
0.07
0.03
0.04
0.06
0.07
0.06
0.08
0.06

0.13
0.14
0.09
0.17
0.09
0.13
0.21
0.29
0.25
0.17

0.13
0.16
0.09
0.04
0.12
0.15
0.13
0.11
0.15
0.12

0.15
0.18
0.09
0.07
0.13
0.05
0.14
0.08
0.12
0.11

0.18
0.16
0.13
0.06
0.17
0.24
0.17
0.16
0.10
0.15

0.19
0.16
0.21
0.27
0.29
0.19
0.19
0.10
0.06
0.18

Inconsistency
0.013
0.016
0.012
0.071
0.005
0.012
0.063
0.008
0.029

Table 31: Contribution of Resources to Indigenous Innovation

20%
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
A8:
FR&D MNCs

Figure 32: Contribution of Resources to Indigenous Innovation

In Table 31, the results show that A8 Multinational companies and subsidiaries (18%)
contribute the most toward Indigenous Innovation, followed by A4 High-tech SMEs
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(17%). Their priority rankings are very close, which indicate both resources should be
encouraged for the improvement of China’s indigenous innovation capability (Figure 32).
A deeper inspection of recent studies reveals that the above findings are reasonable.
Research claimed that “MNCs pave the way for an innovative pharmaceutical industry in
China” [298]. MNCs’ penetration will set the quality standards for local industries. They
will initially absorb and be responsible for the training of local talents. MNCs’
investment in local businesses will also be a substantial source of capital for Chinese
R&D. As opportunities provided by domestic players improve, the migration of skilled
talents from conglomerates will nurture the thriving small businesses [298].
Biotech SMEs constitute the largest group of players in the Chinese
biopharmaceutical sector [299]. Almost all of the private SMEs emerged during the
1990’s and 2000’s. Private ownership of companies was not allowed in China until the
mid 1980’s. The majority of biotech SMEs consists of spinoffs from other institutions
such as universities, research institutes, SOEs, and MNCs. In recent years, an increasing
number of firms were founded by foreign-trained returnees from developed countries.
Biotech SMEs have gradually become more influential players in the local industry. The
innovation capability of SMEs will largely decide the competitiveness of China’s
biopharmaceutical industry.

5.1.3.2 Imitative Innovation
As presented in Table 32 and Figure 33, the experts think that A4 High-tech SMEs
(23%) contribute more to imitative Innovation, followed by A1 University Research
Programs (17%) and A2 Public Research Institutes 13%.
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S2:
Imitative
Innovation
Exp7
Exp8
Exp10
Exp11
Exp14
Exp17
Exp18
Exp19
Exp20
Mean

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
FR&D

A8:
MNCs

0.12
0.06
0.13
0.16
0.20
0.24
0.16
0.21
0.23
0.17

0.10
0.06
0.10
0.23
0.18
0.15
0.08
0.15
0.09
0.13

0.06
0.08
0.06
0.06
0.17
0.12
0.10
0.08
0.07
0.09

0.14
0.18
0.18
0.35
0.22
0.19
0.19
0.28
0.31
0.23

0.11
0.16
0.09
0.06
0.08
0.10
0.14
0.11
0.07
0.10

0.14
0.17
0.12
0.09
0.07
0.05
0.14
0.06
0.09
0.10

0.18
0.16
0.14
0.04
0.05
0.07
0.10
0.06
0.08
0.10

0.16
0.15
0.19
0.02
0.04
0.08
0.09
0.05
0.06
0.09

Inconsistency
0.012
0.004
0.011
0.044
0.034
0.012
0.050
0.006
0.013

Table 32: Contribution of Resources to Imitative Innovation

25%
20%
15%
10%
5%
0%
A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
A8:
FR&D MNCs

Figure 33: Contribution of Resources to Imitative Innovation

High-tech SMEs may contribute more toward imitation for several reasons [299]:
aggressive thinking and action; flexible business strategy; low operational cost and high
efficiency; better control in designated territory; and good service provision. University
Research Programs and Public Research Institutes are ranked high because they possess a
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huge number of biotechnical R&D personnel as well as considerable technical capability
and experience [295]. Such factors are essential elements for technological learning in
high-tech areas.

5.1.3.3 Collaborative Innovation

S3:
Collaborative
Innovation
Exp7
Exp8
Exp10
Exp11
Exp14
Exp17
Exp18
Exp19
Exp20
Mean

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
FR&D

A8:
MNCs

0.11
0.05
0.13
0.13
0.08
0.19
0.16
0.16
0.15
0.13

0.12
0.09
0.10
0.22
0.07
0.15
0.10
0.13
0.12
0.12

0.08
0.09
0.07
0.10
0.10
0.12
0.10
0.10
0.11
0.10

0.14
0.13
0.13
0.34
0.12
0.24
0.21
0.18
0.17
0.18

0.14
0.17
0.11
0.07
0.11
0.08
0.14
0.13
0.08
0.11

0.14
0.15
0.13
0.10
0.14
0.10
0.10
0.13
0.16
0.13

0.14
0.16
0.16
0.04
0.14
0.05
0.09
0.11
0.09
0.11

0.15
0.16
0.18
0.02
0.25
0.06
0.10
0.08
0.12
0.12

Table 33: Contribution of Resources to Collaborative Innovation
20%
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
A8:
FR&D MNCs

Figure 34: Contribution of Resources to Collaborative Innovation
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Inconsistency
0.013
0.008
0.016
0.023
0.016
0.012
0.020
0.012
0.011

In Table 33 and Figure 34, the results show that A4 High-tech SMEs contributed the
most toward collaborative innovation at 18%. A1 University Research Programs and A6
Contract Research/Manufacturing Organizations tied at 13% and ranked in second place.
High-tech SMEs are often very active players in collaborative activities. SMEs need
to seek complementary resources due to limited company size, financial funding, and
research capacity [299]. Cooperation with other players is among the best choices for
them. Universities are well known to be specialized in the area of basic research. Both
domestic and foreign players collaborate with Chinese universities in early-stage
preclinical studies. Contract Research/Manufacturing Organizations are more focused on
providing clinical trial or production services for other players.

5.1.3.4 International Technology Transfer

S4:
Int’l Tech
Transfer
Exp7
Exp8
Exp10
Exp11
Exp14
Exp17
Exp18
Exp19
Exp20
Mean

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
FR&D

A8:
MNCs

0.08
0.05
0.11
0.05
0.05
0.10
0.09
0.05
0.07
0.07

0.09
0.07
0.09
0.07
0.03
0.08
0.10
0.06
0.06
0.07

0.09
0.08
0.08
0.18
0.02
0.06
0.20
0.08
0.10
0.10

0.14
0.15
0.16
0.06
0.05
0.13
0.09
0.10
0.13
0.11

0.15
0.16
0.11
0.15
0.05
0.15
0.18
0.12
0.11
0.13

0.15
0.15
0.13
0.12
0.09
0.05
0.15
0.13
0.11
0.12

0.15
0.18
0.15
0.12
0.16
0.24
0.11
0.19
0.16
0.16

0.15
0.17
0.17
0.25
0.56
0.19
0.09
0.28
0.26
0.24

Inconsistency

Table 34: Contribution of Resources to International Technology Transfer
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0.007
0.007
0.009
0.078
0.030
0.012
0.049
0.028
0.011

25%
20%
15%
10%
5%
0%
A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
A8:
FR&D MNCs

Figure 35: Contribution of Resources to International Technology Transfer

In Table 34 and Figure 35, the results show that A8 MNCs contributed the most
toward international technology transfer at 24%, followed by A7 Foreign R&D Centers at
16%. A5 Equity Joint Ventures ranked third at 13%.
As seen from the literature review, most China-related technology transfer studies
deal with multinational companies, which are the most important technology carriers in
the international technology transfer process [71]. Foreign R&D Centers and Joint
Ventures were also ranked high because they have better access to foreign technologies.
However, in recent years, there have been more cases of technical transactions from
domestic players to foreign players. Many MNCs have acquired domestic companies or
research outcomes to broaden their research pipelines [300]. International technology
transfer has become a mutual process to benefit both sides in the Chinese
biopharmaceutical sector.
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5.1.4 Overall Contributions
After validating the values of relative priority at each level, the contribution of lower
level elements toward the overall mission can be calculated by vector and matrix
manipulations. The following matrix calculations demonstrate the process and results.
This includes: Innovation Strategies to Mission [S/M], Resource Alternatives to
Prospective Technology Areas [A/T], and Resource Alternatives to Mission [A/M]. The
other two matrixes represent Strategies to Technology Areas [S/T] and Resource
Alternatives to Strategies [A/S].

Contribution of Strategies to Mission:
[S/M] = [S/T] x [T/M]
0.30
0.33
0.18
0.19

0.36
0.28
0.22
0.14

0.25
0.38
0.23
0.14

0.26
0.31
0.26
0.17

0.25
0.35
0.25
0.15

Equation (1)
0.20
0.36
0.25
0.19

0.24
0.34
0.25
0.17

0.21
0.37
0.23
0.19

0.25
0.36
0.24
0.15

0.31
0.28
0.25
0.16

174

0.24
0.34
0.24
0.18

0.22 0.21
0.31 0.34
0.27 0.25
0.20 0.20

0.14 0.26
0.13 = 0.33
0.13 0.23
0.06 0.17
0.06
0.04
0.05
0.07
0.05
0.06
0.06
0.07
0.08

Contribution of Resource Alternatives to Technology Areas:
[A/T] = [A/S] x [S/T]
0.11
0.10
0.06
0.17
0.12
0.11
0.15
0.18

0.17
0.13
0.09
0.23
0.10
0.10
0.10
0.09

0.13
0.11
0.08
= 0.18
0.11
0.11
0.13
0.15

0.13
0.12
0.10
0.18
0.11
0.13
0.11
0.12

0.13
0.11
0.08
0.18
0.11
0.11
0.13
0.15

0.07
0.07
0.10
0.11
0.13
0.12
0.16
0.24

0.13
0.11
0.09
0.19
0.11
0.11
0.12
0.14

Equation (2)

0.30
0.33
0.18
0.19

0.13
0.11
0.09
0.18
0.11
0.11
0.13
0.15

0.36
0.28
0.22
0.14

0.13
0.11
0.09
0.18
0.11
0.11
0.12
0.14

0.25
0.38
0.23
0.14

0.13
0.11
0.09
0.18
0.11
0.11
0.12
0.14

0.26
0.31
0.26
0.17

0.13
0.11
0.09
0.18
0.11
0.11
0.12
0.14

0.25
0.35
0.25
0.15

0.13
0.11
0.09
0.18
0.11
0.11
0.12
0.14

0.20
0.36
0.25
0.19

0.13
0.11
0.09
0.19
0.11
0.11
0.12
0.14

0.24
0.34
0.25
0.17

0.13
0.11
0.08
0.18
0.11
0.11
0.13
0.15

0.21
0.37
0.23
0.19

0.13
0.11
0.09
0.18
0.11
0.11
0.13
0.15

0.25
0.36
0.24
0.15

0.13
0.11
0.09
0.18
0.11
0.11
0.13
0.15

0.31
0.28
0.25
0.16

0.24
0.34
0.24
0.18

0.22
0.31
0.27
0.20

0.21
0.34
0.25
0.20

0.13
0.11
0.09
0.18
0.11
0.11
0.13
0.15

Contribution of Resource Alternatives to Mission:
[A/M] = [A/S] x [S/T] x [T/M] = [A/T] x [T/M]

Equation (3)

0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.14
0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.11 0.13
0.08
0.18
0.11
0.11
0.13
0.15

0.08
0.18
0.11
0.11
0.13
0.15

0.09
0.19
0.11
0.11
0.12
0.14

0.09
0.18
0.11
0.11
0.13
0.15

0.09
0.18
0.11
0.11
0.12
0.14

0.09
0.18
0.11
0.11
0.12
0.14

0.09
0.18
0.11
0.11
0.12
0.14

0.09
0.18
0.11
0.11
0.12
0.14

0.09
0.19
0.11
0.11
0.12
0.14

0.08
0.18
0.11
0.11
0.13
0.15
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0.09
0.18
0.11
0.11
0.13
0.15

0.09
0.18
0.11
0.11
0.13
0.15

0.09
0.18
0.11
0.11
0.13
0.15

0.13
0.11

0.13 = 0.09
0.06 0.18
0.06 0.11
0.04 0.11
0.05 0.13
0.07 0.15
0.05
0.06
0.06
0.07
0.08

5.1.4.1 Overall Contribution of Strategies to Mission
The relative contribution of the strategies to the mission can be calculated by
multiplying the arithmetic mean of the strategic priority and the mean values of the
relative contribution of technology areas to mission. According to Matrix [S/M], the
results are presented in Figure 36.

Figure 36: Contribution of Strategies to Mission

The above results show that technology development strategy should focus more on
imitative innovation (33%). Indigenous innovation (26%) is regarded as the second best
option to improve national competitive capability and to obtain high industry value for
China. Collaborative innovation ranked third at 23%. Lastly, international technology
transfer contributed 17% to the overall mission.
Imitative innovation strategy has the highest overall ranking because it ranks highest
for 11 technology areas out of the total 13 areas. This conforms to the fact that China has
limited capability in developing novel drugs. Referring to Figure 16, generic drugs are
the mainstay of China's pharmaceutical industry, and that is unlikely to change in the
short term. While the government encourages and relies upon innovation to meet industry
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targets, China will probably continue to rely upon widespread prescriptions of generics in
public insurance plans to reduce the overall healthcare expenditures, and the current
R&D capability also limits the possibility of launching domestic patented drugs in the
near future [301]. It is more realistic for the country to focus on catching up with
advanced countries in the high-tech areas. Biosimilars offer one legal way of widening
access and enabling better value to be obtained for latecomer countries like China. Here,
the need to broaden healthcare coverage to large populations must be balanced against
limited budgets and growing demand for innovative drugs [302].

5.1.4.2 Overall Contribution of Resource Alternatives to the Mission
The relative contribution of bottom level resources toward the mission can be
calculated by multiplying the arithmetic mean of the resources to strategies, strategies to
technology areas, and technology areas to mission. The results are presented in Figure 37.

0.20
0.18
0.16
0.14
0.12
0.10
0.08
0.06
0.04
0.02
0.00

18%
15%
13%

13%
11%

11%

11%

A5:
EJVs

A6:
A7:
A8:
CROs FR&D MNCs

9%

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

Figure 37: Contribution of Resources to Mission
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From the above results, we can observe that A4 High-tech SMEs contributed about
18% and ranked first toward the overall mission, indicating its important position in
technological innovation. A8 MNCs ranked second in overall contribution at 15%. Lastly,
A3 SOEs are ranked surprisingly low with 9% in overall contribution, indicating an area
for improvement in terms of innovative performance.
There are several reasons for high-tech SMEs to rank the highest. Firstly, biotech
SMEs have a higher contribution toward indigenous innovation. After a burst of growth
for 20 years, SMEs have become the mainstay players in China’s biopharmaceutical
sector. China is now home to more than 700 biopharmaceutical companies, among which
over 500 are small enterprises with net assets of less than US$10 million [303] [304]. The
capabilities of these SMEs have a significant impact on China’s indigenous innovation.
Secondly, SMEs contribute more toward the imitative innovation strategy, which has
been identified as the most preferred strategy in China’s biopharmaceutical sector today.
As discussed in the above sections, biotech SMEs are more flexible and efficient in
product development. They have cost advantages and are more focused in specialty hightech areas. Thirdly, SMEs contribute more toward collaborative innovation. Due to
limited scale, biotech SMEs actively cooperate with other players for complementary
resources. The areas of cooperation include all aspects such as financial investment, joint
research, and production.
Multinational companies and subsidiaries ranked second toward the overall mission,
indicating that foreign investments are important sources in China’s current innovation
ecosystems. Firstly, MNCs ranked very high in terms of international technology transfer.
These companies have brought some of the latest technologies into the local market.
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MNCs played important roles in upgrading the local industrial structure during the last
two decades. Secondly, MNCs also ranked high for indigenous innovation. MNCs are
expected to lead the way for the innovative biopharmaceutical industry in China [298].
Through demonstration effects, MNCs set the industrial standards according to
internationally accepted practice. Employee training and turnovers also benefited the
domestic players in the long run [160]. In fact, without the open door policy and foreign
investment from MNCs, the local industries would not have achieved what is happening
today. Therefore, it can be predicted that the presence of MNCs will continue to
contribute to technological innovations in China.

5.2 Measurement of Disagreement
It is natural to have different opinions among the experts during the research process.
The diverse social backgrounds and working experiences of the experts may cause
significant differences in opinions or perspectives toward any research topic. This section
addresses such disagreement issues at each level of the research model.
According to the methdology illustrated in Section 3.6, the intraclass correlation
coefficient RIC was calculated to measure the disagreement among experts. Shrout and
Fleiss (1979) developed a statistical procedure to test the hypothesis about whether or not
there is an absolute disagreement among the judges [271]. F-test was applied in the
calculation process. The application of this methodology on HDM was first done by N.
Gerdsri (2004), and expanded by P. Gerdsri (2009) [210, 211] [208, 209].

179

5.2.1 Technology Level
Referring to the data presented in Section 5.1.1, the following hypothesis was tested
for disagreement among the experts:
H0: RIC = 0

there is disagreement

H1: RIC > 0

there is statistically significant evidence that there is some level of
agreement

The calculation process of the intraclass correlation coefficient and F-test was done
through SPSS software (Appendix E). The results are shown in Table 35.
The coefficient for the ten experts in Group A is 0.67, and for Group B it is 0.57.
Both values are relatively high (scale 0 to 1). Therefore, it can be argued that there is high
agreement among the group of experts. F-test was further applied to approve this
argument. The process was done through computing the FBS value and comparing it to
the F-critical value. The FBS value of Group A is 18.08. The F-critical with df1 = 6 and
df2 = 6*9 = 54 at the 0.01 level is less than 3.29. While df2 = 54 is not provided in the
table, an even larger value of df2 = 40 is used. This is a more conservative value which
makes it more difficult to obtain significance. Since the FBS value is larger than F-critical
(0.01), the null hypothesis can be rejected. This result confirms that there is statistically
significant agreement in Group A at F-test 0.01 level. Similarly, the FBS value of Group B
is 12.11, which is also larger than F-critical (0.01); the null hypothesis is also rejected.
The result confirms that significant agreement exists in Group B at F-test 0.01 level.

P-value

FBS

Fcritical(0.01)

F-test Results

Group A

<0.001

18.08

3.29

H0 rejected at 0.01 level

Group B

<0.001

12.11

3.29

H0 rejected at 0.01 level

Table 35: Calculation of Disagreement at the Technology Level
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Since the null hypotheses in both tables were rejected at the 0.01 level, we may
conclude that the experts reached a very high level of agreement for the technology level.
Although the experts come from different sources and have different backgrounds, their
perceptions about prospective technology areas for China are very similar.

5.2.2 Strategy Level
Referring to the data presented in Section 5.1.2, the intraclass correlation coefficient
and F-test were calculated for the strategy level (Table 36). The results show that RIC
coefficients range from 0.20 to 0.49, indicating that a certain degree of agreement exists
among the experts in all examined technology areas. F-test was further applied to
compare the FBS value and the F-critical value with df1 = 3 and df2 = 21. As we examine
the results from Table 36, the results have the following features:
1) All of the FBS values are larger than F-critical at the 0.1 level. This means
disagreements among experts for all technology areas can be rejected at the 0.1 level.
2) There are 11 of 13 technology areas where the FBS value is larger than F-critical
(0.05). This indicates that the disagreements for these 11 areas can be rejected at the 0.05
level. The two exceptions are T4 Cell and Tissue Engineering and T12 Gene Sequencing,
where the values of FBS are smaller than the F-critical (0.05). The results indicate that
disagreements for these two areas cannot be rejected at the 0.05 level.
3) There are four technology areas, where the FBS values are larger than the F-critical
(0.01), indicating that disagreements for these four areas can be rejected at the 0.01 level.
These areas include T1 Recombinant Therapeutic Proteins, T2 Recombinant Vaccines,
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T5 Gene Therapy, and T8 Nanobiotechnology. For the remaining nine technology areas,
where the FBS values are smaller than the F-critical (0.01), disagreements cannot be
rejected at this highest level at 0.01.

P-value

FBS

Fcritical(0.01)

F-test results

T1

0.002

6.80

4.87

H0 rejected at 0.01 level

T2

0.003

6.21

4.87

T3

0.011

4.79

4.87

T4

0.084

2.53

4.87

H0 rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.1 level, but
cannot be rejected at 0.05 level

T5

0.008

5.16

4.87

T6

0.023

3.89

4.87

T7

0.015

4.41

4.87

T8

0.009

4.94

4.87

T9

0.015

4.36

4.87

T10

0.029

3.67

4.87

T11

0.022

3.96

4.87

T12

0.058

2.92

4.87

T13

0.022

3.94

4.87

H0 rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.1 level, but
cannot be rejected at 0.05 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level

Table 36: Calculation of Disagreement at the Strategy Level

When compared with the technology level, the strategy level has more disagreement
issues. Although all null hypotheses can be rejected at the 0.1 level, the degree of
agreement is relatively low. In many available studies, the 0.05 level has been used as a
medium range. However, in the above results, two technology areas are still below the
medium level. Moreover, most technology areas cannot reach the highest 0.01 level.
Therefore, more discussions are needed below.
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5.2.2.1 Contribution of Strategies to T4 Cell and Tissue Engineering
In Table 36, we can see that T4 Cell and Tissue Engineering has a FBS value of 2.53
which is less than the F-critical at 0.05 level (3.07). This indicates that as a whole group,
the experts’ disagreement cannot be rejected at the medium level. In this section, the
experts’ judgmental data will be reevaluated in subgroups for RIC and F-test. The results
are illustrated in Table 37:

T4

P-value

FBS

Fcritical(0.01)

Subgroup-G

0.023

6.81

9.78

Subgroup-F

0.030

6.03

9.78

Subgroup-L

0.043

10.32

29.5

F-test results
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level

Table 37: Subgroup Analysis on T4 Cell and Tissue Engineering

5.2.2.2 Contribution of Strategies to T12 Gene Sequencing
Another area that has higher disagreement (cannot be rejected at the 0.05 level) is
T12 Gene Sequencing. Following a similar process, the data was reevaluated in expert
subgroups. The results are presented in Table 38:

T12

P-value

FBS

Fcritical(0.01)

Subgroup-G

0.041

5.24

9.78

Subgroup-F

0.048

4.88

9.78

Subgroup-L

0.041

10.79

29.5

F-test results
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level

Table 38: Subgroup Analysis on T12 Gene Sequencing

The above analyses provides positive results. The disagreement values among
experts within subgroups improved to have values higher than the 0.05 level. This is true
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for both T4 and T12. This also indicates that there are certain differences of opinion
among subgroups which need more exploration.

5.2.3 Variance among Subgroups
Due to the disagreement issues raised in the above analyses, this section further
explores the different perspectives of the three expert subgroups. Tables with
disagreements that cannot be rejected at the 0.01 level will be reexamined based on each
expert’s judgmental rankings.

5.2.3.1 Subgroup-G
There are 9 technology areas where disagreements cannot be rejected at the 0.01
level. The judgmental rankings of Subgroup-G experts were first pulled out and
examined in Table 39. These experts have backgrounds in government agencies. The
rankings range from 1 – 4, meaning from the highest to the lowest. A smaller mean value
in the bottom row means a higher average ranking.

Exp4
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
2
1
1
1
2
1
2
1
1
1.3

S2
1
2
1
1
1
2
1
2
1
1.3

S3
3
3
3
3
3
3
3
3
3
3.0

S4
4
4
4
4
4
4
4
4
4
4.0

Exp6
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
3
3
4
4
1
3
3
2
4
3.0

S2
1
1
1
1
3
1
1
1
1
1.2

S3
2
2
2
2
2
2
3
3
3
2.3

S4
4
4
3
3
4
4
2
4
2
3.3

Table 39: Subgroup-G Ranking Analysis
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Exp16
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
1
1
2
2
1
1
2
2
2
1.6

S2
2
2
1
1
2
2
1
1
1
1.4

S3
3
3
3
4
3
3
3
3
3
3.1

S4
4
4
4
3
4
4
4
4
4
3.9

The results reveal that Subgroup-G experts tend to give the highest rank to S2
Imitative Innovation Strategy. They tend to give a lower rank to S4 International
Technology Transfer. Expert4 and Expert16 also tend to give a higher rank to S1
Indigenous Innovation.

5.2.3.2 Subgroup-F
The individual judgmental rankings of Subgroup-F experts are presented in Table 40.
These experts have backgrounds or interests from various foreign organizations.
Exp12
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
1
3
4
3
4
1
2
4
4
2.9

S2
2
2
1
2
1
4
3
1
1
1.9

S3
3
1
1
1
2
2
1
2
2
1.7

S4
4
4
1
4
3
3
4
3
2
3.1

Exp15
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
4
3
2
3
2
2
2
4
3
2.8

S2
3
4
4
4
4
4
3
3
3
3.6

S3
1
1
1
1
1
1
1
1
1
1.0

S4
2
2
3
2
2
2
4
2
2
2.3

exp19
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
2
2
4
2
3
1
3
4
4
2.8

S2
3
4
2
3
1
3
2
2
2
2.4

S3
1
1
1
1
2
2
1
1
1
1.2

S4
4
3
3
4
4
4
3
3
3
3.4

Table 40: Subgroup-F Ranking Analysis

The above information reveals that Subgroup-F experts tend to give a higher rank to
S3 Collaborative Innovation Strategy. Among others, expert15 ranks S3 as the first
priority for all technology areas.
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5.2.3.3 Subgroup-L
The individual judgmental rankings of Subgroup-L experts were pulled out and are
presented in Table 41. These are experts from the local industry or domestic research
organizations (non-government and without foreign backgrounds).
Exp11
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
2
4
4
4
3
4
4
4
4
3.7

S2
1
1
1
1
1
1
1
1
1
1.0

S3
3
2
2
2
2
2
2
2
3
2.2

S4
4
3
3
3
3
3
3
3
2
3.0

Exp20
T3
T4
T6
T7
T9
T10
T11
T12
T13
Mean

S1
2
4
2
2
3
1
2
4
4
2.7

S2
1
1
1
1
1
3
1
1
1
1.2

S3
3
2
3
3
2
2
3
2
2
2.4

S4
4
3
4
4
4
4
4
3
3
3.7

Table 41: Subgroup-L Ranking Analysis

The above results indicate that Subgroup-L experts tend to give a higher rank to S2
Imitative Innovation Strategy. For example, Expert11 ranked S2 as the first priority for
all technology areas. Another observation is that the experts are more likely to rank S3
Collaborative Innovation as the second highest option.
For the strategy level, the subgroup analysis confirms that experts from different
subgroups tend to give different weight for different strategies. The experts showed
certain tendencies in their judgments as a whole in terms of subgroups. These tendencies
caused some disagreements in the last section. The reasons for such disagreements were
investigated during the result validation stage, which will be discussed in the next chapter.
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5.2.4 Resource Level
Referring to the data presented in Section 5.1.3, the intraclass correlation coefficient
was calculated and F-test was applied for the resource level. The results show that RIC
coefficients range from 0.12 to 0.42, indicating that agreement exists among the experts
in all examined tables. F-test was carried out to test the FBS value, and the F-critical value
at df1 = 7 and df2 = 56. Since df2 = 56 is not provided in the table, an even larger value of
df2 = 40 is used. This is because we always act conservatively and choose a larger value,
which makes it more difficult to obtain significance.
As we examine the data from Table 42, the results show that FBS values are larger
than the F-critical (0.01) for S1 Indigenous Innovation, S2 Imitative Innovation, and S4
International Technology Transfer. This indicates that disagreements can be rejected at
the 0.01 level in these tables. For S3 Collaborative Innovation, FBS = 2.44 is larger than
the F-critical (0.05) = 2.25, but smaller than the F-critical (0.01) = 3.12. Therefore, the
null hypothesis can be rejected at the 0.05 level, but it cannot be rejected at the 0.01 level.

P-value

FBS

Fcritical(0.01)

F-test Results

S1

<0.001

4.94

3.12

H0 rejected at 0.01 level

S2

<0.001

6.76

3.12

S3

0.030

2.44

3.12

S4

<0.001

6.40

3.12

H0 rejected at 0.01 level
H0 rejected at 0.05 level, but
cannot be rejected at 0.01 level
H0 rejected at 0.01 level

Table 42: Calculation of Disagreement at the Resource Level

The above results indicate that the contribution of resource alternatives toward
collaborative innovation has an acceptable but slightly higher disagreement level (0.05
level). A careful analysis of the data reveals that expert 14 has a very different judgement
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when compared to others. This expert gave a higher priority value for A8 MNCs but a
lower value for A4 SMEs. The researcher contacted the experts to verify their
judgemental inputs. They were confident about their judgements and confirmed that the
judgemental values represented their opinion regarding the issue. Expert 14 chose to
retain the original judgement and provided a website to the researcher for more
information. The website of this MNC clearly indicates that a dedicated organization for
collaboration and partnering was established in 2009. The Chinese branch is one of the
four global collaboration centers, while the other three are located in the US, EU, and
Japan respectively. This fact explained the disaggreement with others. The existance of
disagreement reveals that even though these experts all have foreign backgrounds, they
may disagree with each other since they came from different companies or institutions.

5.2.5 Summary on Disagreement Analysis
The experts have very low disagreement in the judgment of technology level toward
mission. It is within a very high acceptable level of 0.01. However, the experts have a
certain level of disagreement regarding the strategies. By using subgroup analysis, we
found that there are lower disagreements within subgroups. The analysis also revealed the
trend of disagreement among subgroups. These disagreements were mainly caused by the
different backgrounds of the subgroups. For the resource level, the only area with higher
disagreement is about collaborative innovation. Through contacting the experts, the
disagreement was explained by the organizational differences.
Instead of trying to eliminate subjectivity and smooth out the differences, it is more
important to understand the disagreement. Assessment of disagreement among experts at
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each level of the model gives valuable insight on the expert’s position on the issues and
provides even more useful information for policy makers.

5.3 Sensitivity Analysis
Since judgments involve subjectivity, the input data always bring uncertainty.
Sensitivity analysis is necessary to test the robustness and stability of the results. There
are several types of methods for carrying out sensitivity analysis on a hierarchical
decision

model,

including:

numerical

incremental

analysis,

simulations,

and

mathematical deduction. Numerical incremental analysis is an iteration-based process
where different numerical values are applied to the model to test corresponding changes
in the ranking orders of the decision alternatives. The simulation method can be done
through software packages such as Crystal Ball. However, the probabilistic input may
return in stochastic output, which is undeterministic in nature. The method is more
suitable to verify the results, but not to conduct the sensitivity analysis.
This study utilizes the sensitivity analysis algorithm for HDM developed in Chen’s
dissertation and Kocaoglu's research [272] [273]. This is a mathematical deduction type
method to examine the impact of changes in different levels. The algorithm has been
applied to the criteria level, which is the technology level. The purpose is find how
changes in the technology areas will impact the rankings of innovation resources. Here
the known conditional figures have been adapted from previous matrix calculations in the
results discussion section (Table 43 and 44).
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Contribution

A1:
URPs

A2:
PRIs

A3:
SOEs

A4:
SMEs

A5:
EJVs

A6:
CROs

A7:
FR&D

A8:
MNCs

0.1279

0.1096

0.0861

0.1821

0.1127

0.1130

0.1257

0.1462

3

7

8

1

6

5

4

2

Ranking

Table 43: Contribution and Ranking of the Input Resources to the Mission

T1

A1:
URPs
0.1258

A2:
PRIs
0.1078

A3:
SOEs
0.0847

A4:
SMEs
0.1802

A5:
EJVs
0.1135

A6:
CROs
0.1122

A7:
FR&D
0.1282

A8:
MNCs
0.1509

T2

0.1256

0.1086

0.0828

0.1806

0.1136

0.1130

0.1286

0.1500

T3

0.1318

0.1118

0.0862

0.1867

0.1115

0.1122

0.1232

0.1404

T4

0.1270

0.1094

0.0865

0.1810

0.1129

0.1138

0.1258

0.1467

T5

0.1300

0.1110

0.0865

0.1845

0.1120

0.1130

0.1240

0.1425

T6

0.1290

0.1101

0.0884

0.1827

0.1122

0.1133

0.1239

0.1440

T7

0.1286

0.1101

0.0870

0.1827

0.1124

0.1133

0.1247

0.1446

T8

0.1292

0.1100

0.0879

0.1831

0.1122

0.1128

0.1242

0.1443

T9

0.1304

0.1111

0.0864

0.1850

0.1119

0.1127

0.1239

0.1422

T10

0.1254

0.1086

0.0848

0.1797

0.1135

0.1138

0.1276

0.1494

T11

0.1280

0.1096

0.0870

0.1820

0.1126

0.1132

0.1252

0.1458

T12

0.1260

0.1087

0.0881

0.1793

0.1131

0.1143

0.1257

0.1479

T13

0.1274

0.1092

0.0882

0.1809

0.1127

0.1136

0.1250

0.1464

Table 44: Intermediate Matrix of Input Resources to Technology

L

For n = 1 and r = 1, based on the definition  o l *   l * 

o

l 1,l  l *

following calculations:

 0.14   1  0.86
C 0  a1  a 2  0.1821  0.1462  0.0359
13

C1  a 2,1  a1,1   a 2,1 
l 2

13

ol

o

ol

  a1,1 

13

l 2
l

l 2

13

o
l 2

 0.1509  0.1802  0.1454  0.1825
 0.0077
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l

l

, we have the

C 0 0.0359

 4.658
C1 0.0077
We can obtain that  1  4.658
Repeating the similar calculation steps for n  1 and r  2, 3..., 7 we get the following
allowable range of 1 .
 0.14   1  0.86

 1  4.658
 1  2.34
 1  4.407
 1  3.29
 1  0.172
 1  1.05
 1  5.441

(When r  1, n  1)
(When r  2, n  1)
(When r  3, n  1)
(When r  4, n  1)
( When r  5, n  1)
( When r  6, n  1)
(When r  7, n  1)

By finding out the intersection of the above inequality sets, we can obtain the
perturbation of the weight of the chemical pharmaceutical technology:

 0.14   1  0.172
The allowable range of the perturbation on O l is denoted as  1l ,  2 l  , and the
tolerance of Ol is defined as 1l  ol ,  2l  ol  . From the calculations above, we can
calculate the result that the tolerance of Ol , which is T1 Recombinant Therapeutic
Proteins, to keep the current ranking of all the input resources is [0, 0.312]. In the HDM
Sensitivity Analysis algorithm [272], the sensitivity coefficient for Ol is defined as:

sens (O l ) 

1
 1l   2 l
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After repeating similar steps for each technology area, the results of calculations are
summarized in Table 45. The related explanations are explained in Table 46.

Criteria
T1: Recombinant
Therapeutic
Proteins
T2: Recombinant
Vaccines
T3: Monoclonal
Antibody
T4: Cell & Tissue
Engineering
T5: Gene Therapy
T6: Antisense
Therapy
T7: RNAi
T8: Nanobiotechnology
T9: Synthetic
Biology
T10: Bioinformatics
T11: Pharmacogenetics
T12: Gene
Sequencing
T13: Biotech
Diagnostics

Range of
Perturbations

Tolerance of
Weights

Sensitivity
Coefficient

[-0.14, 0.172]

[0, 0.312]

3.205

[-0.13, 0.306]

[0, 0.436]

2.293

[-0.13, 0.794]

[0, 0.924]

1.082

[-0.06, 0.94]

[0, 1]

1

[-0.06, 0.94]

[0, 1]

1

[-0.04, 0.96]

[0, 1]

1

[-0.05, 0.95]

[0, 1]

1

[-0.07, 0.93]

[0, 1]

1

[-0.05, 0.95]

[0, 1]

1

[-0.06, 0.464]

[0, 0.524]

1.908

[-0.06, 0.94]

[0, 1]

1

[-0.07, 0.93]

[0, 1]

1

[-0.08, 0.92]

[0, 1]

1

Table 45: Sensitivity Analysis on Technologies to the Ranks of Input Resources

The most critical criterion for keeping the current ranking of input resources
corresponds to the technology area with the biggest sensitivity coefficient. As seen in the
results, T1 Recombinant Therapeutic Proteins is determined as the most critical criterion
among the technology areas in keeping current resource rankings, followed by T2
Recombinant Vaccines. T1 Recombinant Therapeutic Proteins contributes the most
toward the overall mission, and at the same time it is also the most critical technology
area to keep the current rankings of resources.
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Tolerance
of
Weights

Criteria
T1: Recombinant
Therapeutic
Proteins

[0, 0.312]

T2: Recombinant
Vaccines

[0, 0.436]

T3: Monoclonal
Antibody

[0, 0.924]

T10: Bioinformatics

[0, 0.524]

Descriptions
When the weight of T1 changes to a value larger than 0.312,
the contribution of Joint Ventures will surpass CROs to
become the 5th. When the changes are within the range from
0 to 0.312, the ranks of the input resources remain the same.
When the weight of T2 is larger than 0.436, the contribution
of Foreign R&D Centers will surpass University Research
Programs to become the 3rd. When the changes are within the
range from 0 to 0.436, the ranks of the input resources remain
the same.
When the weight of T3 changes to a value larger than 0.924,
the contribution of Joint Ventures will surpass CROs to
become the 5th. When the changes are within the range from
0 to 0.924, the ranks of the input resources remain the same.
When the weight of T10 is larger than 0.524, the contribution
of Foreign R&D Centers will surpass University Research
Programs to become the 3rd. When the changes are within the
range from 0 to 0.524, the ranks of the input resources remain
the same.

Table 46: Explanation of the Results of Sensitivity Analysis

Sensitivity analysis gives more information on how changes in upper level criteria
can impact on lower level alternatives. In this case, the overall results are not very
sensitive to changes, especially for the top-ranked strategy criteria and resource
alternatives. This is primarily due to the high priority in favor of imitative innovation
strategies for most technology areas and high contribution of certain resources (SMEs
and MNCs) toward strategies. The results have demonstrated the process of how to assess
the impact of technology changes on the resource rankings. Sensitivity analysis is a
useful supplemental tool for policy makers to explore the relationships of the decision
criteria.
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Chapter 6 – Discussions and Recommendations

Based on the data analysis and expert feedback, this chapter focuses on the
discussions and policy recommendations. During the result validation process,
aggregated results and a short summary regarding the disagreement issues were sent to
the expert panel for further review. The experts were asked to validate the findings of this
research. They provided valuable feedback and opinions, which largely facilitated the
following discussions and recommendations. These findings are summarized in several
major aspects according to each level of the model, including: 1) prospective technology
areas, 2) technology development strategies, and 3) innovation resources. Table 47
illustrates the main results from the data analysis.

6.1 Prospective Technology Areas
With achieving technological competitiveness and sustained innovation as the
mission, this research examines a number of prospective technology areas in the
biopharmaceutical industry. Although the experts come from different backgrounds, they
have reached a high level of agreement in their judgments. The results can be classified
under three categories: high >10%, medium 6%-10%, and low 1%-5% (Table 47).

6.1.1 High Priority Technology Areas
The “high” category is defined where the contribution is larger than 10%. These are
the technology areas that should be China’s highest priorities for R&D. The
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recommended areas include T1 Recombinant Therapeutic Proteins, T2 Recombinant

Medium (6-10)%

High >10%

Category

Vaccines, and T3 Monoclonal Antibody Technology.

Prospective
Technology Areas

Preferred Technology Preferred Innovation Resource Alternatives
Development Strategies (Top Three)

T1: Recombinant
therapeutic
proteins

S2: Imitative
Innovation

T2: Recombinant
vaccines

S1: Indigenous
Innovation

T3: Monoclonal
antibody
technology

S2: Imitative
Innovation

T4: Cell and tissue
engineering

S2: Imitative
Innovation

T5: Gene therapy

S2: Imitative
Innovation

T8: Nanobiotechnology

S2: Imitative
Innovation

T10: Bioinformatics

S1: Indigenous
Innovation

T11: Pharmacogenetics

S2: Imitative
Innovation

T12: Gene
sequencing

S2: Imitative
Innovation

Low (1-5)%

T13: Biotechnology S2: Imitative
Diagnostics
Innovation
T6: Antisense
therapy

S2: Imitative
Innovation

T7: RNAi

S2: Imitative
Innovation

T9: Synthetic
biology

S2: Imitative
Innovation

1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. MNCs and Subsidiaries
2. High-tech Small-to-Medium Enterprises
3. Foreign R&D Centers
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. MNCs and Subsidiaries
2. High-tech Small-to-Medium Enterprises
3. Foreign R&D Centers
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes
1. High-tech Small-to-Medium Enterprises
2. University Research Programs
3. Public Research Institutes

Table 47: Summary of Findings

195

For T1 Recombinant Therapeutic Proteins, the preferred strategy is imitative
innovation. The ideal innovation resources include: high-tech SMEs, university research
programs, and public research institutes. The development of recombinant proteins is
well known to have relied on blockbuster revenue, primarily derived from 16 brands. For
example, Amgen's blockbusters Enbrel, Neulasta and Aranesp are the sector's key leading
blockbusters, with combined sales of more than US$10.8billion in 2010. The expected
growth during 2012-2014 will be around 13% [305]. Hematology, diabetes,
endocrinology and oncology are the most valuable therapy areas for recombinant proteins.
Taking the imitative innovation strategy means that China should focus on developing
biosimilars in this area; and biotech SMEs, Universities, and Research Institutes should
play more important roles.
For T2 Recombinant Vaccines, the preferred strategy is indigenous innovation. The
recommended innovation leaders include: MNCs and subsidiaries, high-tech SMEs, and
foreign R&D centers. Vaccines are among the most lucrative segments in the global
pharmaceutical market. With an average growth of over 13% during 2009-2012, the
global market for human vaccines is forecasted to reach US$32 billion by the year 2017
[306]. The US and EU are the two largest vaccine markets in the world. The vaccine
market in China has the potential to record phenomenal growth in the coming years. The
growth rate will be around 20% and its size will reach CNY 12 billion by 2013 [296].
The quantity and the variety of vaccines produced in China are similar to those of
developed countries, but China needs to improve the production capability and critical
technology in order to produce higher quality vaccines [279]. Taking the indigenous
innovation strategy indicates that China should develop more novel products, and focus
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on the improvement of local competence. For such a purpose, innovation resources like
multinationals and subsidiaries, biotech SMEs, and Foreign-invested R&D centers can
take the lead.
For T3 Monoclonal antibody technology, the preferred strategy is imitative
innovation. The recommended innovation leaders include: high-tech SMEs, university
research programs, and public research institutes. In the global market, the antibody
bandwagon has been joined by 200 companies with hundreds of new projects and targets
that have attracted billions of dollars in R&D investment, acquisitions and licensing deals
leading to monoclonal antibody [277]. The total global monoclonal antibody (mAb) sales
are forecasted to reach US$49 billion by 2013. The “big ﬁve” mAbs – Avastin, Herceptin,
Rituxan, Humira, and Remicade – have dominated the market, cornering almost 80
percent of sales [297]. There has been a great gap between China and Western countries
in the research, development and manufacture of monoclonal antibody drugs [307]. Since
the imitative innovation strategy has a higher priority, China should focus on the
development of biosimilars, especially for the blockbuster drugs. Ideally, biotech SMEs,
Universities, and Research Institutes should play more important roles in this process.

6.1.2 Medium Priority Technology Areas
The “medium” category is defined as being where the contribution ranges from 6%
to 10%. These technology areas are recommended as medium priorities for China to carry
out R&D. This list consists of seven technology areas including T4 Cell and tissue
engineering, T5 Gene therapy, T8 Nanobiotechnology, T10 Bioinformatics, T11
Pharmacogenetics, T12 Gene sequencing, and T13 Biotechnology Diagnostics.
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For T4 Cell and tissue engineering, the preferred strategy is imitative innovation.
The recommended innovation leaders include: high-tech SMEs, university research
programs, and public research institutes. According to market reports, there are more than
60 tissue engineering products in the global market and about 30 in clinical trials. China’s
biomedical materials industry is largely driven by foreign technology, and domestic
companies accounted for a mere 3% of global market share in 2011 [308]. By following
the imitative innovation strategy, China should focus on catching up with the advanced
countries. The results suggest that biotech SMEs, Universities, and Research Institutes
should play more important roles.
For T5 Gene therapy, the preferred strategy is imitative innovation. The
recommended innovation leaders include: high-tech SMEs, university research programs,
and public research institutes. Gene therapy is a high-tech area with very few available
products. However, there about 80 gene therapies are in clinical trials [281]. Many
experts believe that gene therapy will play a significant role in future medical treatment.
The research recommends imitative innovation strategy, indicating that China should
focus on learning from advanced countries. The results also suggest that biotech SMEs,
Universities, and Research Institutes play more important roles.
For T8 Nanobiotechnology, the preferred strategy is imitative innovation. The
recommended innovation leaders include: high-tech SMEs, university research programs,
and public research institutes. The applications of nanobiotechnology in the biomedical
field are principally directed towards development of novel drug delivery systems.
According to a market report in 2012, the global nanobiotechnology market will reach
$6.0 billion by 2017 [309]. As a catching up country in this area, it is recommended that
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China follow the imitative innovation strategy. The results also suggest that biotech
SMEs, Universities, and Research Institutes should play more important roles in the
process.
For T10 Bioinformatics, the preferred strategy is indigenous innovation. The
recommended innovation leaders include: MNCs and subsidiaries, high-tech SMEs, and
foreign R&D centers. The applications in bioinformatics are increasingly powerful,
allowing researchers to garner more knowledge about more complex organisms and
systems. The worldwide bioinformatics market was estimated at US$3.0 billion in 2010,
and the applications will continue to have very rapid growth to 2015 [281]. Today,
bioinformatics research in China still lags behind the best in the world. There are
relatively few applications for drug discovery in the domestic market [310]. Since the
indigenous innovation strategy is recommended, China should focus on developing new
applications in bioinformatics. To support this strategy, innovators such as MNCs, hightech SMEs, and Foreign R&D centers can take the leading roles.
For T11 Pharmacogenetics, the preferred strategy is imitative innovation. The
recommended innovation leaders include: high-tech SMEs, university research programs,
and public research institutes. Pharmacogenetics is a prospective field that could lead to
personalized medicines. According to market reports, the worldwide pharmacogenetics
market was estimated at US$3.7 billion in 2009, but there will be a limited number of
new pharmacogenetic products arriving on the market by 2015 [281]. The experts
recommend the imitative innovation strategy, indicating that China should focus on
catching up with advanced countries. The results also suggest that biotech SMEs,
universities, and research institutes should play more important roles in this process.
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For T12 Gene sequencing, the preferred strategy is imitative innovation. The
recommended innovation leaders include: high-tech SMEs, university research programs,
and public research institutes. Applications of gene sequencing technology will help
researchers to find genes associated with human disease. China is catching up rapidly in
the field of gene sequencing. The acquisition in 2012 of a California-based DNA
sequencing company by a Chinese firm (BGI) led to wide concerns. Some American
scientists, politicians and industry executives said the takeover represented a threat to
American competitiveness in DNA sequencing [311]. So far, the experts in this research
still recommend an imitative innovation strategy, where biotech SMEs, Universities, and
Research Institutes should take the lead in China’s catching-up process.
For T13 Biotechnology Diagnostics, the preferred strategy is imitative innovation.
The recommended innovation leaders include: high-tech SMEs, university research
programs, and public research institutes. The diagnostics market was estimated at $ 52.4
billion in 2012, and it is expected to grow at a rate of 7% during 2012-2017 [312]. Roche
Diagnostics is the dominant leader with 20% market share. Nine of the world’s top 15
firms are based in the United States. Other firms are based in either Europe or Japan. In
this research, the experts recommend an imitative innovation strategy for China. The
country should focus on catching up with advanced countries. The results suggest that
biotech SMEs, universities, and research institutes play more important roles in this
process.
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6.1.3 Low Priority Technology Areas
The “low” category is where the contribution is equal to or less than 5%. These
technology areas are regarded as having lower priorities for China. This list consists of
three technology areas including T6 Antisense therapy, T7 RNAi, and T9 Synthetic
biology.
The above three technology areas have one thing in common: there are still very few
or even no approved applications in the market today. However, these drugs have good
prospects in that some candidate drugs are already in clinical trials [281]. The related
studies in China are still in initial stages. The experts recommend an imitative innovation
strategy for all three technology areas. China should focus on catching up with advanced
countries. The results also suggest that biotech SMEs, universities, and research institutes
should play more important roles in this process.

6.1.4 Summary on Prospective Technology Areas
The research results of technology levels highlights the directions for investment and
improvement. For most of the above discussed high-tech areas, the Unites States is the
dominant leader worldwide. Research has shown that American academic publications
and patents comprise more than 40% of the world. China and some major European
countries belong to the second tier in these areas. As a latecomer country in the
biopharmaceutical industry, China’s innovation capabilities have been steadily growing
since the mid 1990s. However, China’s technology level is still lagging behind the
world’s leading standard, and the country needs to take a learning position as discussed in
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the above analyses. In order to accelerate the catching-up process, the government’s role
of long-term investment in these identified areas cannot be overemphasized.

6.2 Technology Development Strategies
Any static strategy is often less effective for latecomer countries since competitive
advantage could be accumulated through multiple approaches or sources. From an
industrial perspective, a country’s technology strategies need to be dynamic for its unique
but changing developmental contexts. Therefore, policy makers should adopt a
comprehensive approach to technology strategy using all possible resources, and engage
various stakeholders in the process of technology development. Such an approach entails
decision makers becoming more involved in governance initiatives to improve the
innovation environment, or scaling their influence over the relevant high-tech areas for
the long-term innovation goals. This involves balancing various technology development
strategies to build up industrial innovation capacity for competitiveness and future
success.

6.2.1 Imitative Innovation and Biosimilars
Accumulation of technological capacities to compete in the global market has
become a major concern for China. The research brings to light that imitative innovation
is still the best option to achieve such a purpose under the current conditions. The experts’
judgments give high priority to imitative innovation (33%) in the development of
biopharmaceutical technologies. This conforms to the fact that technology leaders in
high-tech areas are mostly foreign enterprises, which mainly belong to the United States
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and Western Europe. If the latecomers want to catch up with the technological frontiers,
their strategies are likely to start from imitation. This has been the case for many of the
East Asian economies – first for Japan, then for Taiwan, Korea and Singapore – and now
for China [82]. The results of this research indicate that China’s biopharmaceutical
industry is at the stage of learning from advanced countries.
When discussing imitative innovation in the biopharmaceutical industry, biosimilars
are topics that cannot be circumvented. Novel biologics are noted for their high
production cost and expensive purchase prices. Biosimilars bring clear potential for
payers in the emerging pharmaceutical or “pharmerging” markets, such as Brazil, India
and China [302]. Developing biosimilar products is also a relatively low-risk strategy for
newcomers entering the health biotech space and generating short-term revenues [313].
Of the approximate 150 approved originator biologic drugs on the market today, almost
half of them have lost or are close to losing their patent protection. This provides an
external condition for cheaper biosimilar products to enter the market and be available for
consumers. However, under the current registration regime, biosimilar drugs and new
biologic drugs are not treated with any differences in China. Both applications require the
same process for clinical trials. Although the United States does not currently have
related regulations, India and the European Union have developed abbreviated approval
processes for biosimilar products [302]. China should consider adopting similar
approaches to remove or lower the legislative hurdles for the development of biosimilars.
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6.2.2 India’s Experience in Pharmaceutical Development
The rise of India’s pharmaceutical industry in the last few decades may provide
some insight for other emerging economies. The Indian government adopted an imitative
strategy in the pharmaceutical industry during the 1970s [314]. The weak IPRs regime
fostered the development of domestic technology capabilities in that period. If an Indian
domestic company could merely modify the manufacturing process of a foreign medicine,
the company was allowed to produce the same product without patent infringement [315].
This strategy established low cost leadership advantage among local companies and
increased domestic social welfare due to the lowered drug prices. It was remarkable
achievement that new drugs can be introduced to India only within four to five years after
their introduction in foreign countries. However, the negative effect was that most MNCs
chose to leave the Indian market for afraid of patent infringement.
As a large number of medicines went off patent protection during the late 1980s,
Indian medicines further experienced a rapid growth of exports to the world market.
Moreover, an interesting effect was that the increased technological capabilities of Indian
pharmaceutical companies have brought back the FDI from the Western developed
countries. New joint ventures or R&D centers were setup mainly draw upon trained
manpower and research infrastructure available in the country, despite the fact that the
Indian patent regime did not provide strong patent protection [316]. By introduction and
assimilation of advanced technologies from abroad, the Indian pharmaceutical companies
have emerged as competitive suppliers in the world.
The Indian experience highlights the fact that government strategy may lead to
industrial success. However, India’s imitative strategy can no longer be duplicated by
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other emerging economies because the global innovation environment has changed
significantly in recent years. Many countries have joined WTO and endorsed the TRIPS
Agreement, which requires strengthened IPR protection. Therefore, direct replication of
foreign products will not be applicable, and even India has to make a change in recent
years. Nowadays, emerging economies should focus on re-innovation or imitative
innovation, which is beyond pure replication. In summary, the Indian experience in
pharmaceutical development strengthened the findings in this research.

6.2.3 Indigenous Innovation, Collaborative Innovation, and Novel Drugs
Indigenous innovation strategy ranks second at 26%, followed by collaborative
innovation strategy at 23%. These strategies cannot be overlooked as optional choices for
China’s current technology capabilities. China should try to develop its indigenous
strengths and also collaborate with leading countries. In most technology areas, China
belongs to the second cohort among the worldwide biopharmaceutical communities.
Therefore, the country cannot afford to totally rely on indigenous innovation. The opendoor policy in the last 30 years has proven that foreign elements are extremely important
resources for the local industries. China would not have achieved the current technology
level if the doors were closed for FDI and MNCs. As a long term goal, indigenous
innovation strategy should be encouraged in China. Past experiences from other countries
have repeatedly demonstrated that an emerging economy will ultimately move from the
imitative stage to the innovative stage [82].
Although the collaborative innovation strategy did not rank the highest for any
specific technology areas, it has been regarded as an increasingly important strategy in
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recent years. In reality, some industrial players have come up with new channels to
develop novel drugs through bridging collaborative and indigenous innovation. For
example, Chinese-based SinoPharm struck a cooperation deal with American-based
Harbor Biosciences to develop novel drugs in the area of therapeutic protein drugs. The
two sides share resources in terms of financial investment, technology know-how, and
research facilities. Regarding the research outcomes, SinoPharm has exclusive rights in
China, while Harbor Biosciences maintains rights in other countries. This type of
collaboration is very attractive to both parties: the foreign player benefits from lowered
investment and more research resources, while the Chinese player is able to gain access
to advanced R&D techniques and essentially obtain their very own novel drugs [298]
[300].

6.2.4 International Technology Transfer
Compared with other strategies, international technology transfer ranks relatively
low in the overall contribution toward mission. MNCs and Foreign R&D Centers are the
major contributors for this strategy. The Chinese industries have benefited substantially
from international technology transfer deals during the 1980s and 1990s. The MNCs
transferred many technologies which helped China to upgrade its industries. However, as
local technology capability matured, the reliance on foreign technologies decreased. In
recent years, there have been many cases where foreign companies began acquiring
domestic firms or technologies [304]. International technology transfer deals no longer
travel in one direction from abroad to local, but also from home to abroad. Nevertheless,
in high-tech areas such as the biopharmaceutical industry, foreign players still play more
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important roles in international technology transfer in China. From a government
perspective, China needs to establish effective macro-level technology policies to guide
and promote technology transfer activities in high-tech areas.

6.2.5 Disagreement on Technology Development Strategies
The experts’ judgments recorded a relatively high disagreement regarding the
strategy level. Experts with different backgrounds suggested different strategies for China
to follow. Government experts have higher expectations for imitative innovation or
indigenous innovation. Indeed, due to noticeable gaps between China and the global
innovation frontiers, it is more realistic to expect some learning and imitative activities.
This process happened to other countries during their catching up stages, such as Japan in
the 1960’s and South Korea in the 1970s. India’s pharmaceutical industry grew very fast
during the 1970’s when the government adopted similar strategies to imitate foreign
drugs [314]. However, in today’s more globalized environment, China’s strategy should
focus on re-innovation or imitative innovation, which goes beyond simple imitation. The
domestic industrial experts have suggested more on imitative innovation strategy,
indicating the catching up trends in the industry. They also have higher expectations for
collaborative innovation, which confirms that collaborations are necessary for domestic
companies. Although the foreign experts suggested relying more on collaborative
innovation, the reality is that some MNCs have limited collaborations with domestic
players, as seen from the results of resource levels. Their major concerns are loss of
technology edge or IPR. However, the results have demonstrated that foreign players
have the motive or interests to collaborate with domestic players.
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The global biotech communities are well aware of the advantages and attractions
China can offer. As China’s economy grows and incomes rise, it can be anticipated that
people will increase their spending on healthcare and medicines. This brings great
opportunities not only for domestic companies, but also for multinationals. The
government should welcome global partners to jointly share the development and
prosperity of the nation's emerging industry. To facilitate internationalization of China's
biopharmaceutical industry, policy makers should plan to establish ideal conditions for
attracting foreign innovators. Promoting research collaboration between domestic
companies and their overseas counterparts will benefit the technology learning process,
as well as the mission of sustained industrial growth. For its innovation goals to be met,
China needs to have more integrated strategies for technology development. Past
experiences revealed that the country needs to be more integrated into the global
innovation networks. This means keeping an open-door policy and encouraging foreign
investment in high-tech areas.

6.3 Supportive Innovation Resources
This case application provides the Chinese biopharmaceutical industry a
performance report of various innovators with regard to their contribution toward global
strategies and technology objectives. This will assist policy makers in determining which
infrastructure items require improvement or investment. Based on the feedback from
result validation, the research suggests improving the conditions and environment for
innovation. The result analyses indicate that High-tech SMEs are the most important
contributors for China’s biopharmaceutical industry in the current development stage.
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The second group of important contributors is considered to be the MNCs and
subsidiaries. The Foreign R&D Centers and University Research Programs tie for the
third place toward mission. These important innovation resources will be discussed in
this section.

6.3.1 High-tech SMEs
Owing to the narrowed gaps of competitive advantages in recent years, many
emerging biotech SMEs have entered the race for technology development. These
companies have certain advantages over large established enterprises, including greater
flexibility, better efficiency, less bureaucracy, and profit-seeking behaviors which allow
them to succeed in the fast-changing markets. Many biotech SMEs in the Chinese
biopharmaceutical sector share similar advantages and traits. For example, they are more
successful in some specialized high-tech areas, and most of them are very eager or active
in collaborative innovations with other players. This is mainly due to the reality that
SMEs are usually not strong as standalone innovators. They need to search for
complementary resources to cover their deficiencies in certain aspects.
Despite a clear evidence of progress in recent years, biotech SMEs still have some
key issues to be addressed. One of the main challenges faced by biotech SMEs is to
obtain funding, not only for their business purposes but also for their R&D activities.
With lower research inputs, most biotech SMEs are not well prepared to compete
globally in many high-tech fields. The government should provide services to expand
biotech SMEs’ networking with other players so that interactions can create a synergy
where knowledge, expertise, and experiences are shared. This is also a measure to avail
209

biotech SMEs with complementary resources and related activities that they lacked.
Moreover, the government has the ability to alleviate biotech SMEs’ tax burdens, and
induce them to invest more in R&D activities with incentives.

6.3.2 Multinational Companies and Subsidiaries
MNCs’ technological strength, institutional heritage, and their global coverage
generate specific advantages for their operations in the Chinese biopharmaceutical sector.
MNCs are in a better competing position because they are better endowed with both
R&D capacities and funding capital. Chiesa and Chiaroni (2005) found that the presence
of foreign pharmaceutical firms can make a number of important contributions to the
success of the industrial networks of the host country. For example, these firms have
better expertise in developing and protecting intellectual property with high commercial
potential, they have well-established marketing and distribution channels, and they are
experienced in both shaping and working within strict regulatory guidelines [317].
Domestic players in the host country may benefit from technology spillover through
MNCs’ demonstration effects, labor turnover, and overall industrial structure upgrading
(both upstream and downstream) [160, 318]. These are essential factors to build up a
better innovation ecosystem for the biopharmaceutical industry in China.
The research results have revealed that there are certain disagreements on whether
MNCs collaborate with other players. According to the feedback from result validation,
the contributions of MNCs toward collaborative innovation are uneven. One expert
claimed that her company has initiated many partnership programs in recent years, which
indicates higher contribution. On the other hand, several other experts argued that their
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collaborative programs are limited in clinical trials which do not contribute much to
innovation. Most of the MNCs in China focus on the collaborations with domestic
players in the late-stage clinical trials, which are required by domestic regulations. The
Chinese government does not allow First-in-Human clinical research for foreign drugs in
China. Even if the drug is approved for marketing in a foreign country, the drug company
still needs to restart all three phases of clinical trials locally. Although some MNCs also
collaborate with Chinese universities and research institutes in early-stage discoveries,
the cases are relatively few, and the MNCs would eventually acquire the research
outcomes to enrich their own product pipelines. Therefore, the government should
provide more favorable policies to facilitate and support collaboration between MNCs
and domestic players, especially in early-stage drug discovery. This presupposes that
both sides will benefit from cooperation or even competition with their counterparts. The
trend of globalization and industrial liberalization needs such a change in attitude or
business orientation where even competitors can cooperate with each other to achieve
mutual success [319]. From a foreign perspective, MNCs also need to achieve a better
balance between their demands in exploiting the potential Chinese market and utilizing
the plentiful local resources.

6.3.3 University Research Programs
According to the results, the contribution of University Research Programs ties with
that of Foreign R&D Centers for third place. This is mainly due to a university’s higher
contribution toward collaborative innovation and imitative innovation. University
programs are more oriented toward basic research. Many biotech startups and spinoffs
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were created to take advantages of discoveries in academic research. MNCs collaborate
with top Chinese universities in early-stage drug discoveries. Many universities also have
academic connections with foreign research institutions. Moreover, university
partnerships are not limited to R&D. They are important for training future talents with
advanced research techniques, as well as providing companies the opportunity to recruit a
highly qualified workforce [313]. In the past two decades, Chinese universities have
trained about 100,000 biotech researchers. Nearly 1,000 universities and colleges in
China offer biology-related courses, and more than 500 universities and colleges offer
biology-related programs. More than 20,000 university students graduated each year in
biology-related fields before 2006 [320]. Universities provide the foundations for China
to catch up with developed countries.

6.3.4 Foreign R&D Centers
Foreign R&D Centers also contribute the third highest toward the overall mission.
This is largely due to their contributions toward international technology transfer and
indigenous innovation. In recent years, more and more foreign-invested R&D centers
have been established in China. This is a new approach to R&D in that it builds Chinese
portals to the global biotech communities. On the one hand, these innovation centers have
stringent ties with research resources in their own countries. On the other hand, they hire
and train many domestic scientists and researchers to carry out local R&D projects. The
vast population and different disease patterns in China provide a convenient condition for
the application of new technologies. There are plenty of opportunities for both early-stage
drug discovery and late-stage clinical trials. These organizations bring some of the latest
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research techniques, routines, and practices to China. Many of these research centers
focus on finding specific biomarkers and genes related to diseases that are more prevalent
in China and Asian regions. This is an important aspect because they contribute to
indigenous innovation as well as technology transfer.

6.3.5 Other Innovation Resources
Although the research model can be utilized to identify a single best contributor
toward the mission, the research goal is far beyond such a finding. The technology
development process in reality involves complementary technologies which can be
developed by different innovators in the innovation systems. In other words, the current
model is not merely for choosing the only innovator for each candidate technology. For
example, when the model proposes high-tech SMEs, as the best contributing resource
toward the overall mission of competitiveness and innovation, it should not be interpreted
that other innovators are excluded from the development strategy; rather, they just
contribute less than the ideal option but still remain as contributors. Because rankings
provide guidelines and direction for the design of technology policies to leverage
investment input, such as time, effort, human capital, and related monetary support.

6.4 Policy Recommendations
Based on the above discussions and experts’ feedback, major areas of policy
recommendations include: 1) Establishing a clear vision for technology objectives and
implementation strategies in the biopharmaceutical sector; 2) Creating actors or
organizations with responsibility for promoting or executing such strategies; 3) Nurturing
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a collaborative environment and innovation ecosystem. 4) Providing service platforms,
education, and training; and 5) Legislating support and financial incentives for innovators
at a micro or organizational level.

6.4.1 Establishing a Clear Vision for Technology Objectives and Strategies
In the development of high-tech industries in emerging economies, the synergies of
two major aspects need to be considered, which will reap some of the benefits of
globalization while remaining responsive to local market needs. Technology objectives
and strategies serve to provide direction and schemes for the making of innovation policy
within the sectoral regime. This research suggests that emerging economies must set clear
technology goals before formulating their global strategies. The decision makers have the
roles of clarifying the vision for those undertaking risky R&D activities in the high-tech
areas, determining proper regulations, and industrial standards to maintain the desired
boundaries of research activities, and making sure that an effective innovation
environment is provided with appropriate market mechanisms. The concern is to enhance
competitiveness for the industry’s present needs in globalization and local applications.
A major achievement of the Technology Level results is that the experts with diverse
backgrounds have reached unanimous agreement for prospective technology areas in
China. This means that the identified high-tech areas are in need of attention not only for
the local biotech community to upgrade but also for the overseas stakeholders to invest.
These high priority areas include Recombinant Therapeutic Proteins, Recombinant
Vaccines, and Monoclonal Antibody Technology. As a large country, China should not
give up developing other technologies, but the focus here is to make priorities based on
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both global trends and local needs. The long-term objective is to develop a full-fledged
biopharmaceutical sector that ranks among the higher end of the global industrial value
chain.

6.4.2 Creating Actors and Organizations to Improve Innovation Capacity
Global strategies often require substantial supporting resources during the
implementation processes. This research suggests that policy makers actively consider
the strategic need and ensure adequate resources are provided. The results bring to light
that China should strive to build an enterprise-centered innovation system for the
biopharmaceutical sector. The change from a structural and institutional context of
scientific

research

to

an entrepreneurial

mode

may

be

beneficial

for

the

biopharmaceutical industry in the long run. This concern needs to be taken for policy
making.
To build a more competitive biopharmaceutical Industry, the government can
strengthen the development of enterprises by enhancing the factors that lead them to
business success. Research shows that institutional support, especially support from the
government, can play a major role in SMEs’ competitiveness development within the
domestic market [319]. The actions can include executing an elite promotion program to
support a number of flagship enterprises, and motivate them toward innovation. In order
to stimulate innovation in the identified priority high-tech areas, policies can be designed
to encourage Chinese scientists overseas to return to China and contribute their
experience and expertise to the local industry. Domestic scientists should be encouraged
to participate in the commercialization process or even to become technological
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entrepreneurs themselves. Policy responses should be developed with regard to
supporting innovation and investment in high-tech areas.

6.4.3 Nurturing a Collaborative Environment and Innovation Ecosystem
A major concern of the government is to improve the innovation ecosystem in the
biopharmaceutical sector. The research results showed that both indigenous innovation
and collaborative innovation are contributing strategies for the biopharmaceutical
industry in China. Under the present conditions and status of China’s biopharmaceutical
industry, imitative innovation is the preferred strategy. However, increasing international
collaboration, as well as appropriate competition, is crucial for technological innovations
and scientific breakthroughs. With increased partnerships and collaborations, both
domestic and foreign actors cooperate to carry out scientific research that leads to
innovations.
The situation of limited collaborations between foreign and domestic biotech
companies has been discussed in the literature. There are suggestions that foreign firms
should adjust their IP strategies and change from a defensive position of filing and
enforcing patents to a more active exploitation of the commercial value of their
technologies in China [321]. First, large MNCs usually have a broad range of noncommercialized patents where they are willing to open their innovation processes through
patent transactions. Chinese firms may have opportunities either to buy or in-license
some of the foreign state-of-the-art technologies. Second, smaller or medium-sized
foreign firms usually have more specific and state-of-the-art technologies. They may
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consider out-licensing such technologies before their IPs are infringed by Chinese firms
[321].
In short, the foreign firms should be encouraged to employ an open innovation
strategy. In China’s context, the government can play a decisive role in promoting
innovation activities in the high-tech areas. Measures can include setting up appropriate
institutional frameworks, opening up more business opportunities, and providing
generous incentives for various innovators. Policy makers must have a strong
commitment to establish a more innovative environment for various players. Promoting
the development of new ventures and encouraging foreign investment from MNCs are
not only very necessary, but also represent the current needs and future trends for hightech development.

6.4.4 Providing Service Platforms, Education, and Training
In order to support innovation, the government can provide various services and
facilities. These include clinical trial facilities and R&D service platforms that align with
international best practices. The government should promote the development of biotech
contract research services for clinical trial phase I & II, and establish biotech contract
manufacturing services for clinical trial phase III. The government can also provide
support through education, information propaganda, and procurement programs. The
need for high quality scientists and engineers arises from both industry and research
institutes. The investment in the higher education system should keep up with rapidly
growing demand. The availability of human resources will ultimately contribute to the
increase of industrial competitiveness.
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6.4.5 Legislating Support and Financial Incentives for Innovators
The nature of innovation networks in China is different from those in developed
countries such as the United States and EU. The infrastructure and supporting systems are
mainly policy driven. Favorable policies and economic support from the government are
key factors to drive continuous growth in the long run. Substantial investments may be
required in reforming established SOEs, cultivating startups, and supporting various
academic/research institutes. Another area that needs improvement is the efficiency of the
drug evaluation process and reviewing mechanism. The bureaucratic nature of decision
making due to the involvement of government agencies has deterred the progress of
technological development and cooperation. Such barriers should be simplified or
removed completely. For example, the registration procedures for biosimilars could be
simplified according to related practices in advanced foreign countries.
Policies can serve to arouse the market participants’ interests in high-tech areas
through fiscal incentives. Such measures may include offering support to SMEs in
preferred research areas through investment incentives or low-interest loans. The
government can provide startups with special funding to lower their burden of initial sunk
cost. Lastly, the competitiveness of companies also depends on how well the companies
handle their networks of complementary relationships with other players in the biotech
sector. Institutional setup, active collaboration, and financial support from the
government will enhance the companies’ capabilities with regard to innovation and
competitiveness [319].
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Chapter 7 – Conclusions

With the implications and recommendations discussed in the last Chapter, this
Chapter summarizes and concludes the project in several major aspects including:
contributions, assumptions, limitations, and future research directions.

7.1 Research Contribution
The research contribution is summarized in Table 48 and explained below.

Research Gaps

Research Outcomes

1. Latecomers face the dilemma of ‘‘make or buy’’
decisions in high tech development [12] [84] [258]
[259].Technology export control at various levels
complicates their problems [16] [80] [138].
2. Latecomer countries and emerging economies
need to identify the “windows of opportunity” for
catching-up and leapfrogging [27] [29].

This research has identified four types of viable
strategies for technology development in the
emerging economies and latecomer countries.

3. International technology transfer activities may
not necessarily result in sustained innovation,
technology diffusion not efficient and spillover not
obvious [23] [25] [34].

The research has suggested more effective
technology development strategies, including
imitative innovation, indigenous innovation,
and collaborative innovation strategies.

4. Different attitudes toward appropriate
technology. Common concerns exist but different
interests and motivations are obvious among the
stakeholders [30] [32] [37].

This research has identified the areas of
disagreement or agreement in different
hierarchy levels.

5. Globalization brought new challenges in the
research of innovation systems, innovation
resources are across boundary [7] [72] [260].

This research has identified eight types of input
resources to support technological innovations
in China’s biopharmaceutical industry.

6. Transitional innovation systems: allocation of
innovation resources is not effectively linked to
national or regional tech development strategies
[196] [197].
7. No viable framework has been developed to deal
with technology policy problems in latecomer
countries. A decision model for the implementation
mechanism of selected technologies is needed in
such countries [180] [208] [261].

This research has prioritized the innovation
resources to support the identified technology
development strategies in China’s
biopharmaceutical industry.
This research has developed a comprehensive
research framework that links various
technologies, strategies, and resources to assist
technology policy decision in emerging
economies.

Identified and categorized thirteen prospective
high-tech areas for the biopharmaceutical
industry in China.

Table 48: Research Contribution
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7.1.1 Contribution to Technology Management Literature
Catching up and leapfrogging development in high-tech industries is a complicated
issue for latecomer countries. It is a great challenge for decision makers because of
limited innovation capacities and input resources. The literature review has revealed the
necessity for proactive technology posture, strategy adaptation, and resource allocation to
gain competitive advantage and innovation capability. However, little was known about
the inner relationships and their combined impact on competitiveness. This research
serves to fill the gap in the technology management literature. The findings of this
research have identified prospective technology areas, effective innovation strategies, and
resource allocation mechanisms. Along with the trend of globalization, technological
innovations are more scattered around the world. The model helps latecomer countries to
deal with the ‘‘make or buy’’ dilemma in technology development. The research process
has considered the interests of both domestic and foreign stakeholders by incorporating
multiple perspectives during data collection. It also combined a top-down and bottom-up
approach to consider the needs and concerns of both governments and enterprises.
Experts from diverse sources provided their valuable judgments for the research.

7.1.2 Contribution to Methodology
Conventional technology assessment methods are applied to evaluate and assign
priority to technology alternatives for economic, social, or environmental objectives.
However, such methods are not an appropriate means for determining a workable
solution during the implementation stages. The biopharmaceutical industry encompasses
many high-tech areas and complex aspects, and the realization mechanism of a particular
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area may involve interconnected decision elements such as technology, strategy, and
resources. Because of the many criteria involved and the different perceptions of experts
with different backgrounds, this study has employed the HDM method proposed by
Dundar Kocaoglu in 1976 to construct a new framework for the assessment of innovation
potential in the biopharmaceutical sector [252].
AHP provides an effective methodology allowing the collective decision making
process among various experts to be systematically integrated. It consolidates different
opinions brought by experts’ backgrounds, and presents the results in an aggregated
manner. Moreover, the disagreement among experts can be measured by the calculation
of the intra-class coefficient and F-test. Through exploring the variance of opinions
among different experts, policy makers can understand the exact area of disagreement
and make tradeoffs accordingly. This provides an effective decision making mechanism
for resource allocation, implementation strategy, and technology directions.

7.1.3 Contribution to the Biopharmaceutical Industry
The case application contributes to policy development in China’s biopharmaceutical industry in time and in need. China is resolute to reform its health sector
and promote innovations in high-tech areas. However, policy controversy exists in
China’s pharmaceutical industry, and technological innovation is remarkably difficult
[278]. Moreover, globalized competition has significantly complicated the innovation
environments for local companies. Since the biopharmaceutical industry is noted for high
regulatory control, the government plays an important role in guiding industrial
development. The case study's most important contribution lies in its having consolidated
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the valuable inputs of policy makers, industry representatives, and specialists from
various biopharmaceutical fields to provide policy directions encompassing innovation
resources, technology development strategies, and prospective high-tech areas. The
resulting information allows the comparison of each innovator's level of development and
provides a robust basis for policy improvement in the biopharmaceutical sector.
In summary, this research continues and broadens the related technology
management research in academic literature, and it develops a new analytic framework to
deal with real world problems in the Chinese biopharmaceutical sector. Findings and
implications of the research can provide new perspectives for high-tech development in
other emerging economies.

7.2 Assumptions and Limitations
This section discusses some research assumptions and limitations, and how such
issues were addressed in this research process.

7.2.1 Research Assumptions
The research has several assumptions in the area of AHP model development and
expert recruitment. The development of an AHP model has its assumptions. The impact
relationships between adjacent levels were assumed to be linear and unidirectional. The
decision criteria at each level were assumed to be preferentially independent. To cope
with such assumptions, the research model was conceptually developed based on a
comprehensive literature review. The model structure was further tested in a pilot study.
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The finalization of criteria and level of relationships were validated by the experts before
the data collection process.
The appropriate selection of experts is critical for the success of this research. The
experts were assumed to be knowledgeable in their fields. Individual biases were
assumed to be balanced in the expert panel and subgroups, and they had minimal effect
on the overall quantification measurement. In order to meet such assumptions, experts
were recruited according to their professional backgrounds and industrial experience. The
researcher tried to minimize the biases by inviting experts from diverse sources including
government agencies, domestic industrial associations, and foreign organizations.
Moreover, the influential biases were avoided since the experts did not know who else
participated in the research.

7.2.2 Limitations
Several limitations need to be clarified for this research. The experts provide their
opinions based on their perception of reality, as well as their professional backgrounds
and experience. The research process evaluated their judgmental preferences at a certain
period of time, and the results only reflected their perceptions during that period of time.
Their judgments may change over time due to other influencing factors such as social or
economic changes. The model has been demonstrated through a case application in the
biopharmaceutical sector. However, due to industrial differences, the research criteria
may need to be modified for applications in other industries.
This research is not to find a panacea for all the problems related to technology
policy. The objective is to develop an analytic approach to assist policy design in
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building a more effective innovation infrastructure to support technology implementation.
The model may yield different outcomes for different countries, different political
institutions, and different development stages. The idiosyncrasies of ideological
frameworks are beyond the consideration of this research.

7.3 Future Research
The limitations discussed above leave some room for future research. Further
exploration may lead to one or more of the following directions.

7.3.1 Other Emerging Economies and Industries.
Although the research framework has been demonstrated with a case study in
China’s biopharmaceutical sector, additional research can be applied to other emerging
economies such as Brazil, India, and Russia. Addressing industry-specific characteristics
and examining the influence of regional characteristics would clearly be a future direction.
The types and number of technologies and resources may vary from industry to industry,
and from country to country. More criteria and alternatives could be identified and
included in new models to reflect the reality according to different conditions.
Policymakers can tailor this framework to the needs of particular sectors in the host
country. The related research outcomes can provide insights for designing policies to
improve the country’s innovation capacity.
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7.3.2 Enterprise-Level Applications
Selection of appropriate technology for a rapidly evolving market environment is a
complicated issue at both the industrial and enterprise level. It should be acknowledged
that the experts provided valuable feedback and suggestions, which was incisive,
intelligent, and very thoughtful. One of them suggested that the model can be applied at
both the industrial level and enterprise level. The future is uncertain and enterprises are
engaged in the effort to sustain innovation. Many decision makers have the question
"How do enterprises innovate consistently?" The difficulties of this go into making the
right decisions about how many resources to pour into innovation, and how to choose the
right products to innovate around. Enterprises leverage various innovation resources, but
funding is relatively internal and constrained by various factors. It is crucial to have a
discipline of execution around the innovation process. The research model can therefore
serve to help enterprises in making balanced investments, innovating in the right areas,
and making the right bets for the future.

7.3.3 Deployment of Policy Tools
The application of an analytical hierarchical structure gave meaningful results in
identifying the effective innovation resources and comparing the relative importance of
strategies. The purpose of this research, as well as the model, is to guide policy directions
that will build up the innovation capability for the country. However, more specific
policy tools and measures are not discussed in detail. Follow up policy research can focus
on the development of favorable policy tools to support the identified criteria. For
example, the results suggest that High-tech SMEs and MNCs have more contributions
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toward the overall mission of competitiveness and innovation. These research outcomes
can lead future work to the deployment of more specific policy tools to support the
identified players. Moreover, technology policies should also be revised in a dynamic
manner to keep up with the rapid trend of globalization and trade liberalization.
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Appendix A – Human Subject Agreement

Informed Consent Form
Policy Choice Framework for Sustainable Technological Innovation

Dear [Expert’s Name],
You are invited to participate in a research study conducted by Leong Chan from Portland State
University, Engineering and Technology Management Department. The researcher hopes to
identify the innovation resources that contribute to the technological competitiveness of an
industry. This project is being conducted in partial fulfillment for the requirements of a PhD’s
degree under supervision by Dr. Tugrul Daim. You are invited as a possible participant because
you have innovation management experience in the industry that the researcher is examining in
the study.
If you decide to participate, you will be asked to provide judgments through pair-wise
comparisons among the model criteria in the research instrument. This is a numerical
quantification process, thus it presents no hazard to the participants. The task takes about 15 to 30
minutes to complete. You will not receive any direct benefit from taking part in this study, but the
study may help to increase knowledge which may help others in the future.
Your name and responses will be confidential and will not be shared with any third party. Any
data linked to your identification will be kept confidential by storing in secured places only
accessible by the researcher. The data will be stored in the researcher’s computer and backed up
in university’s secured server. The data will be destroyed within one year after the completion of
research. Participation in this research is totally voluntary. You have the right to withdraw at any
time or refuse to participate entirely. You may also withdraw from this study at any time without
affecting your relationship with the researcher or any institute.
If you have concerns or problems about your participation in this study or your rights as a
research subject, please contact the Human Subjects Research Review Committee, Office of
Research Strategic Partnerships, 1600 SW Fourth Avenue, Suite 620, Portland, OR, 97201, (503)
725 3423. If you have any questions about the study itself, contact Leong at 1802 SW 11th Ave
#404, Portland, OR, 97201, (503) 442 8428.
Your signature indicates that you have read and understand the above information and agree to
take part in this study. Please understand that you may withdraw your consent at any time without
penalty, and that by signing, you are not waiving any legal claims, rights or remedies. The
researcher will provide you with a copy of this form for your records.

Signature:

Date:
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Appendix B – Subject Recruitment Letter

Policy Choice Framework for Sustainable Technological Innovation

Dear Sir or Madam,
My name is Leong Chan, and I am a Ph.D. student at Department of Engineering and Technology
Management (ETM), Portland State University. I am conducting a research to develop a policy
choice framework for sustainable technological innovation, and would like to invite you to
participate. You are being asked to take part because you are considered as an expert in the area
of innovation management due to your qualification and professional experience. I am impressed
with your expertise in innovation management, and I hope that your expert judgment will help me
to better understand the innovation mechanism from different perspectives. Your participation
will help to increase the knowledge in policy decisions to foster technological innovation. This
study is being conducted in partial fulfillment of the requirements for a doctoral degree in
Technology Management at Portland State University.
If you decide to participate, an Informed Consent Form will be sent to you for signature before
the research. I will be sending some data collection instruments to you after I receive the signed
form. You will be asked to provide your opinions by doing some pair-wise comparisons among
the research criteria. The research instrument will take about 15-30 minutes to complete. When
you return the research instruments, I will quantify the judgmental data and prioritize the related
research criteria. The result can demonstrate what strategies and resources are more important in
policy decisions.
There is no risk for the involvement in this research. No identifiable data is collected, and will not
be reported. All data will remain confidential by the researcher. The data obtained from the
participants will only be reported in the aggregate format, and the individual information will be
kept confidential. All responses will be concealed, and no one other than the researcher will have
access to them. The information will be deleted or destroyed by the researcher within one year
after the completion of this research.
The benefits for participation include two things: 1) at the end of the research, a copy of the
aggregated results will be provided to you at no cost; 2) through your participation as an expert,
researcher, and decision-maker, we will all learn more about how innovation resources contribute
to technology policy decisions, which will ultimately lead to the benefit of whole society.
Participation in this research is completely voluntary. You have the right to withdraw at any time
or refuse to participate entirely and it will not affect your relationship with the investigator or any
institute.
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If you have questions regarding this study, you may contact Leong Chan at leong@pdx.edu, 1802
SW 11th Ave #404, Portland, OR, 97201, (503) 442 8428. If you have concerns or problems
about your participation in this study or your rights as a research subject, please contact the
Human Subjects Research Review Committee, Research and Strategic Partnerships, Market
Center Building, 6th Floor, 1600 SW 4th Ave, Portland, OR 97201, (503) 725-4288 / 1-877-4804400.

Sincerely,

Leong Chan
Ph.D. student
Department of Engineering and Technology Management
Portland State University
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Appendix C – Validation Instruments

Validation Instrument I A
Identification and validation of Prospective Technology Areas in the Biopharmaceutical
Industry
1. Introduction
Identification and investment on prospective technology areas are crucial for improving
competiveness in the biopharmaceutical industry. Emerging countries not only need to
identify global technology trends, but also have to adapt to local needs and capabilities.
The purpose of this instrument is to identify and validate such technology areas.
A preliminary list of technology areas has been prepared according to comprehensive
literature review. The following list contains the prospective technology areas in the
biopharmaceutical industry as suggested by OECD’S forecasting report. However, the
lists might need to be updated and validated because it was originally published in 2009.
2. Instructions
In the following table, you are invited to validate the technology areas and provide
suggestions. The goal is to identify a list of prospective high tech areas to enhance
competitiveness from a global perspective.
In your opinion, if you think the technology is novel and prospective in the future, please
check the YES column; or if you think a technology is matured enough or less
prospective, please check the NO column.
Moreover, you can suggest new technology areas that you think as prospective in the
biopharmaceutical industry. Please kindly provide your opinions in the following table.
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3. List of prospective technology areas and your opinions:
Prospective
in future?
Yes
No

Prospective Technology Areas
Recombinant therapeutic proteins - treat many non-communicable diseases;
provide affordable and sustainable sources for treatment of chronic disease.
Recombinant vaccines - vaccines produced using recombinant DNA
technology; can be used to effectively treat infectious diseases.
Monoclonal antibody technology - used for both therapeutic treatment and
diagnostic tests. Most are concerned with immunological and oncology targets.
Tissue engineering technologies - replace or act directly on cells and tissues
in the body; repairs damaged tissues from injuries and diseases.
Stem cell therapy - the use of stem cells as a therapeutic or to repair specific
tissues or to grow organs. Treatment leads to the production of entire organs.
Gene therapy - treatment of diseases by introducing new gene into a cell.
These technologies either use or act directly on nucleic acids.
Antisense therapy - treat a wide range of diseases such as cardiovascular
diseases, asthma, and arthritis.
RNAi (ribonucleic acid interference) - products that act therapeutically via
an RNA interference mechanism. Most are aimed at treating infections.
Nanobiotechnology - aim for improved drug delivery systems from the
convergence between biotechnology and nanotechnology.
Synthetic biology - the design and construction of new biological parts,
devices and systems that do not exist naturally; the redesign of existing
biological systems to perform specific tasks
Bioinformatics - manipulation and analysis of large datasets of genetic and
health information to identify drug targets
Pharmacogenetics - identify inherited differences (variation) between
individuals in drug metabolism and response. It can be applied in clinical trials
and in prescribing practice.
Gene sequencing - provides ways to identify new antimicrobials. It can
accelerate the process of drug discovery and fight against infectious diseases.
Biotechnology Diagnostics - includes both in vitro diagnostics and in vivo
diagnostics; Provides affordable, simple diagnosis for infectious diseases.

Other Suggestions (if necessary):
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Validation Instrument I B
Identification and validation of Technology Development Strategies for the
Biopharmaceutical Industry in Emerging Countries
The technology development strategies describe how new technologies should be realized
and implemented. As latecomers in technology development, emerging countries face the
decisions of “make or buy”, or somewhere in between. This means to develop the
technology locally, or import from advanced countries, etc.
The following innovation strategies have been identified through literature review. Please
indicate whether these strategies are observable in the biopharmaceutical industry. You
are also welcome to suggest other innovation strategies, that you believe, are observable
in the biopharmaceutical industry.

Technology Development Strategies in Emerging Countries
Indigenous Innovation – relies on local technology base and available
innovation resources to build up indigenous competence
Imitative Innovation – based on imitating, following, and
improvement of leading innovators’ technology
Collaborative Innovation – cooperates with other innovators, shares
resources and develops new technology altogether
International Technology Transfer – technology import and
acquisitions, introducing new technology from leaders

Other Suggestions (if any):
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Observable in biopharmaceutical industry?
Yes
No

Validation Instrument I C
Identification and Validation of Innovation Resources to Support Technology
Development Strategies in the Biopharmaceutical Industry
The Innovation Resources contribute to the implementation of technology development
strategies. These are innovators that generate various innovative outputs such as patents,
publications, and new products or designs. The innovation resources can include all the
entities that develop, implement, or provide support for the realization of prospective
technologies. These resources can come from different sources such as public sector,
private sector, or even foreign countries.
For the biopharmaceutical industry, various types of innovation resources have been
extracted through literature review. In the following tables, please indicate and validate
whether these innovators are supportive to the technology strategies identified in
Validation Instrument I b.
You are also welcome to suggest other innovation resources that you believe important
for the biopharmaceutical industry in emerging countries.

1. Supportive Innovators and resources for the technology development
strategies
University Research Programs
Public Research Institutes
State-owned Enterprises
High-tech Small-to-Medium Enterprises
Equity Joint Ventures
Contract Research/Manufacture Organizations
Foreign R&D Centers
Multinational Companies and Wholly-owned Subsidiaries

Other Suggestions (if necessary):
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Contributor?
Yes

No

Appendix D – Research Instruments
Pair-wise Comparison Instrument I A
Prioritization of Prospective Technology Areas in the Biopharmaceutical Industry
1. Introduction
Identification and investment on prospective technology areas are crucial for improving
competiveness in the biopharmaceutical industry. Emerging countries not only need to
identify global technology trends, but also have to adapt to local needs and capabilities.
The purpose of this instrument is to prioritize such technology areas. The following
prospective technology areas in the biopharmaceutical industry were suggested by
literature review and validated by experts. As an expert, you will be asked to make pairwise comparisons among the technologies for the objective of enhancing competitiveness
and innovation in the biopharmaceutical industry.
2. Instructions
In the pair-wise comparison tables, please allocate a total of 100 points to represent your
perceived judgment about how many times an element is more or less important than the
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75)
in the cell on the right. If you believe that one element is completely irrelevant in
comparison to the other element of a pair, allocate 1 and 99 respectively. The working
process is similar for other pairs, but the judgment values might be very different even for
the same pair when under a different upper level criterion. The following 2 tables
demonstrate this procedure. For example:
Contribution to upper level Criterion1
Sub-criterion1
75
Vs.
25
Sub-criterion2

Contribution to upper level Criterion2
Sub-criterion1

1

Vs.

253

99

Sub-criterion2

3. Descriptions of Criteria
Overall Objective:
The mission is to achieve technology competitiveness and sustainable innovation in the
biopharmaceutical industry.
Prospective Technology Areas:
T1 Recombinant therapeutic proteins - treat many non-communicable diseases;
provide affordable and sustainable sources for treatment of chronic disease.
T2 Recombinant vaccines - vaccines produced using recombinant DNA
technology; can be used to effectively treat infectious diseases.
T3 Monoclonal antibody technology - used for both therapeutic treatment and
diagnostic tests. Most are concerned with immunological and oncology targets.
T4 Cell and tissue engineering - replace or act directly on cells and tissues in the
body; repairs damaged tissues from injuries and diseases. Including stem cell
therapy.
T5 Gene therapy - treatment of diseases by introducing new gene into a cell.
These technologies either use or act directly on nucleic acids.
T6 Antisense therapy - treat a wide range of diseases such as cardiovascular
diseases, asthma, and arthritis.
T7 RNAi (ribonucleic acid interference) - products that act therapeutically via an
RNA interference mechanism. Most are aimed at treating infections.
T8 Nanobiotechnology - aim for improved drug delivery systems from the
convergence between biotechnology and nanotechnology.
T9 Synthetic biology - the design and construction of new biological parts,
devices and systems that do not exist naturally; the redesign of existing
biological systems to perform specific tasks
T10 Bioinformatics - manipulation and analysis of large datasets of genetic and
health information to identify drug targets
T11 Pharmacogenetics - identify inherited differences (variation) between
individuals in drug metabolism and response. It can be applied in clinical trials
and in prescribing practice.
T12 Gene sequencing - provides ways to identify new antimicrobials. It can
accelerate the process of drug discovery and fight against infectious diseases.
T13 Biotechnology Diagnostics - includes both in vitro diagnostics and in vivo
diagnostics; Provides affordable, simple diagnosis for infectious diseases.

Please provide you judgment in the next 2 tables.
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Group A:
T1 Recombinant therapeutic proteins

Vs.

T2 Recombinant vaccines

T1 Recombinant therapeutic proteins

Vs.

T3 Monoclonal antibody

T1 Recombinant therapeutic proteins

Vs.

T4 Cell and tissue engineering

T1 Recombinant therapeutic proteins

Vs.

T5 Gene therapy

T1 Recombinant therapeutic proteins

Vs.

T6 Antisense therapy

T1 Recombinant therapeutic proteins

Vs.

T7 RNAi

T2 Recombinant vaccines

Vs.

T3 Monoclonal antibody

T2 Recombinant vaccines

Vs.

T4 Cell and tissue engineering

T2 Recombinant vaccines

Vs.

T5 Gene therapy

T2 Recombinant vaccines

Vs.

T6 Antisense therapy

T2 Recombinant vaccines

Vs.

T7 RNAi

T3 Monoclonal antibody technology

Vs.

T4 Cell and tissue engineering

T3 Monoclonal antibody technology

Vs.

T5 Gene therapy

T3 Monoclonal antibody technology

Vs.

T6 Antisense therapy

T3 Monoclonal antibody technology

Vs.

T7 RNAi

T4 Cell and tissue engineering

Vs.

T5 Gene therapy

T4 Cell and tissue engineering

Vs.

T6 Antisense therapy

T4 Cell and tissue engineering

Vs.

T7 RNAi

T5 Gene therapy

Vs.

T6 Antisense therapy

T5 Gene therapy

Vs.

T7 RNAi

T6 Antisense therapy

Vs.

T7 RNAi
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Group B:
T1 Recombinant therapeutic proteins

Vs.

T8 Nanobiotechnology

T1 Recombinant therapeutic proteins

Vs.

T9 Synthetic biology

T1 Recombinant therapeutic proteins

Vs.

T10 Bioinformatics

T1 Recombinant therapeutic proteins

Vs.

T11 Pharmacogenetics

T1 Recombinant therapeutic proteins

Vs.

T12 Gene sequencing

T1 Recombinant therapeutic proteins

Vs.

T13 Biotechnology Diagnostics

T8 Nanobiotechnology

Vs.

T9 Synthetic biology

T8 Nanobiotechnology

Vs.

T10 Bioinformatics

T8 Nanobiotechnology

Vs.

T11 Pharmacogenetics

T8 Nanobiotechnology

Vs.

T12 Gene sequencing

T8 Nanobiotechnology

Vs.

T13 Biotechnology Diagnostics

T9 Synthetic biology

Vs.

T10 Bioinformatics

T9 Synthetic biology

Vs.

T11 Pharmacogenetics

T9 Synthetic biology

Vs.

T12 Gene sequencing

T9 Synthetic biology

Vs.

T13 Biotechnology Diagnostics

T10 Bioinformatics

Vs.

T11 Pharmacogenetics

T10 Bioinformatics

Vs.

T12 Gene sequencing

T10 Bioinformatics

Vs.

T13 Biotechnology Diagnostics

T11 Pharmacogenetics

Vs.

T12 Gene sequencing

T11 Pharmacogenetics

Vs.

T13 Biotechnology Diagnostics

T12 Gene sequencing

Vs.

T13 Biotechnology Diagnostics

Overall level of confidence (Please circle the appropriate number):
5: Very high

4: High

3: Medium
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2: Low

1: Very Low

Pair-wise Comparison Instrument I B
Prioritization of Technology Development Strategies for the Biopharmaceutical Industry
in Emerging Countries
1. Introduction
The technology development strategies describe how new technologies should be realized
and implemented. As latecomers in technology development, emerging countries face the
decisions of “make or buy”, or somewhere in between. This means to develop the
technology locally, or import from advanced countries, etc. The following innovation
strategies have been identified through literature review and validated by experts. As an
expert, you will be asked to make pair-wise comparisons among these strategies for the
identified technology areas in the biopharmaceutical industry.
2. Instructions
In the pair-wise comparison tables, please allocate a total of 100 points to represent your
perceived judgment about how many times an element is more or less important than the
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75)
in the cell on the right. If you believe that one element is completely irrelevant in
comparison to the other element of a pair, allocate 1 and 99 respectively. The working
process is similar for other pairs, but the judgment values might be very different even for
the same pair when under a different upper level criterion. The following 2 tables
demonstrate this procedure. For example:
Contribution to upper level Criterion1
Sub-criterion1
75
Vs.
25
Sub-criterion2

Contribution to upper level Criterion2
Sub-criterion1

1

Vs.
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99

Sub-criterion2

3. Descriptions of Criteria
Technology Development Strategies in China:
Indigenous Innovation – relies on local technology base and available innovation
resources to build up indigenous competence
Imitative Innovation – based on imitating, following, and improvement of leading
innovators’ technology
Collaborative Innovation – cooperates with other innovators, shares resources and
develops new technology altogether
International Technology Transfer – technology import and acquisitions, introducing
new technology from leaders
4. Prioritization of Strategies for Identified Technologies (T1-T13)
For T1: Recombinant therapeutic proteins
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T2: Recombinant vaccines
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T3: Monoclonal antibody technology
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer
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For T4: Cell and tissue engineering
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T5: Gene therapy
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T6: Antisense therapy
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T7: RNAi (ribonucleic acid interference)
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer
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For T8: Nanobiotechnology
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T9: Synthetic biology
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T10: Bioinformatics
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T11: Pharmacogenetics
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer
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For T12: Gene sequencing
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

For T13: Biotechnology Diagnostics
S1: Indigenous Innovation

Vs.

S2: Imitative Innovation

S1: Indigenous Innovation

Vs.

S3: Collaborative Innovation

S1: Indigenous Innovation

Vs.

S4: Int’l Technology Transfer

S2: Imitative Innovation

Vs.

S3: Collaborative Innovation

S2: Imitative Innovation

Vs.

S4: Int’l Technology Transfer

S3: Collaborative Innovation

Vs.

S4: Int’l Technology Transfer

Overall level of confidence (Please circle the appropriate number):
5: Very high

4: High

3: Medium

2: Low

1: Very Low

------------------------------------ Thank You -------------------------------------
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Pair-wise Comparison Instrument I C
Prioritization of Innovation Resources to Support Technology Development Strategies in
the Biopharmaceutical Industry
1. Introduction
The Innovation Resources contribute to the implementation of technology development
strategies. These are innovators that generate various innovative outputs such as patents,
publications, and new products or designs. The innovation resources can include all the
entities that develop, implement, or provide support for the realization of prospective
technologies. These resources can come from different sources such as public sector,
private sector, or even foreign countries. Various types of innovation resources have been
extracted through literature review and validated by experts. You will be asked to make
pair-wise comparisons among the innovation resources to supportive the technology
development strategies.
2. Instructions
In the pair-wise comparison tables, please allocate a total of 100 points to represent your
perceived judgment about how many times an element is more or less important than the
other. Use any number from 1 to 99 to represent your judgment (Exclude 0 or 100). For
example, if you think ‘sub-criterion1’ is 3 times more important than ‘sub-criterion2’ for
the upper level Criterion, then fill "75" in the blank cell on the left, and then “25” (100-75)
in the cell on the right. If you believe that one element is completely irrelevant in
comparison to the other element of a pair, allocate 1 and 99 respectively. The working
process is similar for other pairs, but the judgment values might be very different even for
the same pair when under a different upper level criterion. The following 2 tables
demonstrate this procedure. For example:
Contribution to upper level Criterion1
Sub-criterion1
75
Vs.
25
Sub-criterion2

Contribution to upper level Criterion2
Sub-criterion1

1

Vs.
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99

Sub-criterion2

3. Contribution of Resource Level to Strategies (S1-S4)
This section contains four tables to prioritize the resources for each of the identified
strategies, which include Indigenous Innovation, imitative Innovation, collaborative
Innovation and international Technology Transfer
3.1 Contribution to S1: Indigenous Innovation Strategy
R1: University Research Programs
R2: Public Research Institutes
R3: State-owned Enterprises
R4: High-tech Small-to-Medium Enterprises
R5: Equity Joint Ventures
R6: Contract Research/Manufacture Organizations
R7: Foreign R&D Centers
R8: Multinational Companies and Wholly-owned Subsidiaries
For S1: Indigenous Innovation Strategy
R1

Vs.

R2

R3

Vs.

R4

R1

Vs.

R3

R3

Vs.

R5

R1

Vs.

R4

R3

Vs.

R6

R1

Vs.

R5

R3

Vs.

R7

R1

Vs.

R6

R3

Vs.

R8

R1

Vs.

R7

R4

Vs.

R5

R1

Vs.

R8

R4

Vs.

R6

R2

Vs.

R3

R4

Vs.

R7

R2

Vs.

R4

R4

Vs.

R8

R2

Vs.

R5

R5

Vs.

R6

R2

Vs.

R6

R5

Vs.

R7

R2

Vs.

R7

R5

Vs.

R8

R2

Vs.

R8

R6

Vs.

R7

R6

Vs.

R8

R7

Vs.

R8
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3.2 Contribution to S2: Imitative Innovation Strategy
R1: University Research Programs
R2: Public Research Institutes
R3: State-owned Enterprises
R4: High-tech Small-to-Medium Enterprises
R5: Equity Joint Ventures
R6: Contract Research/Manufacture Organizations
R7: Foreign R&D Centers
R8: Multinational Companies and Wholly-owned Subsidiaries
For S2: Imitative Innovation Strategy
R1

Vs.

R2

R3

Vs.

R4

R1

Vs.

R3

R3

Vs.

R5

R1

Vs.

R4

R3

Vs.

R6

R1

Vs.

R5

R3

Vs.

R7

R1

Vs.

R6

R3

Vs.

R8

R1

Vs.

R7

R4

Vs.

R5

R1

Vs.

R8

R4

Vs.

R6

R2

Vs.

R3

R4

Vs.

R7

R2

Vs.

R4

R4

Vs.

R8

R2

Vs.

R5

R5

Vs.

R6

R2

Vs.

R6

R5

Vs.

R7

R2

Vs.

R7

R5

Vs.

R8

R2

Vs.

R8

R6

Vs.

R7

R6

Vs.

R8

R7

Vs.

R8

264

3.3 Contribution to S3: Collaborative Innovation Strategy
R1: University Research Programs
R2: Public Research Institutes
R3: State-owned Enterprises
R4: High-tech Small-to-Medium Enterprises
R5: Equity Joint Ventures
R6: Contract Research/Manufacture Organizations
R7: Foreign R&D Centers
R8: Multinational Companies and Wholly-owned Subsidiaries
For S3: Collaborative Innovation Strategy
R1

Vs.

R2

R3

Vs.

R4

R1

Vs.

R3

R3

Vs.

R5

R1

Vs.

R4

R3

Vs.

R6

R1

Vs.

R5

R3

Vs.

R7

R1

Vs.

R6

R3

Vs.

R8

R1

Vs.

R7

R4

Vs.

R5

R1

Vs.

R8

R4

Vs.

R6

R2

Vs.

R3

R4

Vs.

R7

R2

Vs.

R4

R4

Vs.

R8

R2

Vs.

R5

R5

Vs.

R6

R2

Vs.

R6

R5

Vs.

R7

R2

Vs.

R7

R5

Vs.

R8

R2

Vs.

R8

R6

Vs.

R7

R6

Vs.

R8

R7

Vs.

R8
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3.4 Contribution to S4: International Technology Transfer
R1: University Research Programs
R2: Public Research Institutes
R3: State-owned Enterprises
R4: High-tech Small-to-Medium Enterprises
R5: Equity Joint Ventures
R6: Contract Research/Manufacture Organizations
R7: Foreign R&D Centers
R8: Multinational Companies and Wholly-owned Subsidiaries
For S4: International Technology Transfer
R1

Vs.

R2

R3

Vs.

R4

R1

Vs.

R3

R3

Vs.

R5

R1

Vs.

R4

R3

Vs.

R6

R1

Vs.

R5

R3

Vs.

R7

R1

Vs.

R6

R3

Vs.

R8

R1

Vs.

R7

R4

Vs.

R5

R1

Vs.

R8

R4

Vs.

R6

R2

Vs.

R3

R4

Vs.

R7

R2

Vs.

R4

R4

Vs.

R8

R2

Vs.

R5

R5

Vs.

R6

R2

Vs.

R6

R5

Vs.

R7

R2

Vs.

R7

R5

Vs.

R8

R2

Vs.

R8

R6

Vs.

R7

R6

Vs.

R8

R7

Vs.

R8

Overall level of confidence (Please circle the appropriate number):
5: Very high

4: High

3: Medium

2: Low

1: Very Low

----------------------------------------- Thank You ------------------------------------------
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Appendix E – Disagreement Analysis
Disagreement Analysis - Technology Level
Group A
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.666(b)
.404
.912
18.080
6
54
Measures
Average
.952
.872
.990
18.080
6
54
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.000
.000

Group B
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.565(b)
.294
.874
12.113
6
54
Measures
Average
.928
.806
.986
12.113
6
54
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.000
.000

Disagreement Analysis - Strategy Level
T1: Recombinant Therapeutic Proteins
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.491(b)
.115
.941
6.799
3
21
Measures
Average
.885
.510
.992
6.799
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.002
.002

T2: Recombinant Vaccines
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.465(b)
.094
.935
6.206
3
21
Measures
Average
.874
.455
.991
6.206
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.003
.003

T3: Monoclonal Antibody Technology
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.387(b)
.040
.917
4.785
3
21
Measures
Average
.835
.252
.989
4.785
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.011
.011

T4: Cell and Tissue Engineering
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.204(b)
-.059
.853
2.534
3
21
Measures
Average
.672
-.813
.979
2.534
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.084
.084

T5: Gene Therapy
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.409(b)
.055
.923
5.158
3
21
Measures
Average
.847
.319
.990
5.158
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.008
.008

T6: Antisense Therapy
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.325(b)
.003
.900
3.890
3
21
Measures
Average
.794
.025
.986
3.890
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.023
.023

T7: RNAi
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.362(b)
.025
.911
4.405
3
21
Measures
Average
.819
.170
.988
4.405
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.015
.015

T8: Nanobiotechnology
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.396(b)
.047
.920
4.940
3
21
Measures
Average
.840
.281
.989
4.940
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.009
.009

T9: Synthetic Biology
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.359(b)
.023
.910
4.361
3
21
Measures
Average
.818
.159
.988
4.361
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.015
.015

T10: Bioinformatics
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.308(b)
-.007
.895
3.665
3
21
Measures
Average
.780
-.057
.985
3.665
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.029
.029

T11: Pharmacogenetics
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.330(b)
.006
.902
3.962
3
21
Measures
Average
.798
.048
.987
3.962
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.022
.022

T12: Gene Sequencing
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.242(b)
-.041
.870
2.919
3
21
Measures
Average
.719
-.458
.982
2.919
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.058
.058

T13: Biotechnology Diagnostics
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.329(b)
.005
.901
3.940
3
21
Measures
Average
.797
.041
.986
3.940
3
21
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.022
.022

Disagreement Analysis - Resource Level
S1: Indigenous Innovation
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.333(b)
.108
.718
4.941
7
56
Measures
Average
.818
.523
.958
4.941
7
56
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.000
.000

S2: Imitative Innovation
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.422(b)
.176
.779
6.761
7
56
Measures
Average
.868
.657
.969
6.761
7
56
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.000
.000

S3: Collaborative Innovation
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.154(b)
-.004
.543
2.436
7
56
Measures
Average
.621
-.041
.915
2.436
7
56
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.030
.030

S4: International Technology Transfer
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.407(b)
.163
.769
6.399
7
56
Measures
Average
.861
.637
.968
6.399
7
56
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.000
.000

Subgroup Disagreement Analysis - Technology Level
T4 Cell and Tissue Engineering: Subgroup-G
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.721(b)
.014
.978
6.813
3
6
Measures
Average
.886
.042
.993
6.813
3
6
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.023
.023

T4 Cell and Tissue Engineering: Subgroup-F
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.691(b)
-.040
.975
6.034
3
6
Measures
Average
.870
-.129
.992
6.034
3
6
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.030
.030

T4 Cell and Tissue Engineering: Subgroup-L
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.861(b)
-.284
.991
10.320
3
3
Measures
Average
.926
-.792
.995
10.320
3
3
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.043
.043

T12 Gene Sequencing: Subgroup-G
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.653(b)
-.101
.971
5.241
3
6
Measures
Average
.850
-.378
.990
5.241
3
6
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.041
.041

T12 Gene Sequencing: Subgroup-F
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.633(b)
-.131
.969
4.878
3
6
Measures
Average
.838
-.533
.990
4.878
3
6
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.

Sig
.048
.048

T12 Gene Sequencing: Subgroup-L
Intraclass Correlation Coefficient
Intraclass
Correlation(a)

95% Confidence Interval

F Test with True Value 0

Lower Bound Upper Bound
Value
df1
df2
Single
.867(b)
-.251
.991
10.788
3
3
Measures
Average
.929
-.671
.995
10.788
3
3
Measures
Two-way random effects model where both people effects and measures effects are random.
a Type A intraclass correlation coefficients using an absolute agreement definition.
b The estimator is the same, whether the interaction effect is present or not.
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Sig
.041
.041

